<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Selenium for preventing cancer - Vinceti, M - 2018 | Cochrane Library</title> <meta content="Selenium for preventing cancer - Vinceti, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005195.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Selenium for preventing cancer - Vinceti, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005195.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005195.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Selenium for preventing cancer" name="citation_title"/> <meta content="Marco Vinceti" name="citation_author"/> <meta content="marco.vinceti@unimore.it" name="citation_author_email"/> <meta content="Tommaso Filippini" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Cinzia Del Giovane" name="citation_author"/> <meta content="Gabriele Dennert" name="citation_author"/> <meta content="University of Applied Sciences Dortmund" name="citation_author_institution"/> <meta content="Marcel Zwahlen" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Maree Brinkman" name="citation_author"/> <meta content="Maurice PA Zeegers" name="citation_author"/> <meta content="Maastricht University" name="citation_author_institution"/> <meta content="Markus Horneber" name="citation_author"/> <meta content="Paracelsus Medical University, Klinikum Nuremberg" name="citation_author_institution"/> <meta content="Roberto D'Amico" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Catherine M Crespi" name="citation_author"/> <meta content="University of California Los Angeles" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD005195.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005195.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005195.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005195.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Case‐Control Studies; Neoplasms [*prevention &amp; control]; Observational Studies as Topic; Odds Ratio; Randomized Controlled Trials as Topic; Selenium [*administration &amp; dosage, adverse effects]; Sex Factors; Trace Elements [*administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005195.pub4&amp;doi=10.1002/14651858.CD005195.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005195\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005195\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","ja","pl","zh_HANS","fa","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005195.pub4",title:"Selenium for preventing cancer",firstPublishedDate:"Jan 29, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005195.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005195.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005195.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005195.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005195.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005195.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005195.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005195.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005195.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005195.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>19648 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005195.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/appendices#CD005195-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/table_n/CD005195StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/table_n/CD005195StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Selenium for preventing cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marco Vinceti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0003">Tommaso Filippini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0004">Cinzia Del Giovane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0005">Gabriele Dennert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0006">Marcel Zwahlen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0007">Maree Brinkman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0008">Maurice PA Zeegers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0009">Markus Horneber</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0010">Roberto D'Amico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information#CD005195-cr-0011">Catherine M Crespi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information/en#CD005195-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005195.pub4">https://doi.org/10.1002/14651858.CD005195.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005195-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005195-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005195-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005195-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005195-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005195-abs-0001" lang="en"> <section id="CD005195-sec-0001"> <h3 class="title" id="CD005195-sec-0001">Background</h3> <p>This review is the third update of the Cochrane review "Selenium for preventing cancer". Selenium is a naturally occurring element with both nutritional and toxicological properties. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancer. </p> </section> <section id="CD005195-sec-0002"> <h3 class="title" id="CD005195-sec-0002">Objectives</h3> <p>To gather and present evidence needed to address two research questions:</p> <p>1. What is the aetiological relationship between selenium exposure and cancer risk in humans?<br/> 2. Describe the efficacy of selenium supplementation for cancer prevention in humans. </p> </section> <section id="CD005195-sec-0003"> <h3 class="title" id="CD005195-sec-0003">Search methods</h3> <p>We updated electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE (Ovid, 2013 to January 2017, week 4), and Embase (2013 to 2017, week 6), as well as searches of clinical trial registries. </p> </section> <section id="CD005195-sec-0004"> <h3 class="title" id="CD005195-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and longitudinal observational studies that enrolled adult participants. </p> </section> <section id="CD005195-sec-0005"> <h3 class="title" id="CD005195-sec-0005">Data collection and analysis</h3> <p>We performed random‐effects (RE) meta‐analyses when two or more RCTs were available for a specific outcome. We conducted RE meta‐analyses when five or more observational studies were available for a specific outcome. We assessed risk of bias in RCTs and in observational studies using Cochrane's risk assessment tool and the Newcastle‐Ottawa Scale, respectively. We considered in the primary analysis data pooled from RCTs with low risk of bias. We assessed the certainty of evidence by using the GRADE approach. </p> </section> <section id="CD005195-sec-0006"> <h3 class="title" id="CD005195-sec-0006">Main results</h3> <p>We included 83 studies in this updated review: two additional RCTs (10 in total) and a few additional trial reports for previously included studies. RCTs involved 27,232 participants allocated to either selenium supplements or placebo. For analyses of RCTs with low risk of bias, the summary risk ratio (RR) for any cancer incidence was 1.01 (95% confidence interval (CI) 0.93 to 1.10; 3 studies, 19,475 participants; high‐certainty evidence). The RR for estimated cancer mortality was 1.02 (95% CI 0.80 to 1.30; 1 study, 17,448 participants). For the most frequently investigated site‐specific cancers, investigators provided little evidence of any effect of selenium supplementation. Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non‐melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants). Certainty of the evidence was high for all of these cancer sites, except for breast cancer, which was of moderate certainty owing to imprecision, and non‐melanoma skin cancer, which we judged as moderate certainty owing to high heterogeneity. RCTs with low risk of bias suggested increased melanoma risk. </p> <p>Results for most outcomes were similar when we included all RCTs in the meta‐analysis, regardless of risk of bias. Selenium supplementation did not reduce overall cancer incidence (RR 0.99, 95% CI 0.86 to 1.14; 5 studies, 21,860 participants) nor mortality (RR 0.81, 95% CI 0.49 to 1.32; 2 studies, 18,698 participants). Summary RRs for site‐specific cancers showed limited changes compared with estimates from high‐quality studies alone, except for liver cancer, for which results were reversed. </p> <p>In the largest trial, the Selenium and Vitamin E Cancer Trial, selenium supplementation increased risks of alopecia and dermatitis, and for participants with highest background selenium status, supplementation also increased risk of high‐grade prostate cancer. RCTs showed a slightly increased risk of type 2 diabetes associated with supplementation. A hypothesis generated by the Nutritional Prevention of Cancer Trial ‐ that individuals with low blood selenium levels could reduce their risk of cancer (particularly prostate cancer) by increasing selenium intake ‐ has not been confirmed. As RCT participants have been overwhelmingly male (88%), we could not assess the potential influence of sex or gender. </p> <p>We included 15 additional observational cohort studies (70 in total; over 2,360,000 participants). We found that lower cancer incidence (summary odds ratio (OR) 0.72, 95% CI 0.55 to 0.93; 7 studies, 76,239 participants) and lower cancer mortality (OR 0.76, 95% CI 0.59 to 0.97; 7 studies, 183,863 participants) were associated with the highest category of selenium exposure compared with the lowest. Cancer incidence was lower in men (OR 0.72, 95% CI 0.46 to 1.14, 4 studies, 29,365 men) than in women (OR 0.90, 95% CI 0.45 to 1.77, 2 studies, 18,244 women). Data show a decrease in risk of site‐specific cancers for stomach, colorectal, lung, breast, bladder, and prostate cancers. However, these studies have major weaknesses due to study design, exposure misclassification, and potential unmeasured confounding due to lifestyle or nutritional factors covarying with selenium exposure beyond those taken into account in multi‐variable analyses. In addition, no evidence of a dose‐response relation between selenium status and cancer risk emerged. Certainty of evidence was very low for each outcome. Some studies suggested that genetic factors might modify the relation between selenium and cancer risk ‐ an issue that merits further investigation. </p> </section> <section id="CD005195-sec-0007"> <h3 class="title" id="CD005195-sec-0007">Authors' conclusions</h3> <p>Well‐designed and well‐conducted RCTs have shown no beneficial effect of selenium supplements in reducing cancer risk (high certainty of evidence). Some RCTs have raised concerns by reporting a higher incidence of high‐grade prostate cancer and type 2 diabetes in participants with selenium supplementation. No clear evidence of an influence of baseline participant selenium status on outcomes has emerged in these studies. </p> <p>Observational longitudinal studies have shown an inverse association between selenium exposure and risk of some cancer types, but null and direct relations have also been reported, and no systematic pattern suggesting dose‐response relations has emerged. These studies suffer from limitations inherent to the observational design, including exposure misclassification and unmeasured confounding. </p> <p>Overall, there is no evidence to suggest that increasing selenium intake through diet or supplementation prevents cancer in humans. However, more research is needed to assess whether selenium may modify the risk of cancer in individuals with a specific genetic background or nutritional status, and to investigate possible differential effects of various forms of selenium. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005195-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005195-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005195-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005195-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005195-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005195-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005195-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD005195-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD005195-abs-0014">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005195-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005195-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005195-abs-0003" lang="en"> <h3>Selenium for preventing cancer</h3> <p><b>Review question</b><br/> We reviewed the evidence investigating the relation between selenium intake and cancer prevention. This review updates the most recent Cochrane review on this topic (<a href="http://Vinceti 2014" target="_blank">Vinceti 2014)</a>, which was an update of <a href="http://Dennert 2011" target="_blank">Dennert 2011</a>. </p> <p><b>Background</b><br/> Selenium is a naturally occurring element that individuals are exposed to mainly through food consumption, although exposure can also occur through air, drinking water, and dietary supplements. Small amounts of selenium are essential for certain biological functions in humans, but slightly higher amounts can pose a toxicity risk, making selenium an element with a narrow, but as yet not well‐defined, safe range of exposure. Selenium occurs in many different chemical forms with different biological activity. From the late 1960s, a few observational studies reported that people with high levels of selenium in their diet or in their body tissues had lower risk of cancer, and some laboratory studies showed that selenium could inhibit the growth of cancer cells. This led to widespread interest in selenium supplements and claims that taking such supplements could prevent cancer. Since that time, many more observational studies have been conducted to compare cancer rates among individuals with high and low selenium exposure. More recently, several randomised controlled trials designed to assess whether selenium supplementation can prevent cancer have been carried out. These trials played a major role in enhancing our understanding of the relation between selenium and cancer risk as a result of their stronger study design as compared with observational studies. The most recent trials in particular have shown high methodological quality and statistical power. Several trials focused on whether selenium could prevent prostate cancer. </p> <p><b>Study characteristics</b><br/> This review includes 10 trials in which adults were randomly assigned to receive selenium supplements or placebo, and 70 observational studies in which adults were followed over time to determine whether their baseline selenium status was associated with their risk of cancer. The evidence is current to January 2017. </p> <p><b>Key results</b><br/> All of the high‐quality randomised trials reported no effect of selenium on reducing overall risk of cancer or risk of particular cancers, including the most investigated outcome ‐ prostate cancer. Some trials unexpectedly suggested that selenium may increase risks of high‐grade prostate cancer, type 2 diabetes, and dermatological abnormalities. </p> <p>Observational studies have yielded inconsistent evidence of a possible effect of selenium exposure on cancer risk, with no evidence of a dose‐response relation. When we pooled results of these studies, overall they suggested an inverse relation between cancer exposure and subsequent incidence of any cancer or some specific cancers, such as colon and prostate cancer. However, observational studies have major weaknesses. The selenium exposure status of participants could have been misclassified owing to limitations of the indicators of selenium exposure used, as well as to uncertainty regarding the particular selenium species contributing to overall exposure. In addition, unmeasured confounding from lifestyle or nutritional factors ‐ a major and well‐known source of bias in nutritional epidemiology studies of observational design ‐ could have been present. Therefore, the internal validity of these studies is limited. </p> <p>Currently, the hypothesis that increasing selenium intake may reduce cancer risk is not supported by epidemiological evidence. Additional research is needed to assess whether selenium may affect the risk of cancer in individuals with specific genetic backgrounds or nutritional status, and to determine how the various chemical forms of selenium compounds may have different effects on cancer risk. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005195-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005195-sec-0116"></div> <h3 class="title" id="CD005195-sec-0117">Implications for practice</h3> <section id="CD005195-sec-0117"> <p>A large body of evidence is now available from high‐quality randomised controlled trials on effects of selenium supplementation on cancer risk, with two new studies published since the last version of this review (<a href="./references#CD005195-bbs2-0314" title="VincetiM , DennertG , CrespiCM , ZwahlenM , BrinkmanM , ZeegersMP , et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005195.pub3; PUBMED: 24683040] ">Vinceti 2014</a>). None of the new relevant studies have provided information to change the conclusions of the previous version of this review. Overall, results of these studies have consistently shown no effect of selenium in preventing the type of cancer most consistently and strongly associated with antecedent selenium exposure ‐ prostate cancer ‐ or in preventing cancer overall, even when assessment focused on participants with the lowest selenium status at baseline. These intervention studies have suggested that selenium administration on the order of 200 µg/d increased risk of non‐melanoma skin cancer, advanced prostate cancer (in individuals with highest baseline exposure), dermatological abnormalities, and type 2 diabetes. No trial involving administration of low doses of selenium, on the order of 50 to 100 µg/d, has been performed so far. </p> <p>An update of the meta‐analysis of observational cohort studies continues to show lower risk of cancer and of some specific cancers (colorectal, prostate, and breast) in participants with highest exposure levels at baseline, but these studies are at substantial risk of bias from exposure misclassification and unmeasured confounding. In addition, results of these observational studies are inconsistent and sometimes are strongly conflicting, and no evidence of any dose‐response relation emerged from our analysis when we considered background selenium status or differences in baseline selenium exposure. </p> <p>Overall, findings of our review do not provide evidence supporting a cancer–preventive effect of selenium in humans. </p> </section> <h3 class="title" id="CD005195-sec-0118">Implications for research</h3> <section id="CD005195-sec-0118"> <p>Some questions regarding selenium, such as whether selenium might influence cancer risk in individuals with very low or very high baseline exposure to this element, or in individuals with different genotypes, have not been fully resolved, although currently available evidence from randomised trials offers little support for such hypotheses. For ethical reasons, in the light of potential toxicity of selenium supplementation and failure of the most recent and well‐conducted experimental cohort studies to find beneficial effects, new randomised trials on the selenium and cancer relation are unlikely to be undertaken in the future. Therefore expanding results of the SELECT trial and of other high‐quality trials to examine additional outcomes such as liver cancer and non‐melanoma skin cancer, as recently happened for other outcomes (<a href="./references#CD005195-bbs2-0211" title="KryscioRJ , AbnerEL , Caban‐HoltA , LovellM , GoodmanP , DarkeAK , et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by vitamin E and selenium trial (preadvise). JAMA Neurology2017;74(5):567‐73. [PUBMED: 28319243] ">Kryscio 2017</a>; <a href="./references#CD005195-bbs2-0214" title="LanceP , AlbertsDS , ThompsonPA , FalesL , WangF , San JoseJ , et al. Colorectal adenomas in participants of the select randomized trial of selenium and vitamin E for prostate cancer prevention. Cancer Prevention Research2017;10(1):45‐54. [PUBMED: 27777235] ">Lance 2017</a>), and to analyse subgroups with specific characteristics (baseline selenium exposure and genetic factors), continues to appear to be the best available option for clarifying these issues. Unfortunately, most of these randomised controlled trials (RCTs), including the Selenium and Vitamin E Cancer Prevention Trial (SELECT), could not address possible sex differences because they enrolled only men. </p> <p>Finally, when interpreting the results of both intervention and observational studies, it must be taken into account that various chemical forms of selenium have very different nutritional and toxicological properties, and that almost all observational studies have assessed only total selenium exposure. Future observational studies would contribute to a better understanding of the selenium and cancer relation by including selenium speciation among their exposure assessment methods when evaluating cancer risk. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005195-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005195-sec-0029"></div> <div class="table" id="CD005195-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Participants in trials with low risk of bias<br/> <b>Setting:</b> out‐patient<br/> <b>Intervention:</b> highest selenium exposure<br/> <b>Comparison:</b> lowest selenium exposure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Without highest</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With highest</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any cancer risk<br/> No. of participants: 19,475<br/> (3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.93 to 1.10) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 0.99 (95% CI 0.86 to 1.14). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1%<br/> (9.3 to 11.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1% more<br/> (0.7 fewer to 1 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cancer mortality risk<br/> No. of participants: 17,448<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.80 to 1.30) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The effect is led from the study SELECT. The RR in all RCTs is 0.81 (95% CI 0.49 to 1.32). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%<br/> (1.1 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% more<br/> (0.3 fewer to 0.4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Colorectal cancer risk<br/> No. of participants: 19,009<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/> (0.69 to 1.43) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 0.74 (95% CI 0.41 to 1.33). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7%<br/> (0.5 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/> (0.2 fewer to 0.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐melanoma skin cancer risk<br/> No. of participants: 2027<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.30 to 4.42) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pooled estimate is imprecise owing to high heterogeneity. The RR in all RCTs is 1.23 (95% CI 0.73 to 2.08). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%<br/> (0.9 to 12.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% more<br/> (2 fewer to 10 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lung cancer risk<br/> No. of participants: 19,009<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.89 to 1.50) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The RR in all RCTs is 1.03 (95% CI 0.78 to 1.37).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2%<br/> (0.9 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2% more<br/> (0.1 fewer to 0.5 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Breast cancer risk<br/> No. of participants: 802<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.04<br/> (0.44 to 9.55) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The RR in all RCTs is 1.44 (95% CI 0.96 to 2.17).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%<br/> (0.3 to 7.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8% more<br/> (0.4 fewer to 6.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bladder cancer risk<br/> No. of participants: 19,009<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.76 to 1.52) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 1.10 (95% CI 0.79 to 1.52). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7%<br/> (0.5 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/> (0.2 fewer to 0.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate cancer risk<br/> No. of participants: 18,942<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.90 to 1.14) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 0.91 (95% CI 0.75 to 1.12). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4%<br/> (4.8 to 6.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1% more<br/> (0.5 fewer to 0.8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SELECT: Selenium and Vitamin E Cancer Prevention Trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for moderate heterogeneity (tau² = 0.69, I² = 72%, P = 0.06) not explained.<br/> <sup>b</sup>Downgraded one level owing to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005195-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Highest compared with lowest selenium exposure for preventing cancer in observational studies</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Highest compared with lowest selenium exposure for preventing cancer in observational studies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Patient or population:</b> Participants in non experimental cohort studies on selenium and cancer<br/> <b>Setting:</b> out‐patient<br/> <b>Intervention:</b> highest selenium exposure<br/> <b>Comparison:</b> lowest selenium exposure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any cancer risk</p> <p>No. of participants: 76,239<br/> (7 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.72<br/> (0.55 to 0.93) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer mortality risk</p> <p>No. of participants: 183,863<br/> (7 observational studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>OR 0.76</p> <p>(0.59 to 0.97)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colorectal cancer risk</p> <p>No. of participants: 712,746<br/> (6 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.82<br/> (0.72 to 0.94) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung cancer risk</p> <p>No. of participants: 371,067<br/> (11 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.82<br/> (0.59 to 1.14) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast cancer risk (women)</p> <p>No. of participants: 169,028<br/> (8 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 1.09<br/> (0.87 to 1.37) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bladder cancer risk</p> <p>No. of participants: 279,100<br/> (5 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.67<br/> (0.46 to 0.97) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate cancer risk</p> <p>No. of participants: 576,667<br/> (21 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.84<br/> (0.75 to 0.95) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>CI: confidence interval; OR: odds ratio.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level owing to risk of bias, which we deemed as serious because of inability to rule out unmeasured confounding, particularly from lifestyle or nutritional factors that might covary with selenium exposure beyond those factors taken into account in the multi‐variable analyses.<br/> <sup>b</sup>Downgraded one level for moderate heterogeneity (tau² = 0.19, I² = 66%, P = 0.0008) not explained.<br/> <sup>c</sup>Downgraded one level owing to imprecision.<br/> <sup>d</sup>Downgraded one level owing to potential presence of publication bias suggested by the funnel plot. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005195-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005195-sec-0030"></div> <p>This review is the third update of the Cochrane review titled "Selenium for preventing cancer" (<a href="./references#CD005195-bbs2-0313" title="DennertG , ZwahlenM , BrinkmanM , VincetiM , ZeegersMP , HorneberM . Selenium for preventing cancer. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD005195] ">Dennert 2011</a>; <a href="./references#CD005195-bbs2-0314" title="VincetiM , DennertG , CrespiCM , ZwahlenM , BrinkmanM , ZeegersMP , et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005195.pub3; PUBMED: 24683040] ">Vinceti 2014</a>). </p> <section id="CD005195-sec-0031"> <h3 class="title" id="CD005195-sec-0031">Description of the condition</h3> <p>Cancer is a leading cause of death worldwide (<a href="./references#CD005195-bbs2-0306" title="WHO . Cancer fact sheet. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed 6 November 2017). e. ">WHO 2017</a>). According to estimates of the International Agency for Cancer Research, 14.1 million people developed and 8.2 million died of cancer in 2012, and more than half of all new cases occurred in less developed regions of the world (<a href="./references#CD005195-bbs2-0195" title="IARC . In: StewartBW , WildCP editor(s). World Cancer Report 2014. Lyon, France: IARC Press, International Agency for Research on Cancer, 2014. ">IARC 2014</a>). </p> <p>The role of diet and nutrition in carcinogenesis and cancer prevention and the identification of nutritional factors and supplements with cancer preventive properties have been areas of active research for decades. Dietary factors that reduce cancer risk would clearly have major public health implications, but unfortunately, investigations into supplementation of various vitamins, trace elements, and other dietary constituents have typically yielded disappointing and even troubling results (<a href="./references#CD005195-bbs2-0150" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , KrsticG , WetterslevJ , et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD007469.pub2] ">Bjelakovic 2014</a>; <a href="./references#CD005195-bbs2-0170" title="FortmannSP , BurdaBU , SengerCA , LinJS , WhitlockEP . Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine2013;159(12):824‐34. ">Fortmann 2013</a>; <a href="./references#CD005195-bbs2-0181" title="GuallarE , StrangesS , MulrowC , AppelLJ , MillerERIII . Enough is enough: stop wasting money on vitamin and mineral supplements. Annals of Internal Medicine2013;159(2):850‐1. ">Guallar 2013</a>; <a href="./references#CD005195-bbs2-0258" title="RocourtCR , ChengWH . Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance?. Nutrients2013;5(4):1349‐65. ">Rocourt 2013</a>; <a href="./references#CD005195-bbs2-0265" title="SchwingshacklL , SchwedhelmC , HoffmannG , LampousiAM , KnuppelS , IqbalK , et al. Food groups and risk of all‐cause mortality: a systematic review and meta‐analysis of prospective studies. American Journal of Clinical Nutrition2017;105(6):1462‐73. [PUBMED: 28446499] ">Schwingshackl 2017</a>). Selenium is one of these nutritional factors (<a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>). </p> </section> <section id="CD005195-sec-0032"> <h3 class="title" id="CD005195-sec-0032">Description of the intervention</h3> <p>The element selenium has received considerable attention as a potential cancer preventive agent, at least in populations with low intake. Selenium is recognised as nutritionally essential for humans, but it is toxic at levels slightly higher than those required for health, with a narrow and still not well‐defined safe range of intake (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). Whether selenium provides various health benefits (including a cancer preventive effect) beyond its essential nutritional role continues to be a matter of debate (<a href="./references#CD005195-bbs2-0141" title="AllingstrupM , AfshariA . Selenium supplementation for critically ill adults. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003703.pub3] ">Allingstrup 2015</a>; <a href="./references#CD005195-bbs2-0152" title="BodnarM , KonieczkaP , NamiesnikJ . The properties, functions, and use of selenium compounds in living organisms. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2012;30(3):225‐52. ">Bodnar 2012</a>; <a href="./references#CD005195-bbs2-0153" title="Brigelius‐FloheR , FloheL . Selenium and redox signalling. Archives of Biochemistry and Biophysics2017;617:48‐59. [PUBMED: 27495740] ">Brigelius‐Flohe 2017</a>; <a href="./references#CD005195-bbs2-0170" title="FortmannSP , BurdaBU , SengerCA , LinJS , WhitlockEP . Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine2013;159(12):824‐34. ">Fortmann 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>; <a href="./references#CD005195-bbs2-0253" title="RaymanMP . Selenium and human health. Lancet2012;379(9822):1256‐68. ">Rayman 2012</a>; <a href="./references#CD005195-bbs2-0275" title="StrangesS , SieriS , VincetiM , GrioniS , GuallarE , LaclaustraM , et al. A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health2010;10:564. ">Stranges 2010;</a><a href="./references#CD005195-bbs2-0289" title="VincetiM , CrespiCM , BonviciniF , MalagoliC , FerranteM , MarmiroliS , et al. The need for a reassessment of the safe upper limit of selenium in drinking water. Science of the Total Environment2013;443:633‐42. ">Vinceti 2013a</a>; <a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>; <a href="./references#CD005195-bbs2-0292" title="VincetiM , MandrioliJ , BorellaP , MichalkeB , TsatsakisA , FinkelsteinY . Selenium neurotoxicity in humans: bridging laboratory and epidemiologic studies. Toxicology Letters2014; Vol. 230:295‐303. ">Vinceti 2014a</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>; <a href="./references#CD005195-bbs2-0300" title="VisserME , DuraoS , SinclairD , IrlamJH , SiegfriedN . Micronutrient supplementation in adults with HIV infection. Cochrane Database of Systematic Reviews2017;5:CD003650. [PUBMED: 28518221] ">Visser 2017</a>; <a href="./references#CD005195-bbs2-0307" title="WichmanJ , WintherKH , BonnemaSJ , HegedusL . Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta‐analysis. Thyroid2016;26(12):1681‐92. [PUBMED: 27702392] ">Wichman 2016</a>). Humans usually ingest this trace element with crop, animal products, fish, and seafood, and sometimes in supplements (<a href="./references#CD005195-bbs2-0193" title="HurstR , CollingsR , HarveyLJ , KingM , HooperL , BouwmanJ , et al. EURRECA‐estimating selenium requirements for deriving dietary reference values. Critical Reviews in Food Science and Nutrition2013;53(10):1077‐96. ">Hurst 2013a</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). </p> <p>Chemical forms and concentrations of selenium in environmental matrices, foods, drinking water, and other sources of exposure vary considerably (<a href="./references#CD005195-bbs2-0168" title="Fairweather‐TaitSJ , BaoY , BroadleyMR , CollingsR , FordD , HeskethJE , et al. Selenium in human health and disease. Antioxidants &amp; Redox Signaling2011;14(7):1337‐83. ">Fairweather‐Tait 2011</a>). Selenium species can be classified into organically bound selenium forms (e.g. selenomethionine, selenocysteine) and inorganic forms (e.g. selenate, selenite) (<a href="./references#CD005195-bbs2-0172" title="GammelgaardB , JacksonMI , Gabel‐JensenC . Surveying selenium speciation from soil to cell ‐ forms and transformations. Analytical and Bioanalytical Chemistry2011;399(5):1743‐63. ">Gammelgaard 2011</a>; <a href="./references#CD005195-bbs2-0303" title="WeekleyCM , AitkenJB , FinneyL , VogtS , WittingPK , HarrisHH . Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems. Nutrients2013;5(5):1734‐56. ">Weekley 2013</a>). Organically bound selenium is present in the large number of selenoproteins identified in living organisms including humans, although the exact activity of some of these proteins remains to be identified (<a href="./references#CD005195-bbs2-0153" title="Brigelius‐FloheR , FloheL . Selenium and redox signalling. Archives of Biochemistry and Biophysics2017;617:48‐59. [PUBMED: 27495740] ">Brigelius‐Flohe 2017</a>; <a href="./references#CD005195-bbs2-0185" title="HatfieldDL , TsujiPA , CarlsonBA , GladyshevVN . Selenium and selenocysteine: roles in cancer, health, and development. Trends in Biochemical Sciences2014;39(3):112‐20. ">Hatfield 2014</a>; <a href="./references#CD005195-bbs2-0213" title="LabunskyyVM , HatfieldDL , GladyshevVN . Selenoproteins: molecular pathways and physiological roles. Physiological Reviews2014;94(3):739‐77. [PUBMED: 24987004] ">Labunskyy 2014</a>). Selenium yeast refers to a selenium‐enriched yeast medium that usually contains selenium that is almost entirely organically bound, along with a high proportion of selenomethionine (<a href="./references#CD005195-bbs2-0151" title="BlockE , GlassRS , JacobsenNE , JohnsonS , KahakachchiC , KaminskiR , et al. Identification and synthesis of a novel selenium‐sulfur amino acid found in selenized yeast: rapid indirect detection NMR methods for characterizing low‐level organoselenium compounds in complex matrices. Journal of Agricultural and Food Chemistry2004;52(12):3761‐71. ">Block 2004</a>; <a href="./references#CD005195-bbs2-0250" title="RaymanMP . The use of high‐selenium yeast to raise selenium status: how does it measure up?. British Journal of Nutrition2004;92(4):557‐73. ">Rayman 2004</a>). </p> <p>Recommended intake of selenium varies considerably among different regulatory agencies and scientific authorities (<a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). For example, the USA Institute of Medicine recommends daily intake of 55 µg/d for adults (<a href="./references#CD005195-bbs2-0196" title="Institute of Medicine. Dietary reference intakes: elements. http://www.iom.edu/Object.File/Master/54/395/DRIs.Elements.pdf (accessed 18 May 2009). ">Institute of Medicine 2009</a>), whereas the World Health Organization (WHO) recommends amounts ranging from 25 to 34 µg/d, depending on age and sex (<a href="./references#CD005195-bbs2-0305" title="Joint FAO/WHO Expert Consultation on HumanVitamin , MineralRequirements . Vitamin and mineral requirements in human nutrition: report of a joint FAO/WHO expert consultation; Bangkok, Thailand; 21‐30 September 1998. http://whqlibdoc.who.int/publications/2004/9241546123.pdf (accessed 9 March 2011). World Health Organization (WHO), 2004. ">WHO 2004</a>). More generally, international bodies have recommended amounts ranging from 25 to 70 µg/d for the adult population (<a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). The main reason for these differences in recommendations is the differing value and weight given to the proteomic effects of selenium, in particular whether or not selenoproteins sensitive to selenium supply must be up regulated to their maximal level, and whether any adverse health effects may arise at lower selenium intakes than those required to maximise selenoprotein expression (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). In addition, these standards generally do not take into account the chemical forms nor the source of selenium (diet, drinking water, air, etc.), despite established relevance of selenium speciation in addressing and assessing the health effects of this element (<a href="./references#CD005195-bbs2-0289" title="VincetiM , CrespiCM , BonviciniF , MalagoliC , FerranteM , MarmiroliS , et al. The need for a reassessment of the safe upper limit of selenium in drinking water. Science of the Total Environment2013;443:633‐42. ">Vinceti 2013a</a>; <a href="./references#CD005195-bbs2-0291" title="VincetiM , SolovyevN , MandrioliJ , CrespiCM , BonviciniF , ArcolinE , et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology2013;38:25‐32. ">Vinceti 2013c</a>; <a href="./references#CD005195-bbs2-0303" title="WeekleyCM , AitkenJB , FinneyL , VogtS , WittingPK , HarrisHH . Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems. Nutrients2013;5(5):1734‐56. ">Weekley 2013</a>; <a href="./references#CD005195-bbs2-0299" title="VincetiM , ChiariA , EichmüllerM , RothmanKJ , FilippiniT , MalagoliC , et al. A selenium species in cerebrospinal fluid predicts conversion to Alzheimer'sdementia in persons with mild cognitive impairment. Alzheimers Res Ther2017;9(1):100. ">Vinceti 2017d</a>). </p> <p>To prevent adverse effects due to excessive selenium intake, the USA Institute of Medicine has set the tolerable upper intake level at 400 µg/d for adults (<a href="./references#CD005195-bbs2-0238" title="Office of Dietary Supplements, NIH Clinical Centers, National Institutes of Health. Dietary Supplement Fact Sheet: Selenium. http://ods.od.nih.gov/factsheets/selenium.asp (accessed 18 May 2009). ">Office of Dietary Supplements 2009</a>). However, recent epidemiological studies suggest overt human toxicity at lower intake levels (Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>; <a href="./references#CD005195-bbs2-0274" title="StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">Stranges 2007</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>), and lower upper safe levels have already been proposed (<a href="./references#CD005195-bbs2-0282" title="Tsubota‐UtsugiM , ImaiE , NakadeM , Tsuboyama‐KasaokaN , MoritaA , TokudomeS . Dietary Reference Intakes for Japanese: the summary report from the Scientific Committee of “Dietary Reference intakes for Japanese 2010”. National Institute of Health and Nutrition (http://www.mhlw.go.jp/bunya/kenkou/sessyu‐kijun.html [Report in Japanese] 2012). ">Tsubota‐Utsugi 2012</a>). In addition to the acute and chronic toxicity of high selenium exposure, possible harmful effects of long‐term overexposure to lower dosages have been a matter of concern. However, these effects, such as those affecting the endocrine system, remain inadequately investigated (<a href="./references#CD005195-bbs2-0286" title="VincetiM , WeiET , MalagoliC , BergomiM , VivoliG . Adverse health effects of selenium in humans. Reviews on Environmental Health2001;16(4):233‐51. ">Vinceti 2001</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). Furthermore, evidence shows different biological activities of the various organic and inorganic forms of selenium (<a href="./references#CD005195-bbs2-0186" title="Hazane‐PuchF , ChampelovierP , ArnaudJ , GarrelC , BallesterB , FaureP , et al. Long‐term selenium supplementation in HaCaT cells: importance of chemical form for antagonist (protective versus toxic) activities. Biological Trace Elements Research2013;154(2):288‐98. ">Hazane‐Puch 2013</a>; <a href="./references#CD005195-bbs2-0220" title="MandrioliJ , MichalkeB , SolovyevN , GrillP , VioliF , LunettaC , et al. Elevated levels of selenium species in cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease‐associated gene mutations. Neuro‐degenerative Diseases2017;17(4‐5):171‐80. [PUBMED: 28478440] ">Mandrioli 2017</a>; <a href="./references#CD005195-bbs2-0291" title="VincetiM , SolovyevN , MandrioliJ , CrespiCM , BonviciniF , ArcolinE , et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology2013;38:25‐32. ">Vinceti 2013c</a>; <a href="./references#CD005195-bbs2-0299" title="VincetiM , ChiariA , EichmüllerM , RothmanKJ , FilippiniT , MalagoliC , et al. A selenium species in cerebrospinal fluid predicts conversion to Alzheimer'sdementia in persons with mild cognitive impairment. Alzheimers Res Ther2017;9(1):100. ">Vinceti 2017d</a>; <a href="./references#CD005195-bbs2-0303" title="WeekleyCM , AitkenJB , FinneyL , VogtS , WittingPK , HarrisHH . Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems. Nutrients2013;5(5):1734‐56. ">Weekley 2013</a>), emphasising the need to better characterise the specific toxicological and nutritional properties of each selenium species in humans, in animals, and in the environment. Recent publications have questioned the adequacy of the current upper safe limit of intake (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>; <a href="./references#CD005195-bbs2-0202" title="Jerome‐MoraisA , DiamondAM , WrightME . Dietary supplements and human health: for better or for worse?. Molecular Nutrition &amp; Food Research2011;55(1):122‐35. ">Jerome‐Morais 2011</a>; <a href="./references#CD005195-bbs2-0221" title="MarschallTA , KroepflN , JensenKB , BornhorstJ , MeermannB , KuehneltD , et al. Tracing cytotoxic effects of small organic Se species in human liver cells back to total cellular Se and Se metabolites. Metallomics : Integrated Biometal Science2017;9(3):268‐77. [PUBMED: 28184394] ">Marschall 2017</a>; <a href="./references#CD005195-bbs2-0230" title="MorrisJS , CraneSB . Selenium toxicity from a misformulated dietary supplement, adverse health effects, and the temporal response in the nail biologic monitor. Nutrients2013;5(4):1024‐57. ">Morris 2013</a>; <a href="./references#CD005195-bbs2-0231" title="MoyadMA . Heart healthy=prostate healthy: SELECT, the symbolic end of preventing prostate cancer via heart unhealthy and over anti‐oxidation mechanisms?. Asian Journal of Andrology2012;14(2):243‐4. ">Moyad 2012</a>; <a href="./references#CD005195-bbs2-0258" title="RocourtCR , ChengWH . Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance?. Nutrients2013;5(4):1349‐65. ">Rocourt 2013</a>; <a href="./references#CD005195-bbs2-0261" title="SaccoJE , DoddKW , KirkpatrickSI , TarasukV . Voluntary food fortification in the United States: potential for excessive intakes. European Journal of Clinical Nutrition2013;67(6):592‐7. ">Sacco 2013</a>; <a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>) and have espoused the need to set different limits for the many different sources of organic and inorganic selenium. On the other hand, other investigators have described claims of widespread deficient intake of selenium (<a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a>). </p> <p>Accurate estimation of selenium exposure in epidemiological studies presents several challenges. Individual exposure is typically assessed by using peripheral biomarkers of exposure, such as blood (usually plasma or serum) or nail concentrations, or by estimating dietary intake (<a href="./references#CD005195-bbs2-0143" title="AshtonK , HooperL , HarveyLJ , HurstR , CasgrainA , Fairweather‐TaitSJ . Methods of assessment of selenium status in humans: a systematic review. American Journal of Clinical Nutrition2009;89(6):2025S‐39S. ">Ashton 2009</a>). Each of these methods has strengths and limitations and has had its validity questioned (<a href="./references#CD005195-bbs2-0143" title="AshtonK , HooperL , HarveyLJ , HurstR , CasgrainA , Fairweather‐TaitSJ . Methods of assessment of selenium status in humans: a systematic review. American Journal of Clinical Nutrition2009;89(6):2025S‐39S. ">Ashton 2009</a>; <a href="./references#CD005195-bbs2-0184" title="HaldimannM , VennerTY , ZimmerliB . Determination of selenium in the serum of healthy Swiss adults and correlation to dietary intake. Journal of Trace Elements in Medicine and Biology1996;10(1):31‐45. ">Haldimann 1996</a>; <a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>). However, levels of selenium in peripheral biomarkers such as blood, toenail, and hair have been found to correlate to a moderate degree with dietary intake as assessed through self‐reported consumption of supplements, food frequency questionnaires, and dietary records (<a href="./references#CD005195-bbs2-0193" title="HurstR , CollingsR , HarveyLJ , KingM , HooperL , BouwmanJ , et al. EURRECA‐estimating selenium requirements for deriving dietary reference values. Critical Reviews in Food Science and Nutrition2013;53(10):1077‐96. ">Hurst 2013a</a>; <a href="./references#CD005195-bbs2-0218" title="LongneckerMP , StramDO , TaylorPR , LevanderOA , HoweM , VeillonC , et al. Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology1996;7(4):384‐90. ">Longnecker 1996</a>; <a href="./references#CD005195-bbs2-0239" title="OvaskainenML , VirtamoJ , AlfthanG , HaukkaJ , PietinenP , TaylorPR , et al. Toenail selenium as an indicator of selenium intake among middle‐aged men in an area with low soil selenium. American Journal of Clinical Nutrition1993;57(5):662‐5. ">Ovaskainen 1993</a>; <a href="./references#CD005195-bbs2-0244" title="PestitschekM , Sonneck‐KoenneC , ZakaviSR , LiS , KnollP , MirzaeiS . Selenium intake and selenium blood levels: a novel food frequency questionnaire. Wiener Klinische Wochenschrift2013;125(5‐6):160‐4. ">Pestitschek 2013</a>; <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a>). Stronger correlation has been seen at high intake levels (<a href="./references#CD005195-bbs2-0230" title="MorrisJS , CraneSB . Selenium toxicity from a misformulated dietary supplement, adverse health effects, and the temporal response in the nail biologic monitor. Nutrients2013;5(4):1024‐57. ">Morris 2013</a>), although results of some studies were not consistent (<a href="./references#CD005195-bbs2-0192" title="HunterDJ , MorrisJS , ChuteCG , KushnerE , ColditzGA , StampferMJ , et al. Predictors of selenium concentration in human toenails. American Journal of Epidemiology1990;132(1):114‐22. ">Hunter 1990</a>; <a href="./references#CD005195-bbs2-0208" title="KaritaK , SasakiS , IshiharaJ , TsuganeS . Validity of a self‐administered food frequency questionnaire used in the 5‐year follow‐up survey of the JPHC Study to assess selenium intake: comparison with dietary records and blood levels. Journal of Epidemiology2003;13(1 Suppl):S92‐7. ">Karita 2003</a>; <a href="./references#CD005195-bbs2-0263" title="SatiaJA , KingIB , MorrisJS , StrattonK , WhiteE . Toenail and plasma levels as biomarkers of selenium exposure. Annals of Epidemiology2006;16(1):53‐8. ">Satia 2006</a>; <a href="./references#CD005195-bbs2-0288" title="VincetiM , CrespiCM , MalagoliC , BottecchiI , FerrariA , SieriS , et al. A case‐control study of the risk of cutaneous melanoma associated with three selenium exposure indicators. Tumori2012;98(3):287‐95. ">Vinceti 2012</a>). Assessment of selenium levels in specific body tissues is extremely complex, as these levels are not necessarily homogeneously reflected by all biomarkers because overall selenium exposure, as well as its chemical forms and other factors, influences distribution of the metalloid into various body compartments (<a href="./references#CD005195-bbs2-0146" title="BehneD , GessnerH , KyriakopoulosA . Information on the selenium status of several body compartments of rats from the selenium concentrations in blood fractions, hair and nails. Journal of Trace Elements in Medicine and Biology1996;103:174‐9. ">Behne 1996</a>; <a href="./references#CD005195-bbs2-0147" title="BehneD , AlberD , KyriakopoulosS . Long‐term selenium supplementation of humans: selenium status and relationships between selenium concentrations in skeletal muscle and indicator materials. Journal of Trace Elements in Medicine and Biology2010;24(2):99‐105. ">Behne 2010</a>; <a href="./references#CD005195-bbs2-0240" title="PanterKE , HartleyWJ , JamesLF , MaylandHF , StegelmeierBL , KechelePO . Comparative toxicity of selenium from seleno‐DL‐methionine, sodium selenate, and Astragalus bisulcatus in pigs. Fundamental and Applied Toxicology1996;32(2):217‐23. ">Panter 1996</a>; <a href="./references#CD005195-bbs2-0285" title="VincetiM , RovestiS , BergomiM , VivoliG . The epidemiology of selenium and human cancer. Tumori2000;86(2):105‐18. ">Vinceti 2000</a>; <a href="./references#CD005195-bbs2-0291" title="VincetiM , SolovyevN , MandrioliJ , CrespiCM , BonviciniF , ArcolinE , et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology2013;38:25‐32. ">Vinceti 2013c</a>). For example, circulating levels of some selenium species and of total selenium did not correlate with selenium content in the central nervous system as assessed by cerebrospinal fluid concentrations (<a href="./references#CD005195-bbs2-0271" title="SolovyevN , BertheleA , MichalkeB . Selenium speciation in paired serum and cerebrospinal fluid samples. Analytical and Bioanalytical Chemistry2013;405(6):1875‐84. ">Solovyev 2013</a>; <a href="./references#CD005195-bbs2-0291" title="VincetiM , SolovyevN , MandrioliJ , CrespiCM , BonviciniF , ArcolinE , et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology2013;38:25‐32. ">Vinceti 2013c</a>), indicating both the tissue‐specific significance of biomarkers and the importance of selenium speciation when the distribution of selenium in different body compartments, representing target organs for different diseases, is assessed. </p> <p>Selenium levels found in human specimens and characterising intake of selenium show high global variability due to variation in factors such as dietary habits, food and soil selenium content, ethnicity, sex, age, individual metabolism, occupational exposure, exposure to coal and other sources of combustion, and smoking (<a href="./references#CD005195-bbs2-0168" title="Fairweather‐TaitSJ , BaoY , BroadleyMR , CollingsR , FordD , HeskethJE , et al. Selenium in human health and disease. Antioxidants &amp; Redox Signaling2011;14(7):1337‐83. ">Fairweather‐Tait 2011</a>; <a href="./references#CD005195-bbs2-0184" title="HaldimannM , VennerTY , ZimmerliB . Determination of selenium in the serum of healthy Swiss adults and correlation to dietary intake. Journal of Trace Elements in Medicine and Biology1996;10(1):31‐45. ">Haldimann 1996</a>; <a href="./references#CD005195-bbs2-0197" title="JablonskaE , GromadzinskaJ , KlosA , BertrandtJ , SkibniewskaK , DaragoA , et al. Selenium, zinc and copper in the Polish diet. Journal of Food Composition and Analysis2013;31(2):259–65. ">Jablonska 2013</a>; <a href="./references#CD005195-bbs2-0251" title="RaymanMP . Food‐chain selenium and human health: emphasis on intake. British Journal of Nutrition2008;100(2):254‐68. ">Rayman 2008</a>). It is interesting to note that smoking tends to lower selenium biomarker concentrations, even though smoking is a source of selenium exposure ‐ a phenomenon that might be related to increased excretion of the metalloid due to interaction with cadmium or other heavy metals (<a href="./references#CD005195-bbs2-0203" title="JossaF , TrevisanM , KroghV , FarinaroE , GiumettiD , FuscoG , et al. Serum selenium and coronary heart disease risk factors in southern Italian men. Atherosclerosis1991;87(2‐3):129‐34. ">Jossa 1991</a>; <a href="./references#CD005195-bbs2-0204" title="KafaiMR , GanjiV . Sex, age, geographical location, smoking, and alcohol consumption influence serum selenium concentrations in the USA: third National Health and Nutrition Examination Survey, 1988‐1994. Journal of Trace Elements in Medicine and Biology2003;17(1):13‐8. ">Kafai 2003</a>). Globally, inconsistencies have been noted as to how these factors are associated with selenium levels (<a href="./references#CD005195-bbs2-0184" title="HaldimannM , VennerTY , ZimmerliB . Determination of selenium in the serum of healthy Swiss adults and correlation to dietary intake. Journal of Trace Elements in Medicine and Biology1996;10(1):31‐45. ">Haldimann 1996</a>; <a href="./references#CD005195-bbs2-0285" title="VincetiM , RovestiS , BergomiM , VivoliG . The epidemiology of selenium and human cancer. Tumori2000;86(2):105‐18. ">Vinceti 2000</a>). For example, selenium levels increased with age in women, but not in men, in the French SU.VI.M.AX cohort study (<a href="./references#CD005195-bbs2-0142" title="ArnaudJ , ArnaultN , RousselAM , BertraisS , RuffieuxD , GalanP , et al. Relationships between selenium, lipids, iron status and hormonal therapy in women of the SU.VI.M.AX cohort. Journal of Trace Elements in Medicine and Biology2007;21(Suppl 1):66‐9. ">Arnaud 2007</a>), but decreased with age in a female population in Ohio (<a href="./references#CD005195-bbs2-0270" title="SmithAM , ChangMP , MedeirosLC . Generational differences in selenium status of women. Biological Trace Element Research2000;75(1‐3):157‐65. ">Smith 2000</a>); however, two studies in Switzerland and Austria could not find an association between age and selenium status among individuals of either sex (<a href="./references#CD005195-bbs2-0157" title="BurriJ , HaldimannM , DudlerV . Selenium status of the Swiss population: assessment and change over a decade. Journal of Trace Elements in Medicine and Biology2008;22(2):112‐9. ">Burri 2008</a>; <a href="./references#CD005195-bbs2-0182" title="GundackerC , KomarnickiG , ZodlB , ForsterC , SchusterE , WittmannK . Whole blood mercury and selenium concentrations in a selected Austrian population: does gender matter?. Science of the Total Environment2006;372(1):76‐86. ">Gundacker 2006</a>). Sex‐specific nutritional and health behaviours, as well as sex‐specific differences in selenium metabolism and distribution across various body compartments, may contribute to observed discrepancies in selenium levels between men and women (<a href="./references#CD005195-bbs2-0161" title="CombsGFJr , JacksonMI , WattsJC , JohnsonLK , ZengH , IdsoJ , et al. Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. British Journal of Nutrition2012;107(10):1514‐25. ">Combs 2012</a>; <a href="./references#CD005195-bbs2-0259" title="Rodriguez RodriguezEM , Sanz AlaejosMT , Diaz RomeroC . Urinary selenium status of healthy people. European Journal of Clinical Chemistry and Clinical Biochemistry1995;33(3):127‐33. ">Rodriguez 1995</a>). </p> </section> <section id="CD005195-sec-0033"> <h3 class="title" id="CD005195-sec-0033">How the intervention might work</h3> <p>The ability of selenium to counteract cancer cell growth as observed in a large number of laboratory studies may be due to its effects on DNA stability, cell proliferation, necrotic and apoptotic cell death in healthy and malignant cells, and/or regulation of oxidative stress and the immune system (for reviews, see: <a href="./references#CD005195-bbs2-0169" title="FernandesAP , GandinV . Selenium compounds as therapeutic agents in cancer. Biochimica et Biophysica Acta2015;1850(8):1642‐60. [PUBMED: 25459512] ">Fernandes 2015</a>; <a href="./references#CD005195-bbs2-0228" title="MisraS , BoylanM , SelvamA , SpallholzJE , BjornstedtM . Redox‐active selenium compounds ‐ from toxicity and cell death to cancer treatment. Nutrients2015;7(5):3536‐56. [PUBMED: 25984742] ">Misra 2015</a>). These abilities have suggested the possible utility of selenium compounds not only for cancer prevention but also for cancer therapy ‐ a hypothesis that has been under active investigation (<a href="./references#CD005195-bbs2-0148" title="BhattacharjeeA , BasuA , BiswasJ , SenT , BhattacharyaS . Chemoprotective and chemosensitizing properties of selenium nanoparticle (Nano‐Se) during adjuvant therapy with cyclophosphamide in tumor‐bearing mice. Molecular and Cellular Biochemistry2017;424(1‐2):13‐33. [PUBMED: 27696310] ">Bhattacharjee 2017</a>; <a href="./references#CD005195-bbs2-0267" title="ShigemiZ , ManabeK , HaraN , BabaY , HosokawaK , KagawaH , et al. Methylseleninic acid and sodium selenite induce severe ER stress and subsequent apoptosis through UPR activation in PEL cells. Chemico‐biological Interactions2017;266:28‐37. [PUBMED: 28161410] ">Shigemi 2017</a>; <a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). Selenium may be involved in cancer prevention through the antioxidant properties of selenoproteins (<a href="./references#CD005195-bbs2-0185" title="HatfieldDL , TsujiPA , CarlsonBA , GladyshevVN . Selenium and selenocysteine: roles in cancer, health, and development. Trends in Biochemical Sciences2014;39(3):112‐20. ">Hatfield 2014</a>; <a href="./references#CD005195-bbs2-0213" title="LabunskyyVM , HatfieldDL , GladyshevVN . Selenoproteins: molecular pathways and physiological roles. Physiological Reviews2014;94(3):739‐77. [PUBMED: 24987004] ">Labunskyy 2014</a>), as well as through several other mechanisms (<a href="./references#CD005195-bbs2-0169" title="FernandesAP , GandinV . Selenium compounds as therapeutic agents in cancer. Biochimica et Biophysica Acta2015;1850(8):1642‐60. [PUBMED: 25459512] ">Fernandes 2015</a>; <a href="./references#CD005195-bbs2-0228" title="MisraS , BoylanM , SelvamA , SpallholzJE , BjornstedtM . Redox‐active selenium compounds ‐ from toxicity and cell death to cancer treatment. Nutrients2015;7(5):3536‐56. [PUBMED: 25984742] ">Misra 2015;</a><a href="./references#CD005195-bbs2-0303" title="WeekleyCM , AitkenJB , FinneyL , VogtS , WittingPK , HarrisHH . Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems. Nutrients2013;5(5):1734‐56. ">Weekley 2013</a>). However, laboratory studies have shown that selenium can promote malignant cell transformation and progression (<a href="./references#CD005195-bbs2-0159" title="ChenX , MikhailSS , DingYW , YangG , BondocF , YangCS . Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats. Carcinogenesis2000;21(8):1531‐6. ">Chen 2000</a>; <a href="./references#CD005195-bbs2-0205" title="KandasNO , RandolphC , BoslandMC . Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutrition and Cancer2009;61(2):251‐64. ">Kandas 2009</a>; <a href="./references#CD005195-bbs2-0209" title="KasaikinaMV , TuranovAA , AvanesovA , SchweizerU , SeeherS , BronsonRT , et al. Contrasting roles of dietary selenium and selenoproteins in chemically induced hepatocarcinogenesis. Carcinogenesis2013;34(5):1089‐95. [PUBMED: 23389288] ">Kasaikina 2013</a>; <a href="./references#CD005195-bbs2-0234" title="National Toxicology Program. Selenium sulfide. Report on carcinogens: carcinogen profiles/U.S. Dept. of Health and Human Services, Public Health Service, National Toxicology Program2011;12:376‐7. ">National Toxicology Program 2011</a>; <a href="./references#CD005195-bbs2-0237" title="NovoselovSV , CalvisiDF , LabunskyyVM , FactorVM , CarlsonBA , FomenkoDE , et al. Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene2005;24(54):8003‐11. ">Novoselov 2005</a>; <a href="./references#CD005195-bbs2-0260" title="RoseAH , BertinoP , HoffmannFW , GaudinoG , CarboneM , HoffmannPR . Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors. American Journal of Pathology2014;184(4):1041‐9. ">Rose 2014</a>; <a href="./references#CD005195-bbs2-0277" title="SuYP , TangJM , TangY , GaoHY . Histological and ultrastructural changes induced by selenium in early experimental gastric carcinogenesis. World Journal of Gastroenterology2005;11(29):4457‐60. ">Su 2005</a>; <a href="./references#CD005195-bbs2-0283" title="TsujiPA , CarlsonBA , AndersonCB , SeifriedHE , HatfieldDL , HowardMT . Dietary selenium levels affect selenoprotein expression and support the interferon‐gamma and IL‐6 immune response pathways in mice. Nutrients2015;7(8):6529‐49. [PUBMED: 26258789] ">Tsuji 2015</a>), thus confirming the complex ‘dual personality’ of both this Janus‐faced element and selenoproteins in preventing and promoting cancer (<a href="./references#CD005195-bbs2-0185" title="HatfieldDL , TsujiPA , CarlsonBA , GladyshevVN . Selenium and selenocysteine: roles in cancer, health, and development. Trends in Biochemical Sciences2014;39(3):112‐20. ">Hatfield 2014</a>). </p> <p>In addition, numerous epidemiological studies of observational design, which have reported an inverse association between selenium exposure and cancer risk (<a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>), have provided support for the potential of selenium in cancer prevention. The first of these studies used an ecological study design (<a href="./references#CD005195-bbs2-0264" title="SchrauzerGN , WhiteDA , SchneiderCJ . Cancer mortality correlation studies ‐ III: statistical associations with dietary selenium intakes. Biological Chemistry1977;7(1):23‐31. ">Schrauzer 1977</a>; <a href="./references#CD005195-bbs2-0266" title="ShambergerRJ , FrostDV . Possible protective effect of selenium against human cancer. Canadian Medical Association Journal1969;100(14):682. ">Shamberger 1969</a>). These were followed by case‐control and cohort observational studies, then by randomised trials, some of which received substantial attention from both the general public and the scientific community (<a href="./references#CD005195-bbs2-0154" title="BrinkmanM , ReulenRC , KellenE , BuntinxF , ZeegersMP . Are men with low selenium levels at increased risk of prostate cancer?. European Journal of Cancer2006;42(15):2463‐71. ">Brinkman 2006</a>; <a href="./references#CD005195-bbs2-0170" title="FortmannSP , BurdaBU , SengerCA , LinJS , WhitlockEP . Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine2013;159(12):824‐34. ">Fortmann 2013</a>; <a href="./references#CD005195-bbs2-0273" title="SteinbrennerH , SpeckmannB , SiesH . Toward understanding success and failures in the use of selenium for cancer prevention. Antioxidants &amp; Redox Signaling2013;19(2):181‐91. ">Steinbrenner 2013</a>; <a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>). Some observational and experimental human studies have suggested that sex‐related differences regarding effects of selenium on cancer risk, as well as differences in selenium tissue distribution, tumour biology, and other factors, may explain the possibly greater beneficial effect of selenium for men than for women in the earliest studies (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0301" title="WatersDJ , ChiangEC , CooleyDM , MorrisJS . Making sense of sex and supplements: differences in the anticarcinogenic effects of selenium in men and women. Mutation Research2004;551(1‐2):91‐107. ">Waters 2004</a>). </p> </section> <section id="CD005195-sec-0034"> <h3 class="title" id="CD005195-sec-0034">Why it is important to do this review</h3> <p>Findings of laboratory studies and early epidemiological studies have led to the suggestion that selenium may be involved in central anticarcinogenic processes. This has resulted in widespread marketing of selenium supplements with associated health claims, particularly claims for prevention of cancer (<a href="./references#CD005195-bbs2-0313" title="DennertG , ZwahlenM , BrinkmanM , VincetiM , ZeegersMP , HorneberM . Selenium for preventing cancer. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD005195] ">Dennert 2011</a>; <a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>), as well as prevention of cardiovascular disease (<a href="./references#CD005195-bbs2-0254" title="ReesK , HartleyL , DayC , FlowersN , ClarkeA , StrangesS . Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2013;1:CD009671. ">Rees 2013</a>). However, accumulating evidence suggests that this early optimism may have been unwarranted (<a href="./references#CD005195-bbs2-0211" title="KryscioRJ , AbnerEL , Caban‐HoltA , LovellM , GoodmanP , DarkeAK , et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by vitamin E and selenium trial (preadvise). JAMA Neurology2017;74(5):567‐73. [PUBMED: 28319243] ">Kryscio 2017</a>; <a href="./references#CD005195-bbs2-0214" title="LanceP , AlbertsDS , ThompsonPA , FalesL , WangF , San JoseJ , et al. Colorectal adenomas in participants of the select randomized trial of selenium and vitamin E for prostate cancer prevention. Cancer Prevention Research2017;10(1):45‐54. [PUBMED: 27777235] ">Lance 2017</a>; <a href="./references#CD005195-bbs2-0219" title="LuJ , ZhangJ , JiangC , DengY , OztenN , BoslandMC . Cancer chemoprevention research with selenium in the post‐SELECT era: promises and challenges. Nutrition and Cancer2016;68(1):1‐17. [PUBMED: 26595411] ">Lu 2016</a>; <a href="./references#CD005195-bbs2-0247" title="RamamoorthyV , RubensM , SaxenaA , ShehadehN . Selenium and vitamin E for prostate cancer ‐ justifications for the SELECT study. Asian Pacific Journal of Cancer Prevention2015;16(7):2619‐27. [PUBMED: 25854337] ">Ramamoorthy 2015</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>; <a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). In particular, additional evidence on selenium and cancer risk gathered by high‐quality randomised controlled trials (RCTs) has become available in recent years, and a few observational studies have been published, thus justifying an update on epidemiological evidence regarding selenium exposure and cancer risk. We undertook this updated review to perform a comprehensive synthesis of current epidemiological evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005195-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005195-sec-0035"></div> <p>To gather and present evidence needed to address two research questions:.</p> <p> <ol id="CD005195-list-0001"> <li> <p>What is the aetiological relationship between selenium exposure and cancer risk in humans? </p> </li> <li> <p>Which is the efficacy of selenium supplementation for cancer prevention in humans?</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005195-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005195-sec-0036"></div> <section id="CD005195-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005195-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included published randomised controlled trials (RCTs) and observational studies of longitudinal design (i.e. cohort studies and nested case‐control studies), irrespective of publication status or language, provided they were published in extenso. We also included conference abstracts in this review when we were able to retrieve them through citation chasing (<a href="./references#CD005195-bbs2-0298" title="VincetiM , FilippiniT , CilloniS , PlattJ , JessC . Implications of different methods for literature searching and assessment in systematic reviews and meta‐analyses: a case study. Global Evidence Summit: Using evidence ‐ Improving lives; September 13‐16, 2017; Cape Town (Meeting Abstract). 2017. ">Vinceti 2017c</a>). </p> </section> <section id="CD005195-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adult participants (18 years of age and older).</p> </section> <section id="CD005195-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We considered RCTs for inclusion if they used selenium supplementation at any dose or route of administration for a minimum of four weeks versus placebo or no intervention. We excluded trials using selenium supplementation as part of a multi‐component preparation if they did not include a study arm using selenium monotherapy supplementation. </p> <p>We considered prospective observational studies (cohort studies and cohort‐nested and nested case‐control studies) for inclusion if they assessed baseline exposure to selenium in apparently cancer‐free individuals as a biomarker of selenium status or as dietary assessment of selenium intake at study entry, provided that such assessment was based on exposure categories ‐ not just on continuous values. </p> </section> <section id="CD005195-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We systematically analysed all (primary and secondary) outcomes.</p> <section id="CD005195-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005195-list-0002"> <li> <p>Incidence of any cancer and of site‐specific cancers, assessed as proportions of participants developing cancers during the study period. </p> </li> <li> <p>Mortality from any cancer and from site‐specific cancer, assessed as proportions of participants dying from cancers during the study period. </p> </li> </ol> </p> </section> <section id="CD005195-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005195-list-0003"> <li> <p>Incidence of selected adverse effects, assessed as proportions of participants developing adverse health conditions (RCTs only). </p> </li> </ol> </p> </section> </section> </section> <section id="CD005195-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>Using the search strategies described previously, we conducted updated electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE (Ovid, 2013 to January 2017, week 4), Embase (2013 to 2017, week 6), CancerLit (cancer literature database; February 2004), and Clinical Contents in Medicine (CCMed; February 2011). We conducted the initial search in 2004 and updated searches in July 2007, January 2009, October 2009, February 2011, February 2013, and February 2017. As MEDLINE now includes the journals indexed in CancerLit no further searches of this database were made after 2004. </p> <p>We also searched the following online clinical trials databases as in the previous review <a href="./references#CD005195-bbs2-0314" title="VincetiM , DennertG , CrespiCM , ZwahlenM , BrinkmanM , ZeegersMP , et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005195.pub3; PUBMED: 24683040] ">Vinceti 2014</a>. </p> <p> <ol id="CD005195-list-0004"> <li> <p>Clinical Trials of the American Cancer Society (<a href="http://www.cancer.gov" target="_blank">http://www.cancer.gov</a>; February 2011). </p> </li> <li> <p>metaRegister of Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">http://www.controlled‐trials.com</a>; February 2011). </p> </li> <li> <p>German Cancer Study Register (<a href="http://www.studien.de" target="_blank">http://www.studien.de</a>; February 2011). </p> </li> <li> <p>System for Information on Grey Literature in Europe (SIGLE) (February 2004, discontinued in 2005). </p> </li> <li> <p>International Standard Registered Clinical/Social Study Number (ISRCTN) registry (<a href="http://www.isrctn.com" target="_blank">http://www.isrctn.com</a>; February 2017). </p> </li> <li> <p>ClinicalTrials.gov registry (<a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a>; February 2017). </p> </li> </ol> </p> <p>We have provided the search strategies in <a href="./appendices#CD005195-sec-0122">Appendix 1</a>. </p> </section> <section id="CD005195-sec-0045"> <h3 class="title" id="CD005195-sec-0045">Data collection and analysis</h3> <section id="CD005195-sec-0046"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently checked all electronic search results for eligibility. When search results could not be rejected with certainty on the basis of title, abstract, or both, we obtained full‐text material. </p> <p>We scanned bibliographies of papers retrieved using the described search strategy to identify additional studies. When additional information was needed, we contacted the correspondent authors of included studies; we also asked investigators for information about unpublished RCTs. </p> <p>Two review authors (MV and TF) independently applied the inclusion and exclusion criteria, if necessary with the assistance of a translator. We resolved disagreements by discussion and with involvement of a third review author (CDG). </p> </section> <section id="CD005195-sec-0047"> <h4 class="title">Data extraction and management</h4> <p>We used piloted extraction forms for epidemiological studies and RCTs to document data from the original material and to assess the quality of studies. One review author (TF) extracted data, and two review authors (MV and CDG) checked extracted data for discrepancies, which the three review authors (TF, MV, and CDG) then discussed. If several reports from the same study were available, we considered as primary publications studies reporting the entire period of follow‐up with active selenium supplementation, when available, but we also extracted study details and results available from other publications, if they were not reported in the primary study reference. </p> <p>For comparison of selenium exposure measured in serum and plasma specimens, we converted all data into the unit µg/L. We converted results provided as ppm (parts per million) or µg/g by using the factor 1.026 g/mL (density of blood plasma), and we converted data provided as µmol/L using the factor 78.96 (atomic weight of selenium). </p> <p>For inclusion, prospective observational studies had to report estimates of risk ratio (RR), such as hazard ratio (HR) or odds ratio (OR), for various selenium category exposure levels. We did not include in the analysis studies reporting only the RR for a one‐unit increase in selenium exposure on a continuous scale. </p> </section> <section id="CD005195-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD005195-sec-0049"> <h5 class="title">Randomised controlled trials</h5> <p>We categorised generation of allocation sequence, allocation concealment, blinding, and completeness of outcome data as adequate (low risk of bias), inadequate (high risk of bias), or unclear, according to the criteria specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and Higgins et al (<a href="./references#CD005195-bbs2-0190" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>; <a href="./references#CD005195-bbs2-0191" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal2011;343:d5928. ">Higgins 2011b</a>). We considered these four items to be key domains for risk of bias assessment. We considered studies that were categorised as 'adequate' in all four domains to have low risk of bias; and studies with 'inadequate' procedures in one or more key domains to have high risk of bias. We considered studies with 'unclear' procedures in one or more key domains to have unclear risk of bias. </p> <p>We assessed fulfilment of ethical standards as follows.</p> <p> <ol id="CD005195-list-0005"> <li> <p>Was informed consent obtained from participants? (yes/no/unclear).</p> </li> <li> <p>Was approval obtained from an ethics board? (yes/no/unclear).</p> </li> </ol> </p> </section> <section id="CD005195-sec-0050"> <h5 class="title">Observational studies</h5> <p>We assessed risk of bias in observational studies by using assessment forms adapted from the Newcastle‐Ottawa Quality Assessment Scale (NOS) for cohort and case‐control studies (<a href="./references#CD005195-bbs2-0304" title="WellsGA , SheaB , O´ConnellD , PetersonJ , WelchV , LososM , et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Ottawa, (accessed 1 April 2004). ">Wells 2004</a>). We used the NOS form for cohort studies for all included observational studies, and the NOS case‐control form for nested case‐control studies. Both forms must be adapted a priori for use in a systematic review according to the research questions examined and the review topic explored. The NOS uses a star system by which studies are judged on key domains pertaining to selection and comparability of study groups, ascertainment of exposure and outcomes, and duration of follow‐up. For each domain, we assigned either a 'star' or 'no star', with a star indicating that study design element was considered adequate and was less likely to introduce bias. A study could receive a maximum of nine stars during the cohort assessment (<a href="./appendices#CD005195-sec-0123">Appendix 2</a>) and nine stars during assessment of the case‐control portion (<a href="./appendices#CD005195-sec-0124">Appendix 3</a>). </p> <p>The risk of bias assessment was based on data provided in the included publications. When relevant data for such assessment were missing, we tried to contact the trial authors to ask that they provide them. </p> </section> </section> <section id="CD005195-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>This review includes only the binary outcome of cancer diagnosis (i.e. cancer incidence) or death from cancer (i.e. cancer mortality), or a combination of both. We used the term 'cancer risk' in this paper as a generic term that refers generally to cancer incidence, cancer mortality, and combined incidence/mortality data. </p> <p>For RCTs, we used risk ratios (RRs) and their 95% confidence intervals (95% CIs). When hazard ratios (HRs) rather than RRs were reported in the original study, we reported individual study results as HRs along with their 95% CIs. </p> <p>For observational studies, we used odds ratios (ORs), risk ratios (RRs), or hazard ratios (HRs) and their corresponding 95% CIs as measures of association between cancer risk and selenium exposure. When adjusted estimates were reported, we used those with the most extensive covariate adjustment reported in the publication. </p> </section> <section id="CD005195-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing or when discrepancies in study publications were found, we tried to contact the study investigators to request further information. In most cases, review authors resolved the issues through collaboration; when no reply came from the trial authors, we did not use the corresponding data. </p> <p>When a study combined subgroups, only some of which fulfilled our eligibility criteria (e.g. including individuals not affected by cancer), or did not report enough information to be included in this update, we systematically contacted trial authors to ask that they provide the additional information. We are grateful to the several trial authors who agreed to provide these additional data. </p> </section> <section id="CD005195-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the Chi² test for heterogeneity and I² statistics to quantify heterogeneity of study results (<a href="./references#CD005195-bbs2-0188" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD005195-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>We evaluated the possibility of reporting bias by using funnel plots.</p> </section> <section id="CD005195-sec-0055"> <h4 class="title">Data synthesis</h4> <p>We performed data synthesis and analysis separately for RCTs and observational studies.</p> <p>For RCTs, we performed meta‐analyses for all cancers or site‐specific cancers when at least two trials could provide data, given their fundamental importance in epidemiological research. When more than one publication from the same trial was available and reported different periods of follow‐up for the same cancer site, we included in the meta‐analysis only the longest period of follow‐up, provided that the experimental protocol was ongoing at the time of follow‐up (i.e. that selenium supplementation was still actively supplied). We assessed the stability of effect estimates through their 95% or 99% confidence intervals. We included lack of precision of effect estimates among the factors used to downgrade the certainty (quality) of evidence generated by studies via the GRADE approach (<a href="http://www.gradeworkinggroup.org" target="_blank">www.gradeworkinggroup.org</a>). For RCTs, we considered pooled data from studies with low risk of bias as the primary analysis. </p> <p>For observational studies, the minimum number of studies for inclusion in the meta‐analysis was five, as in the previous version of the review. We applied this latter restriction not only to limit the number of analyses performed, but also because results were largely expected to be heterogeneous, and heterogeneity cannot be described and quantified adequately if too few studies are available (<a href="./references#CD005195-bbs2-0189" title="HigginsJPT , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society Series A (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). </p> <p>We calculated RRs and 95% CIs using numbers of participants and cases when these were provided in the publication and the meta‐analysis tool provided by <a href="./references#CD005195-bbs2-0255" title="Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. Review Manager 5 (RevMan 5) [Computer program]. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014, 2014. ">Review Manager 2014</a>; otherwise, we used RRs reported in the original publication, and, in particular, we selected RRs with the least adjustment for potential confounders. We used the same approach in calculating the RRs of adverse outcomes. We conducted random‐effects meta‐analyses of summary statistics for both observational studies and RCTs. For observational studies, we used the OR or RR comparing highest and lowest selenium exposure categories. We entered effect estimates as the natural logarithm of the OR or RR, and we used the squared standard error of the natural logarithm of the OR or RR as a weight. We calculated the latter from reported upper and lower boundaries of the 95% CI of the OR or RR. If a 95% CI was not reported, we used the total number of cases and the total number of controls, as well as the number of categories of selenium exposure, to estimate numbers of cases and controls per exposure category. We then used the standard normal approximation formula to calculate the standard error of the OR, comparing the highest versus the lowest exposure category (lnOR = (1/a + 1/b + 1/c + 1/d), where a, b, c, and d are the four counts needed to calculate the OR via (a*d)/(b*c)). For experimental studies, we computed the RR of cancer in the intervention group compared with that in the placebo group. For one study, which included more than one treatment (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), we used only results for the lowest dose (200 µg/d) for consistency with other studies. We conducted all meta‐analyses by using Review Manager 5.3.5 and Stata‐15 statistical tools. To do this, we copied logarithmic data for the OR and the standard error from Stata into Review Manager, then double‐checked results for errors. </p> </section> <section id="CD005195-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out a subgroup meta‐analysis for high‐quality RCTs while excluding from analysis all trials showing high or uncertain risk of bias. </p> <p>For observational studies, we used sex‐disaggregated data from mixed‐sex studies, together with data from single‐sex cohorts, to conduct subgroup analyses by sex. We also carried out subgroup analyses specific for baseline selenium status. For these analyses, we assessed the evidence for an exposure‐response relation by examining studies in ascending order from the bottom category of selenium exposure and by examining differences between highest and lowest exposure categories. </p> </section> <section id="CD005195-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>For RCTs, we considered risk estimates derived by pooling data from all studies, regardless of risk of bias, as part of a sensitivity analysis. </p> <p>For observational studies, we conducted sensitivity analyses to assess the effects of different methods used to assess selenium status (i.e. assessment of intake via dietary assessment methods or measurement of exposure biomarkers such as blood and toenail selenium content). </p> <section id="CD005195-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We presented the overall certainty (quality) of evidence for the risk of any cancer, cancer mortality, colorectal cancer, lung cancer, non‐melanoma skin cancer, breast cancer, bladder cancer, and prostate cancer from RCTs with low risk of bias. We also presented the overall certainty of evidence for these outcomes from observational studies, with the exception of non‐melanoma skin cancer. </p> <p>We evaluated the overall certainty of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD005195-bbs2-0178" title="GRADE Working Group 2004. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490–4. ">GRADE Working Group 2004</a>), which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results (<a href="./references#CD005195-bbs2-0215" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchunemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;23(2):81. ">Langendam 2013</a>). We created two 'Summary of findings' tables (<a href="./full#CD005195-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD005195-tbl-0002">summary of findings Table 2</a>) while adhering to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005195-bbs2-0190" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>) and using <a href="./references#CD005195-bbs2-0179" title="Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available from gradepro.org. GRADEproGDT [Computer program]. Version accessed 10 May 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available from gradepro.org, 2015. ">GRADEpro GDT</a> We used the GRADE checklist and GRADE Working Group certainty (quality) of evidence definitions (<a href="./references#CD005195-bbs2-0223" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>), as follows. </p> <p> <ul id="CD005195-list-0006"> <li> <p><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>When possible, for each outcome in RCTs, we based the assumed risk in the control group on the proportion of events in the included studies. In accordance with GRADE methodological criteria, we based our assessment of the certainty (quality) of evidence on RCTs with low risk of bias (<a href="./references#CD005195-bbs2-0183" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011)</a>. We downgraded the evidence from 'high' quality by one level for serious (or by two levels for very serious) concerns regarding each of the validity issues. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005195-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005195-sec-0059"></div> <section id="CD005195-sec-0060"> <h3 class="title">Description of studies</h3> <p>Citation style: Please note that we reference the sources of relevant information in a certain way to enhance traceability of our results for interested readers. When the source of information is not the primary publication of an included study, we also reference the specific publication of interest. For example "Hakama 1990, in: <a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a>" indicates that the cited paper is "Hakama 1990" as part of the mentioned study. </p> <p>We could not access three full‐text theses published in the United States (Coates 1987, in: <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a>; <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a>a, in: <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a>; Schober 1986, in: <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a>). However, later journal publications were available, and we included them in this review as main study publications (<a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a>, in: <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a>; <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a>b, in: <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a>; Schober 1987, in: <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a>). Thus we considered retrieval of the full‐text theses to be unnecessary. </p> <section id="CD005195-sec-0061"> <h4 class="title">Results of the search</h4> <p>In the previous Cochrane review, of 4082 hits of potential relevance, we retrieved 268 publications in full text. Of these, we considered 137 papers as relevant (see the flow chart of the literature search in <a href="./references#CD005195-bbs2-0313" title="DennertG , ZwahlenM , BrinkmanM , VincetiM , ZeegersMP , HorneberM . Selenium for preventing cancer. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD005195] ">Dennert 2011</a>). </p> <p>In our first updated search, after we excluded internal duplicates and duplicates against the database of the literature search conducted in January 2011, we retrieved 766 hits. Of these, we excluded 744 references as clearly irrelevant on the basis of title and abstract review (see the flow chart of the literature search in <a href="./references#CD005195-bbs2-0314" title="VincetiM , DennertG , CrespiCM , ZwahlenM , BrinkmanM , ZeegersMP , et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005195.pub3; PUBMED: 24683040] ">Vinceti 2014</a>). </p> <p>In the second updated search process, conducted in February 2017, including online database searches and searches within grey literature, study references, and trial databases, we identified 859 new hits after de‐duplication. Of these, we excluded 831 references as clearly irrelevant on the basis of the title and abstract review (see the flow chart of the literature search in <a href="#CD005195-fig-0001">Figure 1</a>). We considered the remaining 28 publications of possible relevance and re‐evaluated and retrieved them in full text from this updated search. Upon further review, we considered 20 of these publications relevant. </p> <div class="figure" id="CD005195-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart." data-id="CD005195-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart.</p> </div> </div> </div> </section> <section id="CD005195-sec-0062"> <h4 class="title">Included studies</h4> <p>In total, from the previous Cochrane review and from our updates, we identified 168 papers for inclusion in this review: 105 papers referred to 70 completed observational studies, and 63 papers referred to one ongoing and 10 completed RCTs (<a href="#CD005195-fig-0001">Figure 1</a>). (The previous version of the review was based on 148 papers; 89 referred to one ongoing and 55 completed observational studies, and 59 papers referred to four ongoing and eight completed RCTs.) </p> <p>We have provided a detailed description of the included studies in the <a href="./references#CD005195-sec-0151" title="">Characteristics of included studies</a> table. </p> <section id="CD005195-sec-0063"> <h5 class="title">Randomised controlled trials</h5> <p>We included in this review 11 randomised controlled trials (RCTs) with a total of 44,743 participants (94% men). All used parallel‐group designs with two arms (<a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>; <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>; <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>), three arms (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), or four arms (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). Three were conducted in China (<a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>; <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>), four in the United States (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>), one in the United States/New Zealand (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), one in the United States/Canada/Puerto Rico (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), and one in Europe (<a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>). </p> <p>Investigators administered selenium supplements and placebos daily. As an active intervention, trials used selenium 200 µg/d (<a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>), or 400 µg/d (<a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>), in the form of selenised yeast tablets, composed almost entirely of organic selenium and particularly of selenomethionine (<a href="./references#CD005195-bbs2-0151" title="BlockE , GlassRS , JacobsenNE , JohnsonS , KahakachchiC , KaminskiR , et al. Identification and synthesis of a novel selenium‐sulfur amino acid found in selenized yeast: rapid indirect detection NMR methods for characterizing low‐level organoselenium compounds in complex matrices. Journal of Agricultural and Food Chemistry2004;52(12):3761‐71. ">Block 2004</a>). <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a> used 200 µg and 400 µg as different arms. <a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a> used 500 µg sodium selenite, and <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a> used 200 µg/d of selenomethionine. <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a> used 250 µg/d of inorganic selenite. </p> <p>Three Chinese trials investigated the preventive efficacy of selenium supplementation against primary liver cancer for different high‐risk populations. Participants were carriers of the hepatitis B surface antigen (HBs‐Ag) with normal liver function, or they were first‐degree relatives of patients with liver cancer. Two trials used selenised yeast (<a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>), and one used sodium selenite (<a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>). </p> <p>The Nutritional Prevention of Cancer Trial (NPCT) investigated the influence of selenium on the development of non‐melanoma skin cancer (basal and squamous cell carcinoma) in a population considered at high risk of the disease, namely, patients with a history of non‐melanoma skin cancer (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). Participants consisted of 1312 men and women from the eastern United States 18 to 80 years of age, with a history of two or more basal cell carcinomas or of one squamous cell carcinoma. Investigators reported RR estimates for basal cell carcinoma, squamous cell carcinoma, and overall non‐melanoma skin cancer for two periods of follow‐up: an intermediate study period (from 15 September 1983 to 31 December 1993: Clark 1996, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), and the entire blinded intervention period (from 15 September 1983 to 31 January 1996: Duffield‐Lillico 2002 for secondary outcomes; Duffield‐Lillico 2003a for the primary outcome, i.e. non‐melanoma skin cancer; and Duffield‐Lillico 2003b for an in‐depth analysis of prostate cancer risk; see <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). In the present analysis, we used only final reports concerning the entire period of blinded follow‐up, which was characterised by active administration of selenium supplements. </p> <p>In 1990, <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a> identified additional secondary endpoints post hoc (i.e. total cancer mortality; total cancer incidence; incidence of lung, prostate, and colorectal cancers). Trial publications also reported incidences of female breast cancer, bladder cancer, oesophageal cancer, melanoma, haematological cancer, and cancers of the head and neck (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). </p> <p>A substudy of the NPCT investigated the efficacy of a higher selenium dose, supplied as selenised yeast orally, for prevention of non‐melanoma skin cancer at one of the NPCT study sites (<a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>). Study design was similar to that of the NPCT study, except that investigators randomly assigned 423 participants at this site to placebo or intervention with 400 µg/d of selenium. <a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a> also reported the incidence of internal cancers. </p> <p><a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a> evaluated the incidence of skin cancer as a secondary outcome in a group of 184 organ transplant recipients who received 200 µg/d of selenium for three years, then were followed up for an additional two years. In this multi‐centre, randomised, placebo‐controlled trial, investigators monitored 91 selenium‐supplemented participants and 93 non‐supplemented participants for development of both non‐malignant (warts and various keratoses) and malignant skin lesions. </p> <p>The Selenium and Vitamin E Cancer Prevention Trial (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>) investigated the effect of selenium as L‐selenomethionine and/or vitamin E supplementation in men of diverse ethnic backgrounds against the development of prostate cancer and other 'secondary' outcomes (i.e. risk of all cancers, lung cancer, colorectal cancer, and bladder cancer). This study was a very large phase 3 randomised, placebo‐controlled trial, activated in June 2001 and originally designed for a 7‐ to 12‐year period of follow‐up, carried out at 427 sites in the United States, Canada, and Puerto Rico. However, the independent Data and Safety Monitoring Committee (DSMC) recommended on 15 September 2008, discontinuation of study supplements based on absence of benefit from vitamin E or selenium and no possibility of benefit to the planned degree with additional follow‐up (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). The Committee also expressed concern about increased prostate cancer risk among vitamin E–treated participants and increased diabetes risk among selenium‐supplemented participants (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>) (RR 1.07, 99% CI 0.94 to 1.22). Therefore, investigators discontinued administration of these supplements on 23 October 2008, in spite of the planned supplementation period of 12 years. Results of SELECT are based on follow‐up provided at the end of the blinded supplementation period, which included 117,660 person‐years of follow‐up ‐ not on an extended period of follow‐up, which encompassed an additional 32 months of surveillance (144,846 person‐years in total) after the end of the supplementation period (Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). Endpoints were prostate cancer (the 'primary' endpoint) and colorectal cancer, lung cancer, all other cancers, and all cancers overall. A subsequent study from SELECT also evaluated the risk of bladder cancer, adding to standard follow‐up an additional post supplementation period of 32 months (Lotan 2012, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). </p> <p>Three phase III trials published in 2011 ‐ <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a> ‐ and in 2013 ‐ <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a> ‐ also evaluated the effect of selenium supplementation on prostate cancer. In <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a> (trial code SWOG S9917), investigators randomly assigned 423 men with high‐grade prostatic intraepithelial neoplasia, and therefore considered to be at very high risk of prostate cancer, to selenium (200 µg/d as selenomethionine) or placebo. <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a> evaluated whether supplementation with 200 or 400 µg/d of selenium as selenised yeast reduced the risk of prostate cancer among men at high risk of the disease, based on a prostate‐specific antigen (PSA) level exceeding 4 ng/L, suspicious digital rectal examination. and PSA velocity greater than 0.75 ng/mL/y. This trial, called the Negative Biopsy Trial (NBT), followed study participants in the United States (where both supplementation and follow‐up were completed for such period) for five years, and in New Zealand for no longer than three years, and was discontinued after an external DSMC issued a recommendation to stop the trial. <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a> investigated the effect of supplementation of 200 µg/d selenium as selenised yeast in 1561 individuals with resected stage I non–small‐cell lung cancer (trial code ECOG 5597). The primary outcome was the incidence of second primary tumours. Investigators enrolled both men and women in the study and investigated all cancer types and a few major side effects during follow‐up. Follow‐up included the period of active supplementation and some additional follow‐up after the trial anticipated discontinuation. This decision was made by the trial DSMC, which, on October 21, 2009, reviewed the first planned interim analysis of the primary endpoint and recommended that the study should be terminated for futility. Based on that DSMC recommendation, on November 5, 2009, accrual for the Eastern Cooperative Oncology Group (ECOG) trial was interrupted, and all current participants were invited to discontinue selenium/placebo tablets and were monitored only for follow‐up of cancer incidence and survival. In accordance with recommendations by the trial DSMC concerning possible adverse effects of selenium supplementation, the incidence of basal and squamous cell skin cancers, as well as type 2 diabetes, was monitored. The main paper reported follow‐up until June 2011 (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>), and results for only second primary lung tumours were updated as of January 2014, including a longer post supplementation period of follow‐up (Pillai 2014, in: <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013)</a>. </p> <p>Investigators conducted a trial in Poland that included a female population of carriers of a breast cancer‐related mutation, <i>BRCA1</i> (<a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>). Trial authors randomised 1135 women carrying that mutation to 250 µg/d of selenium in its inorganic tetravalent form (selenite), or to placebo, in a double‐blind trial. Median follow‐up lasted 35 months (ranging from 6 to 62 months), and final analysis was based on 105 incident cases diagnosed during follow‐up ‐ 60 cases in the selenium‐supplemented arm and 45 cases in the placebo arm. </p> </section> <section id="CD005195-sec-0064"> <h5 class="title">Observational studies</h5> <p>We included in this review 70 completed observational studies. Forty‐five studies were nested case‐control studies, the others were subcohort‐controlled or cohort studies, and one study used a cohort together with a nested case‐control design. Subcohort‐controlled studies used (random) samples of the cohort as controls. The original papers were published between 1983 and 2017. Eight studies were conducted in Asia (China, Iran, Japan, and Taiwan), one in Australia, 30 in Europe (Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, Channel Islands, Finland, France, and UK), 30 in the United States, and one in Canada. Overall, studies included more than 2,300,000 participants. Study populations in Europe made up 42.9%, North America 44.3%, Asia 11.4%, and Australia 1.4% of all study participants. The median size of study populations was 11,457. Forty‐one studies included men and women, one did not report sex, 22 included only men, and six included only women. Eleven studies with mixed‐sex populations reported results stratified by sex. Study populations were derived from 55 different cohorts. Twenty‐four cohorts were non‐randomly recruited (e.g. included volunteers), and 31 cohorts consisted of a random sample of the population of interest. Fifty‐two studies reported mean or median age, 12 studies reported only age range, and six studies did not report this information on study participants. Most studies included adults older than 40 years of age. </p> <p>Sixteen studies investigated nutritional and/or supplemental selenium intake by using food frequency questionnaires or interviews. Fifty‐four studies assessed biochemical selenium status whereby: </p> <p> <ol id="CD005195-list-0007"> <li> <p>9 used toenail specimens;</p> </li> <li> <p>14 used plasma specimens;</p> </li> <li> <p>29 used serum specimens;</p> </li> <li> <p>1 used both serum and plasma specimens; and</p> </li> <li> <p>1 measured both serum selenium levels and intake.</p> </li> </ol> </p> <p>The mean follow‐up period lasted up to three years in five studies, and longer than three years in the remaining studies. Generally, study authors grouped cases according to the version of the International Classification of Diseases (ICD) that was up‐to‐date at the inception of the cohort observation. The level of disaggregation of data varied markedly between studies. Although some studies reported cancer risk according to organ system (e.g. urinary tract, respiratory tract), others reported cancer risk for one or two organs (e.g. female breast, urinary bladder). Only in the case of skin cancer did studies also differentiate according to histological type (e.g. melanoma, basal cell carcinoma). </p> <p>For the following outcomes, we included five or more studies in the review and meta‐analysed observational data. </p> <p> <ol id="CD005195-list-0008"> <li> <p>Any cancer (16 studies).</p> </li> <li> <p>Female breast cancer (8 studies).</p> </li> <li> <p>Urinary bladder cancer (6 studies).</p> </li> <li> <p>Lung cancer (15 studies).</p> </li> <li> <p>Prostate cancer (21 studies).</p> </li> <li> <p>Stomach cancer (5 studies).</p> </li> <li> <p>Colorectal cancer (6 studies) and colon cancer (5 studies).</p> </li> </ol> </p> <p><a href="./references#CD005195-bbs2-0021" title="GoyalA , TerryMB , SiegelAB . Serum antioxidant nutrients, vitamin A, and mortality in US adults. Cancer Epidemiology, Biomarkers &amp; Prevention2013;22(12):2202‐11. [PUBMED: 23897583] ">Goyal 2013</a> updated results of <a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a>, which reported longer follow‐up for the same population. </p> <p><a href="#CD005195-tbl-0003">Table 1</a> provides an overview of the studies examining each outcome. Five studies provided data for the group of 'other' cancers, which encompassed any type of cancer not reported separately in study publications. The definition of 'other' cancers varied between studies, including rare cancers but also cancers of unknown origin. We have mentioned results of studies within the category 'other cancers' for the sake of completeness; however, because of the diversity of outcomes, we have not included these results in further analysis or discussion of this review. </p> <div class="table" id="CD005195-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included observational studies by outcome</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Organ system</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies/case definitions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Meta‐</b> <br/> <b>analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Countries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of cases</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selenium assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reporting study</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 16</p> <p>incidence: 7<br/> mortality: 7<br/> incidence and mortality combined: 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland<br/> Netherlands<br/> Sweden<br/> Norway<br/> Belgium<br/> France </p> <p>China</p> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 276,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6488</p> <p>male: 3196</p> <p>female: 1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 12</p> <p>plasma: 2</p> <p>serum + plasma: 1</p> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0079" title="WillettWC , PolkBF , MorrisJS , StampferMJ , PresselS , RosnerB , et al. Prediagnostic serum selenium and risk of cancer. Lancet1983;2(8342):130‐4. ">Willett 1983</a> </p> <p><a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> </p> <p><a href="./references#CD005195-bbs2-0059" title="PelegI , MorrisS , HamesCG . Is serum selenium a risk factor for cancer?. Medical Oncology and Tumor Pharmacotherapy1985;2(3):157‐63. ">Peleg 1985</a> </p> <p><a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a><br/> <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a><br/> <a href="./references#CD005195-bbs2-0076" title="VirtamoJ , ValkeilaE , AlfthanG , PunsarS , HuttunenJK , KarvonenMJ . Serum selenium and risk of cancer. A prospective follow‐up of nine years. Cancer1987;60(2):145‐8. ">Virtamo 1987</a> </p> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a><br/> <a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a> </p> <p><a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a><br/> <a href="./references#CD005195-bbs2-0064" title="RingstadJ , JacobsenBK , TretliS , ThomassenY . Serum selenium concentration associated with risk of cancer. Journal of Clinical Pathology1988;41(4):454‐7. ">Ringstad 1988</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a><br/> <a href="./references#CD005195-bbs2-0002" title="AkbaralyNT , ArnaudJ , Hininger‐FavierI , GourletV , RousselAM , BerrC . Selenium and mortality in the elderly: results from the EVA study. Clinical Chemistry2005;51(11):2117‐23. ">Akbaraly 2005</a><br/> <a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a> </p> <p><a href="./references#CD005195-bbs2-0017" title="FujishimaY , OhsawaM , ItaiK , KatoK , TannoK , TurinTC , et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrology, Dialysis, Transplantation2011;26(10):3331‐8. ">Fujishima 2011</a> </p> <p><a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Gynaecological cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female breast cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 8</p> <p>incidence: 8<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland<br/> Netherlands<br/> Channel Islands </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 169,028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 1277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>plasma: 1</p> <p>serum + plasma: 1</p> <p>toenail: 3</p> <p>intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0075" title="vanNoordPAH , ColletteHJA , MaasMJ , deWaardF . Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort‐nested case‐referent study among women screened in the DOM project. International Journal of Epidemiology1987;16(2):318‐22. ">van Noord 1987</a><br/> <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0056" title="OvervadK , WangDY , OlsenJ , AllenDS , ThorlingEB , BulbrookRD , HaywardJL . Selenium in human mammary carcinogenesis: a case‐cohort study. European Journal of Cancer1991;27(7):900‐2. ">Overvad 1991</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0013" title="DorganJF , SowellA , SwansonCA , PotischmanN , MillerR , SchusslerN , et al. Relationships of serum carotenoids, retinol, alpha‐tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). Cancer Causes and Control1998;9(1):89‐97. ">Dorgan 1998</a> </p> <p><a href="./references#CD005195-bbs2-0057" title="PantavosA , RuiterR , FeskensEF , deKeyserCE , HofmanA , StrickerBH , et al. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: the Rotterdam Study. International Journal of Cancer2015;136(9):2178‐86. [PUBMED: 25284450] ">Pantavos 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cervical cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2</p> <p>incidence: 2<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: &gt; 15,161</p> <p>(1 study did not report cohort size by sex)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uterine cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 62,641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ovarian cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: ˜ 214,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>toenail: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a><br/> <a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecological cancer (without breast cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 18,096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Urological cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kindom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 23,658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary bladder cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6</p> <p>incidence: 6<br/> mortality: 0<br/> incidence &amp; mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii<br/> Finland<br/> Netherlands </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 279,100</p> <p>female: 130,786</p> <p>male: 128,009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1295</p> <p>female: 175</p> <p>male 755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>toenail: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a> </p> <p><a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> </p> <p><a href="./references#CD005195-bbs2-0029" title="HotalingJM , WrightJL , PocobelliG , BhattiP , PorterMP , WhiteE . Long‐term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. The Journal of Urology2011;185(4):1210‐5. ">Hotaling 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary tract cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence &amp; mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 38,500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 47</p> <p>male: 34</p> <p>female: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Respiratory tract cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 15</p> <p>incidence: 13<br/> mortality: 2<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> Japan<br/> USA<br/> Finland<br/> Netherlands </p> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 371,067</p> <p>male: 125,341</p> <p>female: 181,895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2223</p> <p>male: 1384</p> <p>female: 416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 9</p> <p>serum + plasma: 2</p> <p>toenail: 2</p> <p>dietary intake: 2</p> <p>(1 study reported both serum levels and food intake)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0040" title="KromhoutD . Essential micronutrients in relation to carcinogenesis. American Journal of Clinical Nutrition1987;45(5 Suppl):1361‐7. ">Kromhout 1987</a><br/> <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a><br/> <a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a><br/> <a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> </p> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a><br/> <a href="./references#CD005195-bbs2-0062" title="RatnasingheD , TangreaJA , FormanMR , HartmanT , GunterEW , QiaoYL , et al. Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes and Control2000;11(2):129‐35. ">Ratnasinghe 2000</a> </p> <p><a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a><br/> <a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> <p><a href="./references#CD005195-bbs2-0071" title="SuadicaniP , HeinHO , GyntelbergF . Serum selenium level and risk of lung cancer mortality: a 16‐year follow‐up of the Copenhagen Male Study. European Respiratory Journal2012;39(6):1443‐8. ">Suadicani 2012</a> </p> <p><a href="./references#CD005195-bbs2-0050" title="MukaT , KrajaB , RuiterR , LahousseL , deKeyserCE , HofmanA , et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition2017;56(4):1637‐46. [PUBMED: 27073037] ">Muka 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral/pharyngeal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 20,305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Andrological cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 21</p> <p>incidence: 21<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> <p>Canada</p> <p>Puerto Rico<br/> Europe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/male: 576,667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/male: 14,950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 8</p> <p>plasma: 5</p> <p>toenail: 4</p> <p>dietary intake: 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0026" title="HartmanTJ , AlbanesD , PietinenP , HartmanAM , RautalahtiM , TangreaJA , et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha‐tocopherol, beta‐carotene cancer prevention study. Cancer Epidemiology, Biomarkers &amp; Prevention1998;7(4):335‐40. ">Hartman 1998</a> </p> <p><a href="./references#CD005195-bbs2-0080" title="YoshizawaK , WillettWC , MorrisSJ , StampferMJ , SpiegelmanD , RimmEB , et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Journal of the National Cancer Institute1998;90(16):1219‐24. ">Yoshizawa 1998</a> </p> <p><a href="./references#CD005195-bbs2-0028" title="HelzlsouerKJ , HuangHY , AlbergAJ , HoffmanS , BurkeA , NorkusEP , et al. Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer. Journal of the National Cancer Institute2000;92(24):2018‐23. ">Helzlsouer 2000</a><br/> <a href="./references#CD005195-bbs2-0052" title="NomuraAMY , LeeJ , StemmermannGN , CombsGFJr . Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2000;9(9):883‐7. ">Nomura 2000</a> </p> <p><a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a><br/> <a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a><br/> <a href="./references#CD005195-bbs2-0042" title="LiH , KantoffPW , GiovannucciE , LeitzmannMF , GazianoJM , StampferMJ , et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research2005a;65(6):2498‐504. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute2004;96(9):696‐703. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. Plasma selenium levels associated with subsequent risk of prostate cancer. American Journal of Urology Review2005b;3(1):28‐34. ">Li 2004a</a><br/> <a href="./references#CD005195-bbs2-0060" title="PetersU , FosterCB , ChatterjeeN , SchatzkinA , RedingD , AndrioleGL , et al. Serum selenium and risk of prostate cancer ‐ a nested case‐control study. American Journal of Clinical Nutrition2007;85(1):209‐17. ">Peters 2007</a> </p> <p><a href="./references#CD005195-bbs2-0004" title="AllenNE . Reply to B Bekaert and MP Rayman. American Journal of Clinical Nutrition2009;89(4):1277. AllenNE , ApplebyPN , RoddamAW , TjønnelandA , JohnsenNF , OvervadK , et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Clinical Nutrition2008;88(6):1567‐75. ">Allen 2008</a><br/> <a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a><br/> <a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> <p><a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> </p> <p><a href="./references#CD005195-bbs2-0058" title="ParkSY , HaimanCA , ChengI , ParkSL , WilkensLR , KolonelLN , et al. Racial/ethnic differences in lifestyle‐related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes &amp; Control2015;26(10):1507‐15. [PUBMED: 26243447] ">Park 2015</a> </p> <p><a href="./references#CD005195-bbs2-0055" title="OutzenM , TjonnelandA , LarsenEH , FriisS , LarsenSB , ChristensenJ , et al. Selenium status and risk of prostate cancer in a Danish population. British Journal of Nutrition2016;115(9):1669‐77. [PUBMED: 26971676] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Outzen 2016</a> </p> <p><a href="./references#CD005195-bbs2-0022" title="GraffRE , JudsonG , AhearnTU , FiorentinoM , LodaM , GiovannucciEL , et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. The Prostate2017;77(6):647‐53. [PUBMED: 28102015] ">Graff 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><b>Gastrointestinal cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2</p> <p>incidence: 2<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> USA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 29,923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: &gt; 959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a><br/> <a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:<i>2</i> </p> <p>incidence: 2<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 168,257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> <p>intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:<i>1</i> </p> <p>incidence:<i>1</i> <br/> mortality:<i>0</i><br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 120,852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal/stomach cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 36,265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 86</p> <p>male: 51</p> <p>female: 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastric cardia adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:<i>1</i> </p> <p>incidence:<i>1</i> <br/> mortality:<i>0</i><br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 120,852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 5</p> <p>incidence: 5<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> Japan<br/> USA/Hawaii<br/> Finland<br/> Netherlands </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 197,000</p> <p>male: 86,311</p> <p>female: 80,669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 955</p> <p>male: 626</p> <p>female: 329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 4</p> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a><br/> <a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary liver cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 3<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> <p>Europe</p> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 701,809</p> <p>male: 61,470</p> <p>female: 74,941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 877</p> <p>male: 567</p> <p>female: 204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma: 1</p> <p>serum: 1</p> <p>toenail: 1</p> <p>intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a><br/> <a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pancreatic cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland </p> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 159,062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 311</p> <p>male: 69</p> <p>female: 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>intake: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colorectal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6</p> <p>incidence: 6<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii<br/> Europe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 712,746</p> <p>male: 216,272</p> <p>female: 442,266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2627</p> <p>male: 810</p> <p>female: 797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>toenail: 2</p> <p>supplement use: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colon cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 5</p> <p>incidence: 5<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii</p> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 636,641</p> <p>male: 195,100</p> <p>female: 361,529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1677</p> <p>male: 525</p> <p>female: 510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>toenail: 1</p> <p>supplement use: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rectal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii<br/> Europe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 610,837</p> <p>male: 195,100</p> <p>female: 361,529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 861</p> <p>male: 303</p> <p>female: 210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>toenail: 1</p> <p>supplement use:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All gastrointestinal cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6,167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma and serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Skin cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 3</p> <p>incidence: 3<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 158,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> <p>toenail: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basal cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 3</p> <p>incidence: 3<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia<br/> USA<br/> Finland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: &gt; 66,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia<br/> USA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 30,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>plasma: 1</p> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a><br/> <a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a><br/> <a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total non‐melanoma skin cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Rare and other cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haematological cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum + plasma: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thyroid cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2</p> <p>incidence: 2<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 582,807</p> <p>male: 287,944</p> <p>female: 194,863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 635</p> <p>male: 269</p> <p>female: 366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> <p>intake:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 3<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> USA<br/> Finland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 109,179</p> <p>male: 21,172</p> <p>female: 80,737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 512</p> <p>male: 169</p> <p>female: 285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>serum + plasma: 1</p> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a><br/> <a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Some studies did not report the sex of participants or cancer cases; consequently, figures for women and men do not always sum up to the total number of participants or cancer cases. </p> </div> </div> </section> </section> <section id="CD005195-sec-0065"> <h4 class="title">Excluded studies</h4> <p>Of 28 potentially relevant papers retrieved in the updated search, eight papers did not fulfil the inclusion criteria. We rejected six of these publications as investigators did not report results according to inclusion criteria; one paper because trial authors reported duplicated data from an already included study; and another paper because the trial was carried out in patients with cancer. The <a href="./references#CD005195-sec-0152" title="">Characteristics of excluded studies</a> table describes the reasons for exclusion of trials from the previous Cochrane review and from this update. </p> </section> </section> <section id="CD005195-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD005195-sec-0067"> <h4 class="title">Randomised controlled trials</h4> <p>We assessed risk of bias of the included RCTs according to Cochrane criteria (<a href="./references#CD005195-bbs2-0190" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>; <a href="./references#CD005195-bbs2-0191" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal2011;343:d5928. ">Higgins 2011b</a>). We presented judgements about each risk of bias item as percentages across all included RCTs, and we provided a summary of the risk of bias assessment in <a href="#CD005195-fig-0002">Figure 2</a>. We provided details on the judgement for each RCT and the reason for that judgement in <a href="./references#CD005195-sec-0151" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD005195-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Review authors’ judgements about each risk of bias item presented as percentages across all included RCTs and summary of review authors’ judgements about each risk of bias item for the included RCTs." data-id="CD005195-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review authors’ judgements about each risk of bias item presented as percentages across all included RCTs and summary of review authors’ judgements about each risk of bias item for the included RCTs. </p> </div> </div> </div> <p>We considered all three trials on liver cancer risk (<a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>; <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>), as well as the trial on breast cancer (<a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>), to have unclear risk of bias. These trials did not report generation of allocation sequence and allocation concealment. One study mentioned that the dropout rate was similar in intervention and control groups; the remaining three studies did not report the completeness of outcome data. We judged blinding as adequate in three studies, as investigators reported the use of placebo supplements. We inferred from this procedure that at least the study participants and the physicians directly involved were blinded towards treatment status. </p> <p>In addition, it is unclear whether <a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a> was an individually randomised controlled trial. Study investigators used the phrase "randomisation based on the residence area" and did not describe the randomisation procedure any further. As participants were recruited from 17 villages, these villages ‐ not individual participants ‐ may have been randomly assigned to intervention and control groups. However, we could not make contact with study investigators to clarify these questions. Randomisation of villages instead of individuals could have introduced bias into the study results, as the incidence of liver cancer is known to differ between geographical areas as a result of lifestyle and environmental factors. </p> <p>It has been found that RCTs with inadequate or unclear allocation concealment, especially those with subjective outcomes, may overestimate the benefit of interventions (<a href="./references#CD005195-bbs2-0245" title="PildalJ , HrobjartssonA , JorgensenKJ , HildenJ , AltmanDG , GotzschePC . Impact of allocation concealment on conclusions drawn from meta‐analyses of randomized trials. International Journal of Epidemiology2007;36(4):847‐57. ">Pildal 2007</a>; <a href="./references#CD005195-bbs2-0308" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. British Medical Journal2008;336(7644):601‐5. ">Wood 2008</a>). All three RCTs on liver cancer did not report follow‐up and case detection procedures, so the influence of subjective factors on case detection, such as interpretation of bodily symptoms as triggers of further diagnostic tests, is unknown. Although we judged blinding as 'adequate' in all three liver cancer trials, we do not know whether blinding was successful in practice for participants, healthcare providers, and outcome assessors. </p> <p>These uncertainties about study methods seriously weaken our confidence in reported RCT results on liver cancer risk. </p> <p>We considered <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>, <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>, <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>, and <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a> to have low risk of bias because they reported adequate generation of allocation sequence, allocation concealment, blinding, and completeness of outcome data. </p> <p>We judged <a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a> and Duffield‐Lillico 2002 to 2003, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a> to have unclear risk of bias. <a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a> provided unclear generation of allocation sequence, allocation concealment, and blinding; only completeness of outcome data was adequate. We considered NPCT to be at unclear risk of bias because of exposure‐related detection bias for its primary outcome, as the percentage of study participants with an abnormal PSA (&gt; 4 ng/mL) who underwent biopsy varied according to selenium treatment group, at 35% in the placebo group and 14% in the selenium‐treated group (Duffield‐Lillico 2003b, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>). As reported by the trial authors themselves in analyses stratified by baseline selenium concentration, the difference was greatest among participants in the lowest tertile, in whom the inverse association between selenium administration and prostate cancer risk was strongest. The difference in biopsy rates could not be accounted for by factors such as PSA concentration, age at which abnormal PSA was detected, or alternative diagnostic procedures. Although a difference this large could have occurred by chance, this finding raises concerns about possible disruption of blinding. Investigators provided no information as to the prostate biopsy rate among participants with lower PSA levels or biopsy rates for the primary outcome of non‐melanoma skin cancer, which also requires pathological confirmation, nor for the secondary outcomes examined in this trial. </p> </section> <section id="CD005195-sec-0068"> <h4 class="title">Observational studies</h4> <p>We presented in <a href="#CD005195-tbl-0004">Table 2</a> a summary of study ratings according to the Newcastle‐Ottawa Scale (NOS). The median number of assigned stars was eight for both (nested) case‐control and cohort study assessments, out of a maximum of nine stars each. </p> <div class="table" id="CD005195-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias: observational studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Publication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Newcastle‐Ottawa Scale (cohort)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Newcastle‐Ottawa Scale (case‐control)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exposure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0001" title="AgalliuI , KirshVA , KreigerN , SoskolneCL , RohanTE . Oxidative balance score and risk of prostate cancer: results from a case‐cohort study. Cancer Epidemiology2011;35(4):353‐61. ">Agalliu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0001" title="AgalliuI , KirshVA , KreigerN , SoskolneCL , RohanTE . Oxidative balance score and risk of prostate cancer: results from a case‐cohort study. Cancer Epidemiology2011;35(4):353‐61. ">Agalliu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0002" title="AkbaralyNT , ArnaudJ , Hininger‐FavierI , GourletV , RousselAM , BerrC . Selenium and mortality in the elderly: results from the EVA study. Clinical Chemistry2005;51(11):2117‐23. ">Akbaraly 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0002" title="AkbaralyNT , ArnaudJ , Hininger‐FavierI , GourletV , RousselAM , BerrC . Selenium and mortality in the elderly: results from the EVA study. Clinical Chemistry2005;51(11):2117‐23. ">Akbaraly 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0004" title="AllenNE . Reply to B Bekaert and MP Rayman. American Journal of Clinical Nutrition2009;89(4):1277. AllenNE , ApplebyPN , RoddamAW , TjønnelandA , JohnsenNF , OvervadK , et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Clinical Nutrition2008;88(6):1567‐75. ">Allen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0004" title="AllenNE . Reply to B Bekaert and MP Rayman. American Journal of Clinical Nutrition2009;89(4):1277. AllenNE , ApplebyPN , RoddamAW , TjønnelandA , JohnsenNF , OvervadK , et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Clinical Nutrition2008;88(6):1567‐75. ">Allen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrass 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0021" title="GoyalA , TerryMB , SiegelAB . Serum antioxidant nutrients, vitamin A, and mortality in US adults. Cancer Epidemiology, Biomarkers &amp; Prevention2013;22(12):2202‐11. [PUBMED: 23897583] ">Goyal 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coates 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0013" title="DorganJF , SowellA , SwansonCA , PotischmanN , MillerR , SchusslerN , et al. Relationships of serum carotenoids, retinol, alpha‐tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). Cancer Causes and Control1998;9(1):89‐97. ">Dorgan 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0013" title="DorganJF , SowellA , SwansonCA , PotischmanN , MillerR , SchusslerN , et al. Relationships of serum carotenoids, retinol, alpha‐tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). Cancer Causes and Control1998;9(1):89‐97. ">Dorgan 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gill 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0017" title="FujishimaY , OhsawaM , ItaiK , KatoK , TannoK , TurinTC , et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrology, Dialysis, Transplantation2011;26(10):3331‐8. ">Fujishima 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0017" title="FujishimaY , OhsawaM , ItaiK , KatoK , TannoK , TurinTC , et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrology, Dialysis, Transplantation2011;26(10):3331‐8. ">Fujishima 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0192" title="HunterDJ , MorrisJS , ChuteCG , KushnerE , ColditzGA , StampferMJ , et al. Predictors of selenium concentration in human toenails. American Journal of Epidemiology1990;132(1):114‐22. ">Hunter 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0022" title="GraffRE , JudsonG , AhearnTU , FiorentinoM , LodaM , GiovannucciEL , et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. The Prostate2017;77(6):647‐53. [PUBMED: 28102015] ">Graff 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0022" title="GraffRE , JudsonG , AhearnTU , FiorentinoM , LodaM , GiovannucciEL , et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. The Prostate2017;77(6):647‐53. [PUBMED: 28102015] ">Graff 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0023" title="GrundmarkB , ZetheliusB , GarmoH , HolmbergL . Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow‐up. BMC Cancer2011;11:431. [EPI_EU_Grundmark 2011] ">Grundmark 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0023" title="GrundmarkB , ZetheliusB , GarmoH , HolmbergL . Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow‐up. BMC Cancer2011;11:431. [EPI_EU_Grundmark 2011] ">Grundmark 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0026" title="HartmanTJ , AlbanesD , PietinenP , HartmanAM , RautalahtiM , TangreaJA , et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha‐tocopherol, beta‐carotene cancer prevention study. Cancer Epidemiology, Biomarkers &amp; Prevention1998;7(4):335‐40. ">Hartman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0026" title="HartmanTJ , AlbanesD , PietinenP , HartmanAM , RautalahtiM , TangreaJA , et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha‐tocopherol, beta‐carotene cancer prevention study. Cancer Epidemiology, Biomarkers &amp; Prevention1998;7(4):335‐40. ">Hartman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0028" title="HelzlsouerKJ , HuangHY , AlbergAJ , HoffmanS , BurkeA , NorkusEP , et al. Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer. Journal of the National Cancer Institute2000;92(24):2018‐23. ">Helzlsouer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0028" title="HelzlsouerKJ , HuangHY , AlbergAJ , HoffmanS , BurkeA , NorkusEP , et al. Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer. Journal of the National Cancer Institute2000;92(24):2018‐23. ">Helzlsouer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hakama 1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knekt 1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knekt 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0109" title="KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , NikkariT , et al. Serum micronutrients and risk of cancers of low incidence in Finland. American Journal of Epidemiology1991;134(4):356‐61. ">Knekt 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0110" title="KokFJ , vanDuijnCM , HofmanA , VermeerenR , DeBruijnAM , ValkenburgHA . Micronutrients and the risk of lung cancer (letter). New England Journal of Medicine1987c;316:1416. ">Kok 1987b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0040" title="KromhoutD . Essential micronutrients in relation to carcinogenesis. American Journal of Clinical Nutrition1987;45(5 Suppl):1361‐7. ">Kromhout 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0040" title="KromhoutD . Essential micronutrients in relation to carcinogenesis. American Journal of Clinical Nutrition1987;45(5 Suppl):1361‐7. ">Kromhout 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0042" title="LiH , KantoffPW , GiovannucciE , LeitzmannMF , GazianoJM , StampferMJ , et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research2005a;65(6):2498‐504. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute2004;96(9):696‐703. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. Plasma selenium levels associated with subsequent risk of prostate cancer. American Journal of Urology Review2005b;3(1):28‐34. ">Li 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0042" title="LiH , KantoffPW , GiovannucciE , LeitzmannMF , GazianoJM , StampferMJ , et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research2005a;65(6):2498‐504. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute2004;96(9):696‐703. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. Plasma selenium levels associated with subsequent risk of prostate cancer. American Journal of Urology Review2005b;3(1):28‐34. ">Li 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heinen 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van der Pols 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Batieha 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breslow 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burney 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helzlsouer 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helzlsouer 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ko 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schober 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schober 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0050" title="MukaT , KrajaB , RuiterR , LahousseL , deKeyserCE , HofmanA , et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition2017;56(4):1637‐46. [PUBMED: 27073037] ">Muka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0050" title="MukaT , KrajaB , RuiterR , LahousseL , deKeyserCE , HofmanA , et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition2017;56(4):1637‐46. [PUBMED: 27073037] ">Muka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0052" title="NomuraAMY , LeeJ , StemmermannGN , CombsGFJr . Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2000;9(9):883‐7. ">Nomura 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0052" title="NomuraAMY , LeeJ , StemmermannGN , CombsGFJr . Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2000;9(9):883‐7. ">Nomura 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0055" title="OutzenM , TjonnelandA , LarsenEH , FriisS , LarsenSB , ChristensenJ , et al. Selenium status and risk of prostate cancer in a Danish population. British Journal of Nutrition2016;115(9):1669‐77. [PUBMED: 26971676] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Outzen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0055" title="OutzenM , TjonnelandA , LarsenEH , FriisS , LarsenSB , ChristensenJ , et al. Selenium status and risk of prostate cancer in a Danish population. British Journal of Nutrition2016;115(9):1669‐77. [PUBMED: 26971676] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Outzen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0056" title="OvervadK , WangDY , OlsenJ , AllenDS , ThorlingEB , BulbrookRD , HaywardJL . Selenium in human mammary carcinogenesis: a case‐cohort study. European Journal of Cancer1991;27(7):900‐2. ">Overvad 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0056" title="OvervadK , WangDY , OlsenJ , AllenDS , ThorlingEB , BulbrookRD , HaywardJL . Selenium in human mammary carcinogenesis: a case‐cohort study. European Journal of Cancer1991;27(7):900‐2. ">Overvad 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0057" title="PantavosA , RuiterR , FeskensEF , deKeyserCE , HofmanA , StrickerBH , et al. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: the Rotterdam Study. International Journal of Cancer2015;136(9):2178‐86. [PUBMED: 25284450] ">Pantavos 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0057" title="PantavosA , RuiterR , FeskensEF , deKeyserCE , HofmanA , StrickerBH , et al. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: the Rotterdam Study. International Journal of Cancer2015;136(9):2178‐86. [PUBMED: 25284450] ">Pantavos 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0058" title="ParkSY , HaimanCA , ChengI , ParkSL , WilkensLR , KolonelLN , et al. Racial/ethnic differences in lifestyle‐related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes &amp; Control2015;26(10):1507‐15. [PUBMED: 26243447] ">Park 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0058" title="ParkSY , HaimanCA , ChengI , ParkSL , WilkensLR , KolonelLN , et al. Racial/ethnic differences in lifestyle‐related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes &amp; Control2015;26(10):1507‐15. [PUBMED: 26243447] ">Park 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0059" title="PelegI , MorrisS , HamesCG . Is serum selenium a risk factor for cancer?. Medical Oncology and Tumor Pharmacotherapy1985;2(3):157‐63. ">Peleg 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0059" title="PelegI , MorrisS , HamesCG . Is serum selenium a risk factor for cancer?. Medical Oncology and Tumor Pharmacotherapy1985;2(3):157‐63. ">Peleg 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0060" title="PetersU , FosterCB , ChatterjeeN , SchatzkinA , RedingD , AndrioleGL , et al. Serum selenium and risk of prostate cancer ‐ a nested case‐control study. American Journal of Clinical Nutrition2007;85(1):209‐17. ">Peters 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0060" title="PetersU , FosterCB , ChatterjeeN , SchatzkinA , RedingD , AndrioleGL , et al. Serum selenium and risk of prostate cancer ‐ a nested case‐control study. American Journal of Clinical Nutrition2007;85(1):209‐17. ">Peters 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asgari 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0029" title="HotalingJM , WrightJL , PocobelliG , BhattiP , PorterMP , WhiteE . Long‐term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. The Journal of Urology2011;185(4):1210‐5. ">Hotaling 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0077" title="WalterRB , BraskyTM , MilanoF , WhiteE . Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(10):2298‐308. ">Walter 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0062" title="RatnasingheD , TangreaJA , FormanMR , HartmanT , GunterEW , QiaoYL , et al. Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes and Control2000;11(2):129‐35. ">Ratnasinghe 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0062" title="RatnasingheD , TangreaJA , FormanMR , HartmanT , GunterEW , QiaoYL , et al. Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes and Control2000;11(2):129‐35. ">Ratnasinghe 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0064" title="RingstadJ , JacobsenBK , TretliS , ThomassenY . Serum selenium concentration associated with risk of cancer. Journal of Clinical Pathology1988;41(4):454‐7. ">Ringstad 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0064" title="RingstadJ , JacobsenBK , TretliS , ThomassenY . Serum selenium concentration associated with risk of cancer. Journal of Clinical Pathology1988;41(4):454‐7. ">Ringstad 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0071" title="SuadicaniP , HeinHO , GyntelbergF . Serum selenium level and risk of lung cancer mortality: a 16‐year follow‐up of the Copenhagen Male Study. European Respiratory Journal2012;39(6):1443‐8. ">Suadicani 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0071" title="SuadicaniP , HeinHO , GyntelbergF . Serum selenium level and risk of lung cancer mortality: a 16‐year follow‐up of the Copenhagen Male Study. European Respiratory Journal2012;39(6):1443‐8. ">Suadicani 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van den Brandt 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van den Brandt 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zeegers 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0075" title="vanNoordPAH , ColletteHJA , MaasMJ , deWaardF . Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort‐nested case‐referent study among women screened in the DOM project. International Journal of Epidemiology1987;16(2):318‐22. ">van Noord 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0075" title="vanNoordPAH , ColletteHJA , MaasMJ , deWaardF . Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort‐nested case‐referent study among women screened in the DOM project. International Journal of Epidemiology1987;16(2):318‐22. ">van Noord 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0076" title="VirtamoJ , ValkeilaE , AlfthanG , PunsarS , HuttunenJK , KarvonenMJ . Serum selenium and risk of cancer. A prospective follow‐up of nine years. Cancer1987;60(2):145‐8. ">Virtamo 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0076" title="VirtamoJ , ValkeilaE , AlfthanG , PunsarS , HuttunenJK , KarvonenMJ . Serum selenium and risk of cancer. A prospective follow‐up of nine years. Cancer1987;60(2):145‐8. ">Virtamo 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mark 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0079" title="WillettWC , PolkBF , MorrisJS , StampferMJ , PresselS , RosnerB , et al. Prediagnostic serum selenium and risk of cancer. Lancet1983;2(8342):130‐4. ">Willett 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0079" title="WillettWC , PolkBF , MorrisJS , StampferMJ , PresselS , RosnerB , et al. Prediagnostic serum selenium and risk of cancer. Lancet1983;2(8342):130‐4. ">Willett 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0080" title="YoshizawaK , WillettWC , MorrisSJ , StampferMJ , SpiegelmanD , RimmEB , et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Journal of the National Cancer Institute1998;90(16):1219‐24. ">Yoshizawa 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0080" title="YoshizawaK , WillettWC , MorrisSJ , StampferMJ , SpiegelmanD , RimmEB , et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Journal of the National Cancer Institute1998;90(16):1219‐24. ">Yoshizawa 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> </tbody> </table> </div> <p>All but one cohort study received five to nine stars on the NOS. The exception (two stars) was an early investigation that was available only in abstract form for assessment (<a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a>). In the NOS cohort assessment, we considered representativeness of the cohort for the target population to be adequate in 59% of studies, which received a star; 79% of studies provided evidence that cancer was not present at study commencement; we considered completeness of follow‐up (≥ 95%) data to be adequate in 93% of studies. The representativeness of the cohort for the target population is a matter of external validity and generalisability of study results, but a systematic deviation of participants from the target population might also introduce bias into study results. The target population of included studies varied with study objectives and could have been the general population, as well as special occupational groups. We did not assign a star for this question to studies that did not identify their target population or to studies that recruited volunteers. Differential selection of study participants (e.g. volunteers) from the target population can lead to confounding by factors associated with selenium status and cancer incidence (e.g. nutritional behaviour, socioeconomic position). All included studies chose comparison groups (cases/controls or exposed/non‐exposed) from the same study population. This approach enhanced comparability between groups. </p> <p>We considered follow‐up data as complete or as missing data unlikely to introduce bias to study results in 47% of included observational studies. In the other cohorts, losses to follow‐up were greater than 5% and trial authors did not provide a description of losses to follow‐up. A high attrition rate may alter the characteristics of the population under investigation and may impede the generalisability of study results to the intended target population (external validity). The presence of attrition does not necessarily mean that study results are biased. However, given the possibility that selenium status may be linked to sociodemographic variables and socioeconomic position, which may also influence participation in follow‐up procedures, a differential effect of attrition may introduce bias towards underestimation or overestimation of the true exposure effect. </p> <p>Forty‐five included observational studies were nested case‐control studies; therefore we assessed them by using the NOS case‐control form. The number of stars in the NOS assessment of case‐control studies ranged from five to nine, with 87% of studies receiving eight or nine stars. Although we generally assessed included prospective case‐control studies as having low risk of bias, we had concerns regarding case definition and the question of the representativeness of cases in some studies. </p> <p>We considered the definition of cases as inadequate in 24% of nested case‐control studies, as cases were identified by self‐reporting; investigators did not describe linkage to databases with unclear validity or procedures. The magnitude and direction of bias that might have been introduced to the study results remain unclear. </p> <p>In 16% of studies, investigators did not include all identified cases (or an appropriate sample of them) in the trial analyses, or they did not report selection procedures for analysed cases. Some studies lost blood specimens as the result of technical problems (e.g. cooler breakdown at one study centre); other studies reported that material available for analysis was insufficient; and others selected cases for analysis in a non‐random manner. This might bias the estimates of association in either direction. </p> <p>We noted no obvious asymmetry (as an indicator of publication bias) in the funnel plots of studies on total cancer risk (<a href="#CD005195-fig-0003">Figure 3</a>) and selected cancer types (<a href="#CD005195-fig-0004">Figure 4</a>; <a href="#CD005195-fig-0005">Figure 5</a>; <a href="#CD005195-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD005195-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.1 Total cancer incidence and mortality." data-id="CD005195-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.1 Total cancer incidence and mortality. </p> </div> </div> </div> <div class="figure" id="CD005195-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.8 Colorectal cancer risk." data-id="CD005195-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.8 Colorectal cancer risk. </p> </div> </div> </div> <div class="figure" id="CD005195-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.12 Lung cancer risk incidence and mortality" data-id="CD005195-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.12 Lung cancer risk incidence and mortality </p> </div> </div> </div> <div class="figure" id="CD005195-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.19 Prostate cancer risk." data-id="CD005195-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.19 Prostate cancer risk. </p> </div> </div> </div> </section> <section id="CD005195-sec-0069"> <h4 class="title">Ethical criteria</h4> <p>All trials fulfilled informed consent and ethics board approval criteria (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), except for <a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>, <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>, <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>, and <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>, which did not mention these criteria. </p> </section> </section> <section id="CD005195-sec-0070"> <h3 class="title" id="CD005195-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD005195-tbl-0001"><b>Summary of findings for the main comparison</b> Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias</a>; <a href="./full#CD005195-tbl-0002"><b>Summary of findings 2</b> Highest compared with lowest selenium exposure for preventing cancer in observational studies</a> </p> <section id="CD005195-sec-0071"> <h4 class="title">1. Randomised controlled trials</h4> <p>We reported results from Duffield‐Lillico 2002 for all outcomes evaluated in the NPCT study (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>) (prostate cancer, lung cancer, bladder cancer, colorectal and breast cancer, any cancer, and death from cancer), except for prostate cancer, for which we also used Duffield‐Lillico 2003a, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>, and for the primary outcome, non‐melanoma skin cancer, whose results were reported in Duffield‐Lillico 2003b, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>. For the SELECT study (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), we included only results from Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>, which reported on the blinded period of follow‐up with continuing selenium supplementation ‐ not from Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>, which reported a longer period of follow‐up, including a subsequent period without selenium supplementation, and was discontinued in 2008 in compliance with the recommendation of the trial's independent DSMC (Lippman 2009 and Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). This second report by Klein et al included an additional period of 32 months (23% person‐time increase), along with the first follow‐up period, and results were essentially similar to those of Lippman et al 2009. For bladder cancer risk in SELECT, we used data from Lotan 2012, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>, which encompassed the same extended period of follow‐up as Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>, but was the only report available from the SELECT trial on this cancer type. For prostate cancer in SELECT, we also evaluated three reports published in 2014 that addressed specific population subgroups and cancer subtypes (<a href="./references#CD005195-bbs2-0084" title="AlbanesD , TillC , KleinEA , GoodmanPJ , MondulAM , WeinsteinSJ , et al. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research (Philadelphia, Pa.)2014;7(9):886‐95. [PUBMED: 24961880] ">Albanes 2014</a>; <a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>; <a href="./references#CD005195-bbs2-0120" title="MartinezEE , DarkeAK , TangenCM , GoodmanPJ , FowkeJH , KleinEA , et al. A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research2014;7(9):950‐7. [PUBMED: 24894197] ">Martinez 2014</a>). For the ECOG trial, we used the 2013 report for all cancer types (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). </p> <section id="CD005195-sec-0072"> <h5 class="title">1.1. Preventive efficacy outcomes</h5> <section id="CD005195-sec-0073"> <h6 class="title">1.1.1. Any cancer incidence and mortality</h6> <p>Five studies evaluated the outcome of any cancer incidence (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>); we assessed three of these trials as having low risk of bias (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). Risk ratios (RRs) were based on detection of 1043 cases among 10,026 participants receiving supplemental selenium and 942 cases among 9449 participants allocated to placebo. We found no evidence of reduced incident cancer risk in studies at low risk of bias (RR 1.01, 95% confidence interval (CI) 0.93 to 1.10), nor in the analysis including all studies (RR 0.99, 95% CI 0.86 to 1.14) (<a href="./references#CD005195-fig-0008" title="">Analysis 1.1</a>). </p> <p>When we evaluated mortality from all cancers as an outcome, we could include only two studies in the analysis (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), one of which was at low risk of bias (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). When we considered only this latter trial, no difference in mortality rates between selenium and placebo arms emerged (RR 1.02, 95% CI 0.80 to 1.30). However, when we considered all studies, risk in the selenium group was lower than risk in the placebo group (RR 0.81, 95% CI 0.49 to 1.32) (<a href="./references#CD005195-fig-0009" title="">Analysis 1.2</a>). </p> </section> <section id="CD005195-sec-0074"> <h6 class="title">1.1.2. Head and neck cancer</h6> <p>Two trials investigated effects of selenium supplementation on risk of head and neck cancer (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), but only one was at low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). In analysis restricted to the study having low risk of bias, no relation emerged for the risk of this cancer type, with a summary RR of 1.00 (95% CI 0.18 to 5.45), and analysis pooling both studies yielded statistically unstable risk estimates (RR 1.22, 95% CI 0.52 to 2.85), based on 13 cases in the selenium arms and 9 cases in the placebo arms (<a href="./references#CD005195-fig-0010" title="">Analysis 1.3</a>). </p> </section> <section id="CD005195-sec-0075"> <h6 class="title">1.1.3. Esophageal cancer</h6> <p>Two RCTs investigated the risk of oesophageal cancer associated with selenium supplementation (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), but only one was at low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). The number of cases in these studies was very low (3 in the selenium arms and 5 in the placebo arms), thus yielding very imprecise RR estimates. The summary RR for oesophageal cancer was 1.50 (95% 0.06 to 36.86) in the only study with low risk of bias, and 0.53 (95% CI 0.12 to 2.28) in overall studies (<a href="./references#CD005195-fig-0011" title="">Analysis 1.4</a>). </p> </section> <section id="CD005195-sec-0076"> <h6 class="title">1.1.4. Colorectal cancer</h6> <p>Three randomised controlled trials investigated the risk of colorectal cancer following selenium supplementation. These studies reported 76 cases in the selenium arms and 83 cases in the placebo arms (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>); two were at low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). The summary RR of colorectal cancer was 0.99 (95% CI 0.69 to 1.43) in the two studies with low risk of bias, and 0.74 (95% CI 0.41 to 1.33) in all studies (<a href="./references#CD005195-fig-0012" title="">Analysis 1.5</a>). </p> </section> <section id="CD005195-sec-0077"> <h6 class="title">1.1.5. Liver cancer</h6> <p>Four RCTs investigated the efficacy of selenium supplementation for liver cancer prevention, three of which were conducted in China with participants of different high‐risk groups in Qidong province, and one in the United States among individuals with resected non‐small‐cell lung cancer (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>; <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>). <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a> reported on a trial with 2474 male and female first‐degree relatives of patients with liver cancer. During the study period of two years, investigators observed 10 participants in the selenium group, who received 200 µg selenium yeast/d, and 13 cases in the placebo group (RR 0.55, 95% CI 0.24 to 1.25). <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a> investigated a four‐year supplementation period with 200 µg selenium yeast/d in 226 male and female hepatitis B‐surface antigen (HBs‐Ag) carriers. Investigators detected 11 cases (person‐time incidence rate: 1573.03/100,000) in the placebo group and four cases in the selenium group (RR 0.36, 95% CI 0.12 to 1.11) during the eight‐year follow‐up period. The mean blood selenium level during the intervention period was 152 µg/L in the intervention group and 107 µg/L in the control group. <a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a> randomly assigned 2065 male HBs‐Ag carriers to receive 0.5 mg sodium selenite or placebo daily for three years. Thirty‐four cases of liver cancer occurred among 1112 participants receiving selenium, and 57 cases occurred among 953 placebo participants (RR 0.51, 95% CI 0.34 to 0.77). </p> <p><a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a> allocated 521 individuals with history of resected non‐small‐cell lung cancer to 200 µg/d selenium as selenised yeast or to placebo. During follow‐up, investigators diagnosed six new cases of liver cancer (actually coded as occurring to the ‘liver, gallbladder and bile duct’)‐ all in the selenium arm. We deemed this study to have low risk of bias. </p> <p>The three Chinese studies had unclear risk of bias owing to lack of clear reporting of generation of allocation sequence or allocation concealment, and/or completeness of outcome data. Limiting analysis to the only study not downgraded owing to risk of bias yielded an RR of 6.52 (95% CI 0.37 to 115.49) (<a href="./references#CD005195-fig-0013" title="">Analysis 1.6</a>). The overall RR of the four studies was 0.52 (95% CI 0.35 to 0.79). </p> </section> <section id="CD005195-sec-0078"> <h6 class="title">1.1.6. Melanoma</h6> <p>Three RCTs investigated the risk of melanoma following selenium supplementation (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), but we judged only two of them to have low risk of bias (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). For eight cases in the selenium arms and four cases in the placebo arms, the summary RR estimate was 1.35 (95% CI 0.41 to 4.52) in RCTs at low risk of bias. The RR estimate was slightly lower when all studies were considered (RR 1.28, 95% CI 0.63 to 2.59) (<a href="./references#CD005195-fig-0014" title="">Analysis 1.7</a>). </p> </section> <section id="CD005195-sec-0079"> <h6 class="title">1.1.7. Non‐melanoma skin cancer</h6> <section id="CD005195-sec-0080"> <p><b>1.1.7.1. Total non‐melanoma skin cancer</b></p> <p>Risk of non‐melanoma skin cancer was the primary outcome of the NPCT,which reported higher risk in the selenium‐supplemented group than in the placebo group (unadjusted RR 1.27, 95% CI 1.11 to 1.45) (Duffield‐Lillico 2003a, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). This increase was confirmed by multi‐variable analysis after adjustment for confounders (hazard ratio (HR) 1.17, 95% CI 1.02 to 1.34) and was concentrated among participants in the highest two tertiles of baseline plasma selenium (≥ 105.6 µg/L), although increased risk for total non‐melanoma skin cancer was seen in all tertiles of baseline plasma selenium levels (<a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>). No variation in this effect appeared to be induced by age, sex, or smoking habits, and eliminating cases that occurred during the first period of selenium supplementation (one to two years) induced a slight decline in RRs. The mean selenium plasma concentration for participants was 114 µg/L at the time of randomisation. In the arm of the NPCT that was carried out in a single location ‐ Macon, Georgia, USA ‐ and included both 200 and 400 µg/d selenium supplementation (<a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>), non‐melanoma skin cancer risk increased in the 200‐µg/d arm after adjustment for age, sex, and smoking (unadjusted RR 1.49, 95% CI 1.10 to 2.03; adjusted HR 1.50, 95% CI 1.13 to 2.04) but not in the 400‐µg/d arm (unadjusted RR 0.88, 95% CI 0.66 to 1.16; adjusted HR 0.91, 95% CI 0.69 to 1.20). At the remaining sites, where only 200 µg/d of supplemental selenium was given, the RR was 1.24 (95% CI 1.07 to 1.45) and the HR was 1.18 (95% CI 1.02 to 1.37). Distribution of baseline plasma selenium levels was similar in this substudy to that in the NPCT main study, and no evidence of effect modification according to baseline selenium exposure emerged. Overall, the NPCT did not support preventive efficacy of selenium yeast supplementation against non‐melanoma skin cancer in these populations; on the contrary, investigators reported a cancer‐promoting effect of selenium for this cancer type, which was the primary trial endpoint, raising concern about potentially harmful effects of such selenium supplementation (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). </p> <p>SELECT, which is the largest selenium supplementation trial conducted to date (Lippman 2009 and Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), thus far has not investigated the incidence of non‐melanoma skin cancer. A small trial in a French population of 184 organ graft recipients who were considered to be at high risk of premalignant and malignant epithelial lesions (<a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>) investigated non‐melanoma skin cancer. This trial detected a higher incidence of skin cancer among 91 selenium‐supplemented participants (six cases; 6.6%) compared with 93 placebo‐supplemented participants (two cases; 2.2%; P = 0.15) during a five‐year follow‐up, which in its first three years comprised daily supplementation with selenised yeast containing 200 µg selenium. </p> <p>A small trial among participants at high risk for prostate cancer also investigated the effects of using selenium supplements of 200 and 400 µg/d on risk of non‐melanoma skin cancer, with a median follow‐up of three years (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>). Results for non‐melanoma skin cancer from this study showed the occurrence of three cases among 232 placebo‐treated participants and 11 cases among 467 selenium‐supplemented participants (eight cases among 234 individuals receiving 200 µg/d of selenium, and three cases among 233 individuals receiving 400 µg/d), with increased risk after overall selenium supplementation (incidence rate ratio from our calculation 1.8, 95% CI 0.5 to 10.2) but no evidence of a dose‐response relation. </p> <p>The ECOG trial investigated non‐melanoma skin cancer and found 19 cases during follow‐up of 521 placebo‐treated participants and 11 cases among 1040 selenium‐allocated participants (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). The RR of non‐melanoma skin cancer in this study was computed as 0.66(95% CI 0.37 to 1.19). </p> <p>Overall, the summary RR for non‐melanoma skin cancer in selenium‐supplemented participants could be computed by pooling RRs from the above trials, rather than by using numbers of participants and cases, because the number of skin cancer cases diagnosed in the NPCT was not reported in the relevant publication (Duffield‐Lillico 2003a, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). The estimated RR limited to the only two trials with low risk of bias indicated a statistically unstable increased risk of non‐melanoma skin cancer associated with selenium supplementation of 200 µg/d (RR 1.16, 95% CI 0.30 to 4.42), with similar risk results when analysis was performed on the four trials overall (RR 1.23, 95% CI 0.73 to 2.08) (<a href="./references#CD005195-fig-0015" title="">Analysis 1.8</a>) (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). </p> </section> <section id="CD005195-sec-0081"> <p><b>1.1.7.2. Basal cell carcinoma (BCC)</b></p> <p><a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a> found in the 200‐ and 400‐µg/d selenium groups an RR of 0.86 (95% CI 0.42 to 1.77) and 0.80 (95% CI 0.38 to 1.66), respectively; and an RR in both treatment groups combined of 0.83 (95% CI 0.45 to 1.54). ECOG 5597 found an RR of 0.54 (95% CI 0.26 to 1.14) (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). </p> <p>At the end of the blinded treatment period in <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>, the unadjusted RR for basal cell carcinoma in the 200‐µg/d selenium group was 1.17 (95% CI 1.02 to 1.35), and the adjusted HR was 1.09 (95% CI 0.94 to 1.26). Eliminating cases that occurred within the first two years of supplementation had no effect on the RR. <a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a> found a crude RR of 0.90 (95% CI 0.65 to 1.24) and an adjusted HR of 0.95 (95% CI 0.69 to 1.29) for this cancer type in the 400‐µg/d selenium substudy. In a small trial with no RR estimates (<a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>), three cases of BCC occurred among 91 selenium‐supplemented participants, along with one case among 93 placebo‐receiving participants. </p> </section> <section id="CD005195-sec-0082"> <p><b>1.1.7.3. Squamous cell carcinoma (SCC)</b></p> <p><a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a> found an RR of 0.58 (95% CI 0.27 to 1.25) and 0.12 (95% CI 0.03 to 0.50) in the 200‐ and 400‐µg/d trial populations, respectively, and for all participants, the RR was 0.35 (95% CI 0.17 to 0.72). ECOG 5597 found an RR of 0.92 (95% CI 0.34 to 2.47) (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). </p> <p>In <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>, selenium supplementation increased the risk of SCC (unadjusted RR 1.32, 95% CI 1.09 to 1.60; adjusted HR 1.25, 95% CI 1.03 to 1.51). Adverse effects of selenium supplementation on SCC risk appeared to increase with increasing plasma selenium levels at baseline, in that higher risk was seen only in participants at the highest two tertiles of baseline levels (≥ 105.6 µg/L), suggesting an interaction between supplementation and baseline exposure. In the 400‐µg/d selenium substudy (<a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a>), investigators reported no change in SCC risk by selenium supplementation (crude RR 1.20, 95% CI 0.85 to 1.68; adjusted HR 1.05, 95% CI 0.71 to 1.56). <a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>, the smaller trial, reported that two among 91 selenium‐supplemented individuals were given a diagnosis of SCC, whereas no cases were observed among placebo participants. </p> </section> </section> <section id="CD005195-sec-0083"> <h6 class="title">1.1.8. Lung cancer</h6> <p>Three RCTs have investigated lung cancer risk associated with selenium administration (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), with two assessed as having low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). Summary RR estimates were 1.16 (95% CI 0.89 to 1.50) when we limited the analysis to studies at low risk of bias, and 1.03 (95% CI 0.78 to 1.37) when we included all studies (<a href="./references#CD005195-fig-0016" title="">Analysis 1.9</a>). </p> </section> <section id="CD005195-sec-0084"> <h6 class="title">1.1.9. Female breast cancer</h6> <p>Three studies evaluated breast cancer risk associated with selenium supplementation (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), one of which we judged as having low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). The RR from the study with low risk of bias was 2.04 (95% CI 0.44 to 9.55), with statistical imprecision due to the small number of cases (eight in the selenium arm, two in the placebo arm). The pooled RR from all studies was 1.44 (95% CI 0.96 to 2.17) (<a href="./references#CD005195-fig-0017" title="">Analysis 1.10</a>). </p> </section> <section id="CD005195-sec-0085"> <h6 class="title">1.1.10. Bladder cancer</h6> <p>Three studies evaluated bladder cancer outcomes (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), two of which we judged as having low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), The summary RR from the only studies at low risk of bias was 1.07 (95% CI 0.76 to 1.52). The corresponding RR for all studies, encompassing a total of 146 cases ‐ 79 in the selenium arms and 67 in the placebo arms ‐ was 1.10 (95% CI 0.79 to 1.52) (<a href="./references#CD005195-fig-0018" title="">Analysis 1.11</a>). </p> </section> <section id="CD005195-sec-0086"> <h6 class="title">1.1.11. Prostate cancer</h6> <p>Five trials evaluated prostate cancer (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), all of which we judged as having low risk of bias, except for <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>. Meta‐analysis for prostate cancer‐based trials at low risk of bias yielded an RR of 1.01 (95% CI 0.90 to 1.14) for the 9630 participants supplemented with selenium (520 cases) compared with the 9312 participants allocated to placebo (500 cases), indicating no effect of intervention (supplementation of organic selenium at 200 µg/d) on prostate cancer risk, with very consistent results and no heterogeneity across these studies (I² = 0.0%). The overall RR was 0.91 (95% CI 0.75 to 1.12) when all studies were considered; moderate heterogeneity (I² = 36%) emerged owing to the addition of the NPCT (<a href="./references#CD005195-fig-0019" title="">Analysis 1.12</a>) (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). </p> <p>The trial that first investigated the relation between selenium exposure and prostate cancer risk (Duffield‐Lillico 2002 and Duffield‐Lillico 2003b, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>) reported a reduction in prostate cancer incidence in the selenium‐treated group, which was particularly strong during the first period of follow‐up (1983 to 1993; adjusted HR 0.35, 95% CI 0.16 to 0.65) and was slightly higher but still much lower than unity during the entire period of follow‐up (1983 to 1996; HR 0.48, 95% CI 0.28 to 0.80). Analyses stratified by baseline plasma selenium category showed greatly reduced risk associated with active treatment among participants with baseline plasma selenium ≤ 106.4 µg/L (HR 0.14, 95% CI 0.03 to 0.61) in the intermediate category (106.8 to 123.2 µg/L; HR 0.33, 95% CI 0.13 to 0.82), while in the upper category (&gt; 123.2 µg/L), the HR was 1.14 (95% CI 0.51 to 2.59). Selenium supplementation in participants with baseline PSA ≤ 4 ng/mL was associated with considerably reduced risk (HR 0.33, 95% CI 0.14 to 0.79) compared with risk in individuals with PSA &gt; 4 ng/mL (HR 0.95, 95% CI 0.42 to 2.14). However, interpretation of these NPCT findings is complicated by a potentially serious source of bias. As reported in 2003 by the study authors, a considerably higher percentage of participants with elevated PSA levels in the placebo group underwent prostatic biopsy as compared with participants in the selenium group (35% vs 14%; P &lt; 0.05; Duffield‐Lillico 2003b, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). Differences in biopsy rates were greatest among participants with the lowest baseline selenium concentrations ‐ the subgroup that appeared to derive the greatest beneficial effects of selenium administration. This may have contributed to substantial overestimation of the effects of selenium supplementation in the NPCT. </p> <p>The SELECT trial found no evidence of benefit derived from selenium supplementation (compared with placebo) over a median of 5.5 years in terms of prostate cancer incidence (HR 1.03, 95% CI 0.90 to 1.18, 99% CI 0.87 to 1.24) (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). The adjusted HR for prostate cancer in the selenium plus vitamin E group compared with the placebo group was 1.05 (95% CI 0.91 to 1.20, 99% CI 0.88 to 1.25). The original report of the trial provided no specific RR estimate according to disease severity, but during an extended follow‐up of this cohort after selenium supplementation had ceased (Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), investigators found increased risk of Gleason 7 or greater disease (HR 1.21, 99% CI 0.90 to 1.63). It is interesting to note that the SELECT trial included only participants with PSA ≤ 4 ng/mL ‐ the group in the NPCT that showed greatest apparent benefit. During this further follow‐up of the SELECT cohort, risk of prostate cancer in the selenium arm also slightly increased compared with that described in the first report, which had included only the active supplementation period (Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). In this longer follow‐up based on 575 prostate cancer cases in the selenium arm and 529 in the placebo arm, the RR of prostate cancer was 1.09 (99% CI 0.93 to 1.27). </p> <p>Three further reports from SELECT on the relation between selenium administration and prostate cancer risk have been published (<a href="./references#CD005195-bbs2-0084" title="AlbanesD , TillC , KleinEA , GoodmanPJ , MondulAM , WeinsteinSJ , et al. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research (Philadelphia, Pa.)2014;7(9):886‐95. [PUBMED: 24961880] ">Albanes 2014</a>; <a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>; <a href="./references#CD005195-bbs2-0120" title="MartinezEE , DarkeAK , TangenCM , GoodmanPJ , FowkeJH , KleinEA , et al. A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research2014;7(9):950‐7. [PUBMED: 24894197] ">Martinez 2014</a>); where investigators looked at more specific associations than were addressed in the two main publications from this trial (Lippman 2009 and Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). <a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> performed a case‐cohort study within the SELECT study by including 1739 total prostate cancer cases (of which 489 showed high‐grade (Gleason 7 to 10) disease) and 3117 randomly selected men composing the control subcohort (<a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>). Administration of selenium (both selenium only and selenium combined with vitamin E) had no effect on prostate cancer risk among men with low baseline selenium status (&lt; 60th percentile of toenail selenium), but among participants in the two upper quintiles of baseline selenium exposure, risk of prostate cancer was increased (HR 1.20, 95% CI 0.85 to 1.81), particularly high‐grade prostate cancer (HR 1.62, 95% CI 0.95 to 2.77). HRs were even higher when any selenium supplementation (alone or with vitamin E) was considered because such supplementation increased the risk of any prostate cancer (RR 1.27, 95% CI 0.92 to 1.74) and high‐grade disease (RR 1.91, 95% CI 1.20 to 3.05). </p> <p><a href="./references#CD005195-bbs2-0120" title="MartinezEE , DarkeAK , TangenCM , GoodmanPJ , FowkeJH , KleinEA , et al. A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research2014;7(9):950‐7. [PUBMED: 24894197] ">Martinez 2014</a> investigated the effect of selenium supplementation on prostate cancer risk among participants in SELECT who had genotypes associated with altered mRNA expression of the androgen‐regulated prostate tumour suppressor protein NKX3.1. The design was still of the case‐cohort type, encompassing 1866 prostate cancer cases and 3135 non‐prostate cancer cases. Trial authors found that selenium administration combined with the CC genotype at rs11781886 increased overall prostate cancer risk (HR 1.68, 95% CI 1.01 to 2.78) and low‐grade prostate cancer risk (HR 1.81, 95% CI 1.02 to 3.23), but they noted no such interaction for the other genotypes. </p> <p>Finally, in a SELECT subpopulation composed of 1746 prostate cancer cases and a subcohort of 3211 men, <a href="./references#CD005195-bbs2-0084" title="AlbanesD , TillC , KleinEA , GoodmanPJ , MondulAM , WeinsteinSJ , et al. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research (Philadelphia, Pa.)2014;7(9):886‐95. [PUBMED: 24961880] ">Albanes 2014</a> investigated a possible association between baseline plasma α‐tocopherol and γ‐tocopherol and active supplementation with selenium (and vitamin E as α‐tocopherol) in terms of prostate cancer risk. Trial authors found a strong excess of risk among participants in the highest baseline α‐tocopherol category (fifth quintile) receiving selenium supplementation (HR 2.04, 95% CI, 1.29 to 3.22, P trend 0.005), which was higher with high‐grade (Gleason grade 7 to 10) disease among men receiving selenium (HR 2.12, 95% CI, 1.32 to 3.40, P‐trend 0.0002). These findings suggest a possible biological interaction between α‐tocopherol status and selenium supplementation in increasing high‐grade prostate cancer risk. </p> <p>In <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>, prostate cancer incidence was 35.6% versus 36.6% in selenium‐supplemented compared with placebo‐treated participants after three years of follow‐up, respectively. The overall RR was 0.91, with a 95% CI of 0.55 to 1.52 (courtesy of James Marshall, unpublished data). Analysis of RRs according to baseline plasma selenium levels showed no dose‐response effect, with point estimates of 0.82 (95% CI 0.40 to 1.69), 1.38 (95% CI 0.68 to 2.78), 0.98 (95% CI 0.58 to 1.68), and 0.91 (95% CI 0.45 to 1.84), when the quartile of selenium status was increased at baseline. </p> <p>The NBT reported an HR of prostate cancer of 0.94 (95% CI 0.52 to 1.70) for participants receiving 200 µg/d and 0.90 (95% CI 0.48 to 1.66) for those receiving 400 µg/d, compared with placebo (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>). Although average baseline selenium status, as assessed through plasma selenium, was higher than in the NPCT (median value 126.1 vs 115.0 µg/L), the lowest tertile of plasma selenium levels had a median value (101.1 µg/L) well below the apparent threshold of around 120 µg/L, at which a beneficial effect of selenium seemed to occur in the NPCT. Furthermore, as noted by study authors, 45% of participants enrolled in this study had baseline plasma selenium levels &lt; 123 µg/L, which is the upper threshold for a protective effect of selenium supplementation according to results of the NPCT. Trial authors also stated: "None of the baseline variables modified the effect of selenium on the primary endpoint", and plasma selenium concentration at baseline was among these variables (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>). </p> <p><a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>, the ECOG trial, carried out in subjects with resected non‐small‐cell lung cancer, reported nine and 16 cases of newly diagnosed prostate cancer among 250 and 509 male participants in the placebo and selenium groups, respectively. This allowed us to compute an RR of 0.87 (95% CI 0.39 to 1.45) for prostate cancer in the selenium‐supplemented arm. </p> <p>Following the NPCT, none of the subsequent, high‐quality RCTs provided evidence suggesting that baseline selenium status could modify the effect of selenium supplementation on subsequent prostate cancer occurrence. In the NBT, the bottom category (tertile) of baseline plasma selenium levels in this trial population was 101.1 µg/L, i.e. lower than the upper bound of the bottom category (106.4 µg/L) and the middle category (106.8 to 123.2 µg/L) in the NPCT, both of which had shown a strongly decreased subsequent prostate cancer occurrence (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>). In the SWOG S9917 study, results of selenium supplementation were also made available for four categories (quartiles) of baseline plasma selenium and showed no effect of treatment in any categories (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>). These categories were &lt; 106, 106–132, 132–162, and &gt; 162 µg/L, and corresponding RRs of prostate cancer in the selenium‐supplemented group were 0.82 (95% CI 0.40 to 1.69), 1.38 (95% CI 0.68 to 2.78), 0.98 (95% CI 0.58 to 1.68), and 0.91 (95% CI 0.45 to 1.84), respectively, versus an overall study RR of 0.97 (95% CI 0.68 to 1.39). Therefore, also in this high‐quality trial, the bottom category of baseline selenium exposure was entirely similar to the corresponding one in the NPCT, but in contrast to NPCT, no effect of selenium supplementation emerged and no evidence showed risk of bias. Finally, a case‐cohort study carried out within SELECT and published in 2014 provided data showing the relation between baseline selenium exposure and effects of selenium supplementation (<a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>). In that study, whose average selenium exposure was higher than that characterising the NPCT and the NBT, investigators reported no effect of selenium supplementation on both overall prostate cancer and low‐grade and high‐grade prostate cancer in the three quintiles of baseline toenail selenium levels, but enhanced risk of high‐grade prostate cancer emerged for the two upper quintiles (alone and combined). Quintile cutoff points for these categories of the trial population were 0.758, 0.832, 0.901, and 1.003 µg/g. Overall, these results clearly indicate that even in subgroups with the lowest baseline selenium status in these Western populations, selenium provided no protective effect for prevention of prostate cancer, although this is the cancer type that once was thought to be most strongly associated with a beneficial effect of selenium supplementation. </p> </section> <section id="CD005195-sec-0087"> <h6 class="title">1.1.12. Haematological cancers</h6> <p>Two trials evaluated the risk of haematological malignancies associated with selenium administration (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>) using 23 cases only ‐ 14 in the selenium arms and 9 in the placebo arms ‐ but we judged only one trial to be at low risk of bias (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). The summary RR was 1.00 (95% CI 0.25 to 3.99) in the study at low risk of bias and 1.21 (95% CI 0.52 to 2.80) when all studies were considered (<a href="./references#CD005195-fig-0020" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD005195-sec-0088"> <h5 class="title">1.2. Adverse effects outcomes</h5> <p>The RCTs on selenium have provided unexpected information about the incidence of adverse effects of selenium supplementation and have unexpectedly become a key source of data for risk assessment of the upper safe level of selenium exposure in humans (<a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>; <a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). Thirty‐five participants withdrew from the NPCT because of adverse effects, mainly gastrointestinal upset. The RR for adverse events in the selenium group was 1.51 (95% CI 0.74 to 3.11) (our calculation, based on the number of randomly assigned participants). Reports of increased risk of glaucoma in <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a> and <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a> prompted additional studies on this issue (<a href="./references#CD005195-bbs2-0156" title="BruhnRL , StamerWD , HerrygersLA , LevineJM , NoeckerRJ . Relationship between glaucoma and selenium levels in plasma and aqueous humour. British Journal of Ophthalmology2009;93(9):1155‐8. ">Bruhn 2009</a>), and likely led to inclusion of cataract and glaucoma among the several potential adverse events monitored during subsequent trials in which investigators administered selenium (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>). </p> <p>In the NPCT, a secondary analysis of participants who did not have diabetes at the start of the study unexpectedly revealed an excess risk of type 2 diabetes mellitus in the selenium group (adjusted HR 1.55, 95% CI 1.03 to 2.33) (<a href="./references#CD005195-bbs2-0274" title="StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">Stranges 2007</a>). That study found increased risk of developing type 2 diabetes associated with selenium supplementation across all tertiles of baseline plasma selenium levels, although the excess was much greater for the upper category of &gt; 121.6 µg/L (RR 2.70, 95% CI 1.30 to 5.61) than for the lower (RR 1.13, 95% CI 0.58 to 2.18) and intermediate (RR 1.36, 95% CI 0.60 to 3.09) categories. Increased risk of diabetes associated with selenium supplementation was independent of baseline age, sex, smoking status, and body mass index (BMI), with the exception of participants in the top tertile of BMI. SELECT reported a slight increase in the incidence of type 2 diabetes in the selenium‐alone group (RR 1.07, 99% CI 0.94 to 1.22). Any such excess risk decreased over time after selenium supplementation ceased, as is shown by results of the Klein study (Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). In this study, the RR of diabetes was 1.04 (99% CI 0.93 to 1.17), thus supporting a short‐term effect of selenium supplementation on diabetes risk. </p> <p>Although the three trials on liver cancer and <a href="./references#CD005195-bbs2-0063" title="ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. ">Reid 2008</a> did not mention the occurrence of adverse effects, and <a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a> and <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a> (the SWOG 2011 trial) apparently performed no assessment of diabetes incidence, three recent phase 3 RCTs have investigated the occurrence of diabetes after selenium supplementation for prevention of malignant and non‐malignant cancer. In the NBT, during five years of follow‐up of 699 participants at high risk for prostate cancer supplemented with 200 or 400 µg/d of selenium or placebo, <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a> reported the occurrence of diabetes in 12, 12, and 7 participants, respectively. This allowed us to compute an incidence rate ratio of 1.70 (95% CI 0.62 to 5.10) and 1.71 (95% CI 0.62 to 5.12) among 200‐ and 400‐µg/d selenium‐supplemented participants, respectively, compared with those given placebo. The ECOG trial, which was carried out in 1561 participants with resected stage I non–small‐cell lung cancer, trial authors did not explicitly report the RR of diabetes during follow‐up (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). However, occurrence during four years of follow‐up (2007 to 2011) was stated as 26 new diagnoses of diabetes in the selenium arm (1040 participants at baseline, of whom 865 underwent toxicity assessment) and 12 new diagnoses among placebo‐treated participants (521/477). On the basis of these numbers, we could compute an RR of 1.09 (95% CI 0.55 to 2.13) or, for participants with toxicity assessment, 1.19 (95% CI 0.61 to 2.35) ‐ values comparable with those observed in the other trials, except for NPCT. Most recently, in an intervention study investigating the effect of selenium supplementation for prevention of colorectal adenoma recurrence compared with placebo (the SELCEL trial), 31 cases of diabetes occurred in the selenium‐treated group and 25 in the placebo group during follow‐up, with an RR of 1.25 (95% CI 0.74 to 2.11) (<a href="./references#CD005195-bbs2-0280" title="ThompsonPA , AshbeckEL , RoeDJ , FalesL , BuckmeierJ , WangF , et al. Selenium supplementation for prevention of colorectal adenomas and risk of associated type 2 diabetes. Journal of the National Cancer Institute2016;108(12):djw152. [PUBMED: 27530657] ">Thompson 2016</a>). Therefore, an excess incidence of type 2 diabetes systematically emerged in all trials that investigated this adverse effect (<a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). </p> <p>The SELECT study also looked at other side effects known to be associated with selenium overexposure (<a href="./references#CD005195-bbs2-0286" title="VincetiM , WeiET , MalagoliC , BergomiM , VivoliG . Adverse health effects of selenium in humans. Reviews on Environmental Health2001;16(4):233‐51. ">Vinceti 2001</a>), finding an association for some of them. Selenium treatment increased the occurrence of alopecia (RR 1.28, 95% CI 1.07 to 1.53, based on 265/206 cases in selenium and placebo arms), dermatitis (RR 1.16, 95% CI 1.03 to 1.29, 619/524), nail changes (RR 1.04, 95% CI 0.96 to 1.13, 1087/1035), and halitosis (RR 1.17, 95% CI 0.99 to 1.38, 503/427). </p> </section> </section> <section id="CD005195-sec-0089"> <h4 class="title">2. Observational studies</h4> <p>When risks of cancer for higher and lower levels of selenium exposure are compared, a summary risk estimate of one suggests no association between selenium exposure and cancer, and summary risk estimates below and above one suggest a beneficial or harmful effect of higher selenium exposure, respectively. We evaluated the statistical precision of the point estimates by assessing the width of their 95% or 99% confidence intervals. </p> <section id="CD005195-sec-0090"> <h5 class="title">2.1. Aetiological association: results from meta‐analyses</h5> <section id="CD005195-sec-0091"> <h6 class="title">2.1.1. Any cancer</h6> <p>We meta‐analysed results of 16 prospective observational studies on total cancer risk, including data on more than 276,000 participants. The cohorts of <a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> and <a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a> overlapped. Hence, we included only data from <a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a> in the meta‐analysis. We had to omit <a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a>, as the CI value was not reported and could not be calculated from available data. </p> <p>For participants in the highest category of pre diagnostic selenium exposure, the summary risk estimate was odds ratio (OR) 0.72 (95% CI 0.55 to 0.93) for cancer incidence and OR 0.76 (95% CI 0.59 to 0.97) for cancer mortality for both sexes combined (<a href="./references#CD005195-fig-0021" title="">Analysis 2.1</a>), when compared with participants in the lowest exposure category. We observed moderate to substantial heterogeneity for both incidence (I² = 45%) and mortality (I² = 67%). </p> <p>Analyses by sex revealed lower point estimates for men (incidence: OR 0.72, 95% CI 0.46 to 1.14; mortality: OR 0.65, 95% CI 0.45 to 0.94) (<a href="./references#CD005195-fig-0022" title="">Analysis 2.2</a>) than for women (incidence: OR 0.90, 95% CI 0.45 to 1.77; mortality: OR 0.91, 95% CI 0.80 to 1.03) (<a href="./references#CD005195-fig-0023" title="">Analysis 2.3</a>). </p> <p>All studies but one (<a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a>) used a circulating biomarker (serum and plasma selenium levels) for assessment of selenium status. <a href="./references#CD005195-fig-0024" title="">Analysis 2.4</a> shows the results in ascending order of baseline exposure for those studies that reported category borders. The graph does not reveal any systematic pattern of changes in the relation between selenium status and cancer risk according to increasing baseline selenium levels. <a href="./references#CD005195-fig-0025" title="">Analysis 2.5</a> shows the results in ascending order for differences in selenium levels. </p> </section> <section id="CD005195-sec-0092"> <h6 class="title">2.1.2. Stomach cancer</h6> <p>No additional cohort studies on stomach cancer and selenium exposure have been published since the last update of this review; therefore meta‐analysis for this cancer type was still based on five studies. The summary risk estimate for both sexes combined was OR 0.66 (95% CI 0.43 to 1.01) in the highest exposure category when compared with the lowest (I² = 51%) (<a href="./references#CD005195-fig-0026" title="">Analysis 2.6</a>). In this meta‐analysis, we included one cohort twice because trial authors reported results stratified according to cardia and non‐cardia gastric cancer (Mark 2000, in: <a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a>). </p> <p>Use of available sex‐stratified results for meta‐analysis yielded a risk estimate for men of OR 0.43 (95% CI 0.14 to 1.32) (I² = 56%), and for women of OR 0.73 (95% CI 0.12 to 4.35) (I² = 62%) (<a href="./references#CD005195-fig-0027" title="">Analysis 2.7</a>). </p> </section> <section id="CD005195-sec-0093"> <h6 class="title">2.1.3. Colorectal/Colon cancer</h6> <p>Six observational studies reported data on the incidence of colorectal cancer. The summary risk estimate was OR 0.82 (95% CI 0.72 to 0.94) for both sexes combined (I² = 0.0%) (<a href="./references#CD005195-fig-0028" title="">Analysis 2.8</a>), with OR 0.86 (95% CI 0.65 to 1.16) for men and OR 0.96 (95% CI 0.61 to 1.50) for women (<a href="./references#CD005195-fig-0029" title="">Analysis 2.9</a>). Five studies reported data stratified or restricted to colon cancer. The summary estimate was OR 0.81 (95% CI 0.69 to 0.96) for both sexes combined (I² = 0.0%) (<a href="./references#CD005195-fig-0030" title="">Analysis 2.10</a>), with OR 0.84 (95% CI 0.56 to 1.25) for men and OR 0.68 (95% CI 0.44 to 1.04) for women (<a href="./references#CD005195-fig-0031" title="">Analysis 2.11</a>). </p> </section> <section id="CD005195-sec-0094"> <h6 class="title">2.1.4. Lung cancer</h6> <p>We included 13 studies in this meta‐analysis. We did not meta‐analyse data from <a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> and <a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a>, as the study population of the former overlapped with that of <a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> (another meta‐analysed study) ‐ and results of the latter were presented in insufficient detail. </p> <p>The summary risk estimate for lung cancer incidence for both sexes combined was 0.82 (95% CI 0.59 to 1.14) (<a href="./references#CD005195-fig-0032" title="">Analysis 2.12</a>). We noted substantial heterogeneity among study results (I² = 66%). We found little difference in summary estimates when results were disaggregated by sex (<a href="./references#CD005195-fig-0033" title="">Analysis 2.13</a>), by indicator of selenium exposure (intake, blood or toenail content) (<a href="./references#CD005195-fig-0034" title="">Analysis 2.14</a>), by baseline serum/plasma bottom exposure category (<a href="./references#CD005195-fig-0035" title="">Analysis 2.15</a>), and by ascending differences in selenium levels (<a href="./references#CD005195-fig-0036" title="">Analysis 2.16</a>). In the latter analyses, we noted no dose‐response relation between baseline selenium and risk. </p> </section> <section id="CD005195-sec-0095"> <h6 class="title">2.1.5. Female breast cancer</h6> <p>We included eight studies in this meta‐analysis. Data show little association between baseline selenium levels and breast cancer risk, with a slightly but imprecisely higher risk for higher exposure (OR 1.09, 95% CI 0.87 to 1.37) (<a href="./references#CD005195-fig-0037" title="">Analysis 2.17</a>). The heterogeneity of results was low (I² = 14%). </p> </section> <section id="CD005195-sec-0096"> <h6 class="title">2.1.6. Bladder cancer</h6> <p>Meta‐analysis of bladder cancer incidence in five observational studies revealed an inverse association, with an overall risk estimate of 0.67 (95% CI 0.46 to 0.97) (<a href="./references#CD005195-fig-0038" title="">Analysis 2.18</a>) (heterogeneity: I² = 30%). Sex‐disaggregated data were available only from <a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> and showed an inverse association between selenium exposure and risk in women, but not in men. Two studies included only male participants (<a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a>; <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a>); both found a reduced but imprecisely estimated bladder cancer risk for higher selenium exposure (<a href="./references#CD005195-fig-0038" title="">Analysis 2.18</a>). Heterogeneity was not reduced by sex stratification (I² = 40% in study results for men). No further studies had been published since the last update of this review (<a href="./references#CD005195-bbs2-0314" title="VincetiM , DennertG , CrespiCM , ZwahlenM , BrinkmanM , ZeegersMP , et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005195.pub3; PUBMED: 24683040] ">Vinceti 2014</a>). </p> </section> <section id="CD005195-sec-0097"> <h6 class="title">2.1.7. Prostate cancer</h6> <p>We included 21 epidemiological studies on prostate cancer incidence in the meta‐analysis. The summary risk estimate for higher selenium exposure was OR 0.84 (95% CI 0.75 to 0.95) (heterogeneity: I² = 27%) (<a href="./references#CD005195-fig-0039" title="">Analysis 2.19</a>). Stratification of the analysis by method of selenium assessment revealed an inverse association between baseline selenium and risk when exposure was assessed through blood selenium levels (OR 0.86, 95% CI 0.75 to 0.99) or toenails (OR 0.60, 95% CI 0.44 to 0.82), but not when dietary assessment methods were used (OR 0.99, 95% CI 0.85 to 1.15) (<a href="./references#CD005195-fig-0040" title="">Analysis 2.20</a>). When we stratified analysis according to baseline (blood) selenium exposure or differences in selenium (blood) levels, no specific relation or pattern emerged between selenium and prostate cancer risk across the entire exposure spectrum (<a href="./references#CD005195-fig-0041" title="">Analysis 2.21</a>; <a href="./references#CD005195-fig-0042" title="">Analysis 2.22</a>). </p> </section> </section> <section id="CD005195-sec-0098"> <h5 class="title">2.2. Aetiological association: other results</h5> <p>For all other types of cancer, data were available from fewer than five epidemiological studies; thus we did not meta‐analyse the results. We have reported in <a href="#CD005195-tbl-0005">Table 3</a> results of observational studies not included in meta‐analyses. None of these study results support an association between selenium exposure and gynaecological cancer risk, and results for cancers of the gastrointestinal, respiratory, or urological tract are inconsistent. For respiratory and urological cancers, studies reported either no association or increased risk for participants with higher selenium exposure. For gastrointestinal cancers including cancer of the liver and other sites not mentioned above, studies found either no association or reduced risk with higher selenium exposure. </p> <div class="table" id="CD005195-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of observational studies not included in meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Organ system</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Case definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio estimate (highest vs lowest exposure category)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selenium marker</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sex</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Gynaecological</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cervix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 2.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Batieha 1993) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecological (without breast)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 to 5.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> (Knekt 1996) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 3.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 to 1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Helzlsour 1996) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 to 1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uterus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 to 3.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="33" valign=""> <p><b>Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal tract (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum/plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oesophageal squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 to 0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 to 1.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 to 1.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Oesophagus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> (Mark 2000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 to 0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> (<a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 to 2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastric cardio adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 to 1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oesophagus and stomach</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> (Knekt 1988) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 to 1.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 to 0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 to to 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 to 1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 to 1.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 to 0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 to 1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 to 1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Pancreas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 to 0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Burney 1989) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 1.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 to 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 to 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>supplemental intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Rectum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 to 2.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 to 2.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 to 4.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 to 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>supplement use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 to 1.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 to 3.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 to 1.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Urological cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 to 0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dietary intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Urinary tract (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 to 1.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0029" title="HotalingJM , WrightJL , PocobelliG , BhattiP , PorterMP , WhiteE . Long‐term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. The Journal of Urology2011;185(4):1210‐5. ">Hotaling 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Respiratory tract</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cavum oris/pharynx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Zheng 1993) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign=""> <p><b>Skin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 to 3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 to 2.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Breslow 1995) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 to 1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> (Asgari 2009) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any non‐melanoma cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Basal cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 to 4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Breslow 1995) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 to 1.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 to 1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 to 0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 to 1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Breslow 1995) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 to 1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 to 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 to 0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Other</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Haematological</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum/plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 to 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0077" title="WalterRB , BraskyTM , MilanoF , WhiteE . Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(10):2298‐308. ">Walter 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Thyroid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 to 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0 to 5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 to 1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 to 1.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 to 2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 to 2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n.r. = not reported.</p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005195-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005195-sec-0099"></div> <section id="CD005195-sec-0100"> <h3 class="title" id="CD005195-sec-0100">Summary of main results</h3> <p>The aims of this review were to examine the efficacy of selenium supplementation in preventing cancer and, more generally, to analyse the association between selenium exposure and risk of cancer in men and women. </p> <section id="CD005195-sec-0101"> <h4 class="title">Randomised controlled trials (RCTs) and preventive efficacy</h4> <p>We aimed to identify all RCTs so far carried out, extending the standard search by using unconventional methods such as citation chasing and scanning of conference proceedings ‐ methods that have proved effective in yielding additional high‐quality evidence for systematic reviews and meta‐analyses for other topics (<a href="./references#CD005195-bbs2-0180" title="GreenhalghT , PeacockR . Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ2005;331(7524):1064‐5. [PUBMED: 16230312] ">Greenhalgh 2005</a>; <a href="./references#CD005195-bbs2-0298" title="VincetiM , FilippiniT , CilloniS , PlattJ , JessC . Implications of different methods for literature searching and assessment in systematic reviews and meta‐analyses: a case study. Global Evidence Summit: Using evidence ‐ Improving lives; September 13‐16, 2017; Cape Town (Meeting Abstract). 2017. ">Vinceti 2017c</a>). Using this approach, we identified a total of 10 RCTs that investigated monoselenium supplements for prevention of non‐melanoma skin cancer, prostate cancer, any cancer, and other site‐specific cancers. Overall, clear and consistent evidence indicates that selenium supplementation did not reduce subsequent cancer incidence, whether this endpoint was considered a primary or secondary outcome. Most of these trials raised concerns about possible harmful effects of selenium supplements, including increased incidence of non‐melanoma skin cancer in the Nutritional Prevention of Cancer Trial (NPCT), dermatological effects in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and type 2 diabetes in all RCTs, although with generally limited and statistically imprecise risk ratios (RRs). </p> <p>Of the three liver cancer prevention trials, one reported a strongly reduced risk of liver cancer for male carriers of the hepatitis B surface antigen (HBs‐Ag) taking inorganic selenium supplements (sodium selenite) for three years, and the other two studies reported little effect of organic selenium supplements (selenium yeast) for the same cancer site (<a href="./references#CD005195-bbs2-0041" title="LiW , ZhuY , YanX , ZhangQ , LiX , NiZ , et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]2000;34(6):336‐8. [Li 2000] ">Li 2000</a>; <a href="./references#CD005195-bbs2-0081" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuS , LiW , ZhuY . Chemoprevention of liver cancer. CCPC‐93: Second International Cancer Chemo Prevention Conference; 1993 April 28‐30; Berlin (Meeting Abstracts).. YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1991</a>; <a href="./references#CD005195-bbs2-0082" title="LiWG . [Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]1992;26(5):268‐71. YuSY , ZhuYJ , LiWG . Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research1997;56(1):117‐24. [MEDLINE: 15873] YuSY , ZhuYJ , LiWG , HuangQS , HuangCZ , ZhangQN , et al. A preliminary report on the intervention trials of primary liver cancer in high‐risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research1991;29(3):289‐94. ">Yu 1997</a>). Owing to several methodological concerns related to randomisation and completeness of outcome data, we judged the risk of bias as unclear for all three of these RCTs. Therefore, we could not conclude that we found strong support for selenium supplements as agents for prevention of liver cancer. Unfortunately, the other trials did not include liver cancer among their secondary outcomes, with the exception of ECOG 5597 (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). In this RCT, investigators reported new cases of liver, gallbladder, and bile duct cancer only among selenium‐treated participants; however, trial authors observed a total of only six cases, making risk estimates highly statistically unstable. In addition, the population included in this trial, which comprised patients with a history of resected non‐small‐cell lung cancer, was rather different from the general population. </p> <p>The NPCT (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>) reported strongly decreased risk for all cancers (‐22%), and for oesophageal (‐59%), colorectal (‐52%), lung (‐28%), and prostate (‐46%) cancers, showing lesser decreases compared with the ad interim report (Clark 1996, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), but still indicative of a strong cancer preventive effect. In addition, when participants were categorised into tertiles according to baseline serum selenium, evidence suggested an inverse relationship between selenium status and effects of supplementation for all cancers and for prostate cancer in the lower two tertiles, and no effect in the upper tertile. However, interpretation of these results is difficult because in 2003, the trial authors acknowledged the occurrence of a detection bias, namely, a considerably higher rate of prostate biopsy in the placebo group, whose cause was not specified. It is unclear whether this detection bias applied only to prostate cancer or applied more generally to other outcomes (as would be the case if the bias was due to unblinding, for example). This major detection bias forced us to downgrade the reliability of this study. Data show an increase in the incidence of its primary outcome ‐ non‐melanoma skin cancer ‐ in selenium‐supplemented participants, as well as in the incidence of five other cancer types, including melanoma, bladder cancer, breast cancer, head and neck cancer, and lymphoma and leukaemia. Trial authors stated: "These results, although non‐significant and based on small case numbers, may indicate potential increased risk with selenium supplementation"; these authors also relied on previous observational studies to provide some support for these positive associations (Duffield‐Lillico 2002, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). </p> <p>The turning point of research on selenium and cancer was the SELECT trial (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), a large, well‐conducted prostate cancer prevention trial carried out in the male general population of North America not at high risk of prostate cancer (≤ 4 ng/mL in serum prostate‐specific antigen (PSA) and digital rectal examination not suspicious for cancer). This trial, widely considered a milestone in cancer prevention and research, found no difference in prostate cancer incidence for selenium–supplemented participants as compared with placebo participants after a median follow‐up of 5.5 years (hazard ratio (HR) 1.04, 95% confidence interval (CI) 0.90 to 1.18), and no effect of selenium on risk of overall cancer or on risk of other cancers (as well as cardiovascular disease). Median selenium at baseline (135 µg/L in serum in the selenium arm vs 137.6 µg/L in the placebo arm) was higher than in the NPCT (average plasma selenium 114 µg/L). The intervention used in this trial was different from that used in the NPCT (selenomethionine in SELECT, and selenised yeast in the former), although this is unlikely to have been responsible for observed differences (<a href="./references#CD005195-bbs2-0302" title="WatersDJ , ShenS , KengeriSS , ChiangEC , CombsGF , MorrisJS , BostwickDG . Toward interpreting the null results of SELECT: Direct comparison of the prostatic tissue potency of Supranutritional Selenomethionine vs. Selenium‐yeast on markers of prostatic homeostasis and cancer risk reduction. Proceedings of the 10th International Symposium on Selenium in Biology and Medicine. Berlin: Deutsche Forschungsgemeinschaft, 2013:62. ">Waters 2013</a>); in both cases, the intervention comprised organic selenium species (<a href="./references#CD005195-bbs2-0151" title="BlockE , GlassRS , JacobsenNE , JohnsonS , KahakachchiC , KaminskiR , et al. Identification and synthesis of a novel selenium‐sulfur amino acid found in selenized yeast: rapid indirect detection NMR methods for characterizing low‐level organoselenium compounds in complex matrices. Journal of Agricultural and Food Chemistry2004;52(12):3761‐71. ">Block 2004</a>). </p> <p>In a small study of organ transplant recipients (<a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>), an unexpected increase in non‐melanoma skin cancer incidence emerged; this was a matter of concern in the light of results of the NPCT. In the Polish trial <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>, which included 1135 women with high genetic susceptibility to breast cancer due to <i>BRCA1</i> mutations, evidence was more consistent with increased risk of both all cancers and primary breast cancer than with decreased risk, although with statistically unstable HRs (1.4, 95% CI 0.9 to 2.0; and 1.3, 95% CI 0.7 to 2.5, respectively). In this trial, the intervention consisted of administration of 250 µg/d of inorganic tetravalent selenium (selenite). </p> <p>More recently, results of three well‐conducted phase 3 trials in participants at higher risk for prostate cancer than the general male population indicated that 200 µg/d of selenium (as selenomethionine in one study ‐ <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a> ‐ and as selenised yeast in the other two ‐ <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>) did not decrease subsequent cancer incidence compared with placebo. The baseline selenium status of populations included in these RCTs was comparable with that in SELECT for Southwest Oncology Group (SWOG) S9917 (135 to 138 µg/L in the two arms) (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>), slightly lower in the Negative Biopsy Trial (NBT) (126.1 µg/L) (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), and unfortunately unspecified for Eastern Cooperative Oncology Group (ECOG) 5597 (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>). Results of these high‐quality RCTs, all characterised by low risk of bias and two of which were discontinued before their planned end for futility, were consistent and showed no beneficial effect of selenium treatment on cancer risk. </p> <p>Although not eligible for our meta‐analyses because their outcome was non‐malignant neoplasms rather than cancer, two recently published RCTs on colorectal adenoma risk in participants receiving selenium are worth noting. One of these trials was embedded in SELECT (<a href="./references#CD005195-bbs2-0214" title="LanceP , AlbertsDS , ThompsonPA , FalesL , WangF , San JoseJ , et al. Colorectal adenomas in participants of the select randomized trial of selenium and vitamin E for prostate cancer prevention. Cancer Prevention Research2017;10(1):45‐54. [PUBMED: 27777235] ">Lance 2017</a>), and the other, the SELCEL trial (an intervention study investigating the effect of selenium supplementation or celecoxib for prevention of colorectal adenoma recurrence), allocated 1374 men and women who had undergone removal of colorectal adenomas to either 200 µg/d selenium as selenised yeast, or placebo (<a href="./references#CD005195-bbs2-0280" title="ThompsonPA , AshbeckEL , RoeDJ , FalesL , BuckmeierJ , WangF , et al. Selenium supplementation for prevention of colorectal adenomas and risk of associated type 2 diabetes. Journal of the National Cancer Institute2016;108(12):djw152. [PUBMED: 27530657] ">Thompson 2016</a>). Both RCTs did not find a beneficial effect of selenium for prevention of colorectal adenoma. </p> <p>The RCTs carried out on selenium have generated clear evidence of adverse effects associated with selenium exposure, showing both the health effects related to overexposure and the amount at which these effects become evident, thus providing much more reliable evidence than that generated by environmental studies such as <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a> for use in risk assessments of the safe upper limit of selenium exposure in humans. The trial that provided the most evidence about selenium‐associated adverse effects was SELECT. These effects include an excess risk of dermatitis and alopecia, non‐melanoma skin cancer, high‐grade prostate cancer, and type 2 diabetes. The excess risk of dermatological effects was anticipated as a potential side effect based on previous knowledge of health consequences of human overexposure to this element (<a href="./references#CD005195-bbs2-0286" title="VincetiM , WeiET , MalagoliC , BergomiM , VivoliG . Adverse health effects of selenium in humans. Reviews on Environmental Health2001;16(4):233‐51. ">Vinceti 2001</a>), although such effects had been predicted to occur at higher amounts of selenium exposure than those experienced by SELECT supplemented participants, thus calling for reassessment of the upper limit of selenium exposure. The increased incidence of non‐melanoma skin cancer in NPCT and of advanced prostate cancer in SELECT was extremely disappointing, as they were the primary endpoints in these studies, and the expectation was that they would be reduced. The excess risk of diabetes in selenium‐supplemented NPCT participants, which was also an unanticipated finding, was mostly limited to participants in the two highest tertiles of baseline plasma selenium (&gt; 105.2 µg/L), raising concern about the safety of selenium amounts that thus far had been considered entirely safe (i.e. on the order of 200 µg/d) (<a href="./references#CD005195-bbs2-0274" title="StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">Stranges 2007</a>). Therefore, subsequent RCTs added this endpoint to monitored adverse effects that contributed to interruption of the SELECT trial, together with the null effect on cancer mortality and adverse effects of vitamin E on prostate cancer risk (Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). So far, all RCTs that included diabetes among trial endpoints, including trials investigating risk of colorectal adenoma, have shown an increased incidence of type 2 diabetes among selenium‐allocated participants, with RRs ranging from 1.08 to 1.71, although most estimates were statistically imprecise (<a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). In addition, in SELECT, a slight decrease in excess risk of diabetes in the intervention arm followed completion of selenium supplementation, further suggesting a causal relation between selenium administration and the disease (Lippman 2009 and Klein 2011, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). Currently, an excess risk of type 2 diabetes appears to be one of the adverse effects of selenium of greatest concern, and its plausibility is supported by the results of observational human studies (cohort, case‐control, and cross‐sectional), as well as by some biological plausibility (<a href="./references#CD005195-bbs2-0171" title="Galan‐ChiletI , Grau‐PerezM , DeMarcoG , GuallarE , Martin‐EscuderoJC , Dominguez‐LucasA , et al. A gene‐environment interaction analysis of plasma selenium with prevalent and incident diabetes: the Hortega study. Redox Biology2017;12:798‐805. [PUBMED: 28437656] ">Galan‐Chilet 2017</a>; <a href="./references#CD005195-bbs2-0278" title="SuLQ , JinYL , UnverzagtFW , ChengYB , HakeAM , RanL , et al. Nail selenium level and diabetes in older people in rural China. Biomedical and Environmental Sciences2016;29(11):818‐24. [PUBMED: 27998388] ">Su 2016</a>; <a href="./references#CD005195-bbs2-0280" title="ThompsonPA , AshbeckEL , RoeDJ , FalesL , BuckmeierJ , WangF , et al. Selenium supplementation for prevention of colorectal adenomas and risk of associated type 2 diabetes. Journal of the National Cancer Institute2016;108(12):djw152. [PUBMED: 27530657] ">Thompson 2016</a>; <a href="./references#CD005195-bbs2-0293" title="VincetiM , GrioniS , AlberD , ConsonniD , MalagoliC , AgnoliC , et al. Toenail selenium and risk of type 2 diabetes: the ORDET cohort study. Journal of Trace Elements in Medicine and Biology2015;29:145‐50. [PUBMED: 25169979] ">Vinceti 2015</a>; <a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>; <a href="./references#CD005195-bbs2-0310" title="ZhouJ , HuangK , LeiXG . Selenium and diabetes ‐ evidence from animal studies. Free Radical Biology &amp; Medicine2013;65:1548‐56. [PUBMED: 23867154] ">Zhou 2013</a>). These side effects, in addition to the null results of RCTs, particularly of those of the highest quality, make implementation of new trials very unlikely owing to ethical concerns. </p> </section> <section id="CD005195-sec-0102"> <h4 class="title">Observational studies and aetiological association</h4> <p>From our meta‐analyses of 16 prospective observational studies on overall cancer risk, we found lower cancer risk associated with highest selenium exposure compared with lowest exposure. Risk of cancer was 28% (95% CI 7% to 45%) lower in the highest category of selenium exposure than in the lowest, and risk of death from cancer was 24% (95% CI 3% to 41%) lower. Subgroup analyses by sex yielded increased evidence of this inverse association between selenium exposure and cancer risk in men compared with women. </p> <p>The inverse association between overall cancer risk and baseline selenium levels was mainly attributable to lower risks of gastrointestinal, lung, and bladder cancer, and for men also prostate cancer. No association was seen between selenium and risk of breast cancer in women. However, when the amount of baseline exposure was taken into consideration, no clear and consistent trend between baseline selenium exposure and risk emerged for any of the major outcomes investigated in observational studies. Lack of lower risk of cancer in the highest versus the lowest selenium category among participants with the lowest baseline exposure levels compared with those with intermediate or high levels, for overall cancer, lung cancer, and prostate cancer, argues against a causal association between selenium exposure and cancer risk. This is supported by lack of a relation between differences in the highest and lowest categories of selenium exposure and the corresponding RR, further suggesting that larger differences in exposure are not associated with large and consistent decreases in RR. Finally, further uncertainty of the evidence generated by observational studies arises from the inconsistent and sometimes sharply conflicting results on the same cancer type that emerged from different studies. </p> <p>We saw little evidence of any effect of modification on the relation of selenium and cancer by geographical area of residence. It should however be noted that most of the observational cohort studies that we examined were conducted in Europe and in the USA, and none were conducted in Africa or South America. This regional distribution seems to reflect the under representation of non‐Western and resource‐poor countries in epidemiological research (<a href="./references#CD005195-bbs2-0241" title="PearceN . The globalization of epidemiology: introductory remarks. International Journal of Epidemiology2004;33(5):1127‐31. ">Pearce 2004</a>). Differential regional representation in epidemiological studies is of special interest for this review, as selenium levels in humans around the world vary significantly. Even if selenium levels measured in included cohorts reflect a broad range of naturally occurring selenium exposure, investigators have reported some of the lowest and highest levels of selenium exposure in populations from South America (<a href="./references#CD005195-bbs2-0201" title="JafféW . Selenio, un elemento esencial y toxico. Datos de Latinoamerica. Archivos Latinoamericanos de Nutrición1992;42(2):90‐3. ">Jaffé 1992</a>), Africa (<a href="./references#CD005195-bbs2-0194" title="HurstR , SiyameEW , YoungSD , ChilimbaAD , JoyEJ , BlackCR , et al. Soil‐type influences human selenium status and underlies widespread selenium deficiency risks in Malawi. Scientific Reports2013;3:1425. [PUBMED: 23478344] ">Hurst 2013b</a>), China (<a href="./references#CD005195-bbs2-0217" title="LiS , XiaoT , ZhengB . Medical geology of arsenic, selenium and thallium in China. Science of the Total Environment2012;421‐422:31‐40. [PUBMED: 21440288] ">Li 2012</a>), and India (<a href="./references#CD005195-bbs2-0158" title="ChawlaR , LoombaR , ChaudharyRJ , SinghS , DhillonKS . Impact of high selenium exposure on organ function and biochemical profile of the rural population living in seleniferous soils in Punjab, India [2015]. Proceedings of the 4th International Conference on Selenium in the Environment and Human Health. 2015:93‐4. ">Chawla 2016</a>) ‐ regions not investigated by any of the reviewed observational studies, with the exception of three Chinese trials. Concerning sex‐related effects, our meta‐analysis of longitudinal studies revealed an inverse association between RR of cancer and selenium status in some cases in men but not in women for the same cancer type. Unfortunately, although more than half of reviewed studies included mixed‐sex populations, most did not report sex‐disaggregated results. In available sex‐specific results, men are over represented ‐ a fact that may potentially hamper assessment of the relation between selenium exposure and cancer risk in women. Theoretically, factors such as variations in body composition between men and women, including lean body mass versus fat composition, or differences in metabolism or in nutritional requirements (e.g. higher antioxidant requirements, particularly for the urological system) between the two sexes might be associated with differential effects of selenium for prevention of cancer. </p> <p>Concerning the indicator used to assess selenium exposure and its relation with cancer risk, we observed generally null associations when evaluating selenium status through assessment of dietary intake, although some inverse associations at specific cancer sites emerged when we used biomarkers such as blood or toenail selenium levels. We extensively reviewed in the previous version of this review the characteristics and limitations of indicators of selenium exposure, with particular reference to dietary assessment methods and biomarkers, and inconsistencies across studies assessing the validity of different indicators (<a href="./references#CD005195-bbs2-0143" title="AshtonK , HooperL , HarveyLJ , HurstR , CasgrainA , Fairweather‐TaitSJ . Methods of assessment of selenium status in humans: a systematic review. American Journal of Clinical Nutrition2009;89(6):2025S‐39S. ">Ashton 2009</a>; <a href="./references#CD005195-bbs2-0168" title="Fairweather‐TaitSJ , BaoY , BroadleyMR , CollingsR , FordD , HeskethJE , et al. Selenium in human health and disease. Antioxidants &amp; Redox Signaling2011;14(7):1337‐83. ">Fairweather‐Tait 2011</a>; <a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>; <a href="./references#CD005195-bbs2-0314" title="VincetiM , DennertG , CrespiCM , ZwahlenM , BrinkmanM , ZeegersMP , et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005195.pub3; PUBMED: 24683040] ">Vinceti 2014</a>). In particular, a large body of literature concerns the limitations of dietary assessment methods, mainly linked to large variations of selenium content in single food types, and the limitations of biomarkers of exposure. Concerning the latter, a major source of exposure misclassification consists of the different behaviours of inorganic and organic selenium species, whose tendency to be retained in the body and to accumulate in specific body tissues greatly varies, although this does not necessarily correlate with their biological activity (<a href="./references#CD005195-bbs2-0146" title="BehneD , GessnerH , KyriakopoulosA . Information on the selenium status of several body compartments of rats from the selenium concentrations in blood fractions, hair and nails. Journal of Trace Elements in Medicine and Biology1996;103:174‐9. ">Behne 1996</a>; <a href="./references#CD005195-bbs2-0147" title="BehneD , AlberD , KyriakopoulosS . Long‐term selenium supplementation of humans: selenium status and relationships between selenium concentrations in skeletal muscle and indicator materials. Journal of Trace Elements in Medicine and Biology2010;24(2):99‐105. ">Behne 2010</a>; <a href="./references#CD005195-bbs2-0210" title="KimYY , MahanDC . Comparative effects of high dietary levels of organic and inorganic selenium on selenium toxicity of growing‐finishing pigs. Journal of Animal Science2001;79(4):942‐8. ">Kim 2001</a>; <a href="./references#CD005195-bbs2-0227" title="MichalkeB , SolovyevN , VincetiM . Se‐speciation investigations at neural barrier. Se2017: The 11th International Symposium on Selenium in Biology and Medicine and the 5th International Conference on Selenium in the Environment and Human Health; August 13‐17, 2017; Stockholm (Meeting Abstract). 2017. ">Michalke 2017</a>; <a href="./references#CD005195-bbs2-0240" title="PanterKE , HartleyWJ , JamesLF , MaylandHF , StegelmeierBL , KechelePO . Comparative toxicity of selenium from seleno‐DL‐methionine, sodium selenate, and Astragalus bisulcatus in pigs. Fundamental and Applied Toxicology1996;32(2):217‐23. ">Panter 1996</a>; <a href="./references#CD005195-bbs2-0269" title="SlavikP , IllekJ , BrixM , HlavicovaJ , RajmonR , JilekF . Influence of organic versus inorganic dietary selenium supplementation on the concentration of selenium in colostrum, milk and blood of beef cows. Acta Veterinaria Scandinavica2008;50:43. ">Slavik 2008</a>; <a href="./references#CD005195-bbs2-0271" title="SolovyevN , BertheleA , MichalkeB . Selenium speciation in paired serum and cerebrospinal fluid samples. Analytical and Bioanalytical Chemistry2013;405(6):1875‐84. ">Solovyev 2013</a>; <a href="./references#CD005195-bbs2-0272" title="SteenA , StromT , BernhoftA . Organic selenium supplementation increased selenium concentrations in ewe and newborn lamb blood and in slaughter lamb meat compared to inorganic selenium supplementation. Acta Veterinaria Scandinavica2008;50:7. ">Steen 2008</a>; <a href="./references#CD005195-bbs2-0281" title="TiwaryAK , StegelmeierBL , PanterKE , JamesLF , HallJO . Comparative toxicosis of sodium selenite and selenomethionine in lambs. Journal of Veterinary Diagnostic Investigation2006;18(1):61‐70. ">Tiwary 2006</a>; <a href="./references#CD005195-bbs2-0291" title="VincetiM , SolovyevN , MandrioliJ , CrespiCM , BonviciniF , ArcolinE , et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology2013;38:25‐32. ">Vinceti 2013c</a>). Investigators have frequently proposed that selenoprotein activity may be an indicator of selenium status and may be tested in association with cancer risk (<a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>), but this relation has been questioned because different sources of oxidative stress, paradoxically including pro‐oxidant selenium species themselves, may upregulate selenoprotein activity (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>). Furthermore, intake of heavy metals and other dietary factors such as vitamins, metalloids, and amino acids (e.g. methionine) may modify the health effects of selenium, or the relations between selenium exposure and biomarkers (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>; <a href="./references#CD005195-bbs2-0285" title="VincetiM , RovestiS , BergomiM , VivoliG . The epidemiology of selenium and human cancer. Tumori2000;86(2):105‐18. ">Vinceti 2000</a>), owing to metabolic interactions or changes in tissue‐specific deposition and retention of selenium (<a href="./references#CD005195-bbs2-0146" title="BehneD , GessnerH , KyriakopoulosA . Information on the selenium status of several body compartments of rats from the selenium concentrations in blood fractions, hair and nails. Journal of Trace Elements in Medicine and Biology1996;103:174‐9. ">Behne 1996</a>; <a href="./references#CD005195-bbs2-0309" title="ZengH , UthusEO , CombsGFJr . Mechanistic aspects of the interaction between selenium and arsenic. Journal of Inorganic Biochemistry2005;99(6):1269‐74. ">Zeng 2005</a>; <a href="./references#CD005195-bbs2-0311" title="ZwolakI , ZaporowskaH . Selenium interactions and toxicity: a review. Cell Biology and Toxicology2012;28(1):31‐46. ">Zwolak 2012</a>). </p> <p>Overall, available evidence indicates the potential for exposure misclassification in observational studies on selenium, as well as the pitfalls associated with an approach based on assessment of total selenium content in peripheral biomarkers, suggesting that in some instances, measurements of nutritional intake might provide better exposure estimates than are provided by biomarkers, particularly in the light of relative exposure to inorganic and organic species of the element. In general, observational cohort studies on selenium and cancer are expected to have been characterised by random exposure misclassification, thus shifting RRs towards the unity and reducing the ability to detect real associations. However, some exposure misclassification may have been non‐random, such as that induced by smoking, which although it is a source of selenium exposure also induces lower body selenium levels, possibly owing to an effect of cadmium in increasing selenium excretion (<a href="./references#CD005195-bbs2-0285" title="VincetiM , RovestiS , BergomiM , VivoliG . The epidemiology of selenium and human cancer. Tumori2000;86(2):105‐18. ">Vinceti 2000</a>). In such cases, exposure misclassification based on biomarkers (serum/plasma selenium levels) may have substantially biased risk estimates and may have been associated with some degree of confounding due to the well‐known effect of smoking on cancer risk, which could not have been adequately captured and controlled for. Inadequate control for smoking has been suggested to be a major confounder inducing spurious associations between low selenium levels and enhanced cancer risk in observational studies (<a href="./references#CD005195-bbs2-0145" title="Beane FreemanLE , KaragasMR , BarisD , SchwennM , JohnsonAT , ColtJS , et al. Is the inverse association between selenium and bladder cancer due to confounding by smoking?. American Journal of Epidemiology2015;181(7):488‐95. [PUBMED: 25776013] ">Beane Freeman 2015</a>). </p> <p>In addition to exposure misclassification, and probably more important than this, a major issue affecting observational studies is unmeasured confounding (<a href="./references#CD005195-bbs2-0294" title="VincetiM , RothmanKJ . More results but no clear conclusion on selenium and cancer. American Journal of Clinical Nutrition2016;104(2):245‐6. [PUBMED: 27413135] ">Vinceti 2016a</a>). This potential bias is a matter of greater concern than exposure misclassification because it may have systematically biased RRs in one direction, particularly for some cancer types. Moreover, detection (and control) of this bias is extremely difficult and nearly impossible, given the hundreds of nutritional and non‐nutritional lifestyle variables that may be associated with both variations in selenium intake and cancer risk. Among these factors are smoking (<a href="./references#CD005195-bbs2-0145" title="Beane FreemanLE , KaragasMR , BarisD , SchwennM , JohnsonAT , ColtJS , et al. Is the inverse association between selenium and bladder cancer due to confounding by smoking?. American Journal of Epidemiology2015;181(7):488‐95. [PUBMED: 25776013] ">Beane Freeman 2015</a>; <a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>), socioeconomic status ‐ which appears to be positively associated with socioeconomic position in both men and women (<a href="./references#CD005195-bbs2-0182" title="GundackerC , KomarnickiG , ZodlB , ForsterC , SchusterE , WittmannK . Whole blood mercury and selenium concentrations in a selected Austrian population: does gender matter?. Science of the Total Environment2006;372(1):76‐86. ">Gundacker 2006</a>; <a href="./references#CD005195-bbs2-0236" title="NiskarAS , PaschalDC , KieszakSM , FlegalKM , BowmanB , GunterEW , et al. Serum selenium levels in the US population: Third National Health and Nutrition Examination Survey, 1988‐1994. Biological Trace Element Research2003;91(1):1‐10. ">Niskar 2003</a>) ‐and most likely hundreds of nutritional and toxicological factors that may vary in the diet, together with selenium intake. An approach that would reduce the risk of unmeasured confounding in observational studies might include investigation of dietary patterns rather than single nutrients, but these investigations seem not to have made adjustments for diet quality. Finally, it should be noted that most studies did not take into account the role of genetic factors (related to selenoproteins or otherwise) in the relation between selenium exposure and cancer risk, although some studies have suggested the importance of such relations (<a href="./references#CD005195-bbs2-0200" title="JablonskaE , RaimondiS , GromadzinskaJ , ReszkaE , WieczorekE , KrolMB , et al. DNA damage and oxidative stress response to selenium yeast in the non‐smoking individuals: a short‐term supplementation trial with respect to GPX1 and SEPP1 polymorphism. European Journal of Nutrition2016;55(8):2469‐84. [PUBMED: 26658762] ">Jablonska 2016</a>; <a href="./references#CD005195-bbs2-0225" title="MeplanC , HeskethJ . Selenium and cancer: a story that should not be forgotten‐insights from genomics. Cancer Treatment and Research2014;159:145‐66. [PUBMED: 24114479] ">Meplan 2014</a>); the true relevance of genetic factors has not yet been well defined. Some studies examining selenoprotein‐related single‐nucleotide polymorphisms have suggested a role for genetic variants among genes coding for selenoproteins in modifying cancer risk, or in determining the relation between selenium exposure and subsequent cancer risk, although results have not been consistent (<a href="./references#CD005195-bbs2-0097" title="GeybelsMS , VerhageBA , vanSchootenFJ , GoldbohmRA , van denBrandtPA . Advanced prostate cancer risk in relation to toenail selenium levels. Journal of the National Cancer Institute2013;105(18):1394‐401. [PUBMED: 23878355] ">Geybels 2013</a>; <a href="./references#CD005195-bbs2-0224" title="MeplanC , RohrmannS , SteinbrecherA , SchomburgL , JansenE , LinseisenJ , et al. Polymorphisms in thioredoxin reductase and selenoprotein K genes and selenium status modulate risk of prostate cancer. PloS One2012;7(11):e48709. [PUBMED: 23133653] ">Meplan 2012</a>; <a href="./references#CD005195-bbs2-0242" title="PenneyKL , SchumacherFR , LiH , KraftP , MorrisJS , KurthT , et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prevention Research (Philadelphia, Pa.)2010;3(5):604‐10. [PUBMED: 20424130] ">Penney 2010</a>; <a href="./references#CD005195-bbs2-0243" title="PenneyKL , LiH , MucciLA , LodaM , SessoHD , StampferMJ , et al. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. The Prostate2013;73(7):700‐5. [PUBMED: 23129481] ">Penney 2013</a>; <a href="./references#CD005195-bbs2-0268" title="SlatteryML , LundgreenA , WelbournB , CorcoranC , WolffRK . Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PloS One2012;7(5):e37312. [PUBMED: 22615972] ">Slattery 2012</a>; <a href="./references#CD005195-bbs2-0279" title="TakataY , KristalAR , KingIB , SongX , DiamondAM , FosterCB , et al. Serum selenium, genetic variation in selenoenzymes, and risk of colorectal cancer: primary analysis from the Women's Health Initiative Observational Study and Meta‐analysis. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(9):1822‐30. [PUBMED: 21765007] ">Takata 2011</a>). </p> <p>With awareness of the fundamental limitations of observational studies, even of those of longitudinal design, which may avoid selection bias or reverse causality, investigators designed and carried out in the 1990s and the 2000s several experimental studies as RCTs investigating the effect of selenium supplements on cancer risk. The evidence base from these intervention studies has become so large and complete as to allow a comprehensive evaluation of cancer risk associated with selenium supplementation for some specific cancer types. It is interesting to note that major interest in the cancer preventive activity of selenium originated not just from observational studies (mainly of ecological and cohort design) (<a href="./references#CD005195-bbs2-0290" title="VincetiM , CrespiCM , MalagoliC , DelGiovaneC , KroghV . Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. Journal of Environmental Science and Health, Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2013;31(4):305‐41. ">Vinceti 2013b</a>), but from a randomised trial ‐ the ad interim analysis of the NPCT, which was published in 1996 and attracted great interest from both the scientific community and the general public because of the apparently large beneficial effect that it reported (Clark 1996, in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). Null results of the most recent low‐bias RCTs ‐ <a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a> ‐ also do not suggest a major or strong role of genetic factors in modifying selenium and cancer relations, given their generally null or troubling results. An exception can be seen in recent data from SELECT, which suggest that a genetic variant of the NKX3.1 androgen‐regulated prostate tumour suppressor protein may modify, or increase, the risk of prostate cancer associated with selenium supplementation (<a href="./references#CD005195-bbs2-0120" title="MartinezEE , DarkeAK , TangenCM , GoodmanPJ , FowkeJH , KleinEA , et al. A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research2014;7(9):950‐7. [PUBMED: 24894197] ">Martinez 2014</a>). </p> <p>From a methodological perspective, we acknowledge that comparison of risks between highest and lowest exposure categories in observational studies, as performed in the present meta‐analysis, is most suitable for identifying an effect when a consistent decrease or increase is seen across absolute exposure levels. Other associations (e.g. threshold effects, U‐shaped relations) may have been missed by this method of meta‐analysis, or their true effect might have been diminished. </p> </section> </section> <section id="CD005195-sec-0103"> <h3 class="title" id="CD005195-sec-0103">Overall completeness and applicability of evidence</h3> <section id="CD005195-sec-0104"> <h4 class="title">RCTs and preventive efficacy</h4> <p>This review investigated a diverse range of cancers, substantially extending the analysis compared with that performed in previous reviews. However, cancer is not a uniform condition, and malignant neoplasms show great differences in tumour biology. Only non‐melanoma skin cancer, liver cancer, and prostate cancer have been investigated as primary outcomes in the included prevention trials, and, regarding these main outcomes, specific characteristics of study populations may limit the generalisability of results. Participants in included RCTs on skin and liver cancer belonged to populations at high risk for the outcome under investigation, and participants in high‐quality prostate cancer trials were at average risk (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), or at high risk (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>), for this disease. Most participants in the NPCT were older and white, predominantly male inhabitants of the United States, and the most recent trials were limited to the USA male population. </p> <p>Average baseline selenium exposure in the NPCT was less than that characterising subsequent trials carried out in the United States, although it was more similar to that seen in some European populations. Although the NPCT suggested that selenium supplementation was beneficial only at the lowest range of baseline selenium exposure, the most recent studies, carried out in populations generally characterised by higher average selenium exposure, did not confirm such an interaction. The NPCT also found an indication of strong effect modification for sex, as demonstrated, for example, by the HR for all cancers associated with selenium supplementation ‐ 0.67 (95% CI 0.50 to 0.89) in men and 1.20 (95% CI 0.66 to 2.20) in women (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). </p> <p>Participants in the SELECT study on prostate cancer prevention were apparently healthy men over 50 years of age from the general population of North America (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). A large sample size and inclusion of non‐white participants from different socioeconomic backgrounds support the generalisability of study findings to other adequately nourished populations. </p> <p>Selenium supplements generally contain organic or inorganic species of selenium, or a mixture of both (e.g. in the form of selenised yeast). Different species of selenium may exhibit different effects on human health and more specifically on proteomic endpoints, as also suggested by human controlled randomised trials though with inconsistent results (<a href="./references#CD005195-bbs2-0249" title="Ravn‐HarenG , BugelS , KrathBN , HoacT , StagstedJ , JorgensenK , et al. A short‐term intervention trial with selenate, selenium‐enriched yeast and selenium‐enriched milk: effects on oxidative defence regulation. The British journal of nutrition2008;99(4):883‐92. [PUBMED: 17888202] ">Ravn‐Haren 2008</a>; <a href="./references#CD005195-bbs2-0257" title="RichieJPJr , DasA , CalcagnottoAM , SinhaR , NeidigW , LiaoJ , et al. Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer prevention research (Philadelphia, Pa.)2014;7(8):796‐804. [PUBMED: 24938534] ">Richie 2014</a>). High‐quality RCTs using selenised yeast supplements, almost entirely comprising organic selenium forms (<a href="./references#CD005195-bbs2-0151" title="BlockE , GlassRS , JacobsenNE , JohnsonS , KahakachchiC , KaminskiR , et al. Identification and synthesis of a novel selenium‐sulfur amino acid found in selenized yeast: rapid indirect detection NMR methods for characterizing low‐level organoselenium compounds in complex matrices. Journal of Agricultural and Food Chemistry2004;52(12):3761‐71. ">Block 2004</a>; <a href="./references#CD005195-bbs2-0302" title="WatersDJ , ShenS , KengeriSS , ChiangEC , CombsGF , MorrisJS , BostwickDG . Toward interpreting the null results of SELECT: Direct comparison of the prostatic tissue potency of Supranutritional Selenomethionine vs. Selenium‐yeast on markers of prostatic homeostasis and cancer risk reduction. Proceedings of the 10th International Symposium on Selenium in Biology and Medicine. Berlin: Deutsche Forschungsgemeinschaft, 2013:62. ">Waters 2013</a>), found no effect of supplementation on the main study outcome and an indication of a harmful effect (i.e. an excess diabetes risk) (<a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). The SELECT trial used supplements of L‐selenomethionine, which is the major component of selenised yeast, and also found no preventive efficacy. The only two RCTs investigating sodium selenite supplements found a protective effect against liver cancer, and null or adverse effects on breast cancer risk, but we considered these trials to have unclear risk of bias. It is unclear how applicable these results are in other settings and in populations with a different nutritional status. Interpretation of the results of clinical trials using selenium supplements should consider the different chemical forms of selenium, as well as their potentially different health effects when used as supplements (<a href="./references#CD005195-bbs2-0291" title="VincetiM , SolovyevN , MandrioliJ , CrespiCM , BonviciniF , ArcolinE , et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology2013;38:25‐32. ">Vinceti 2013c</a>; <a href="./references#CD005195-bbs2-0303" title="WeekleyCM , AitkenJB , FinneyL , VogtS , WittingPK , HarrisHH . Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems. Nutrients2013;5(5):1734‐56. ">Weekley 2013</a>). Most studies used organic selenium as selenised yeast (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), or as selenomethionine (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). However, the chemical form used is unlikely to explain the differences in results between NPCT and the other trials (<a href="./references#CD005195-bbs2-0302" title="WatersDJ , ShenS , KengeriSS , ChiangEC , CombsGF , MorrisJS , BostwickDG . Toward interpreting the null results of SELECT: Direct comparison of the prostatic tissue potency of Supranutritional Selenomethionine vs. Selenium‐yeast on markers of prostatic homeostasis and cancer risk reduction. Proceedings of the 10th International Symposium on Selenium in Biology and Medicine. Berlin: Deutsche Forschungsgemeinschaft, 2013:62. ">Waters 2013</a>). With reference to this issue, of interest are the results of a 'natural experiment' that occurred in Northern Italy, wherein a small population unintentionally consumed for several years drinking water with an unusually high content of selenium in its inorganic hexavalent form ‐ selenate (<a href="./references#CD005195-bbs2-0285" title="VincetiM , RovestiS , BergomiM , VivoliG . The epidemiology of selenium and human cancer. Tumori2000;86(2):105‐18. ">Vinceti 2000</a>). Follow‐up of that population revealed increased risk of neurodegenerative disease ‐ a not entirely unexpected finding owing to the potential neurotoxicity of inorganic selenium (<a href="./references#CD005195-bbs2-0292" title="VincetiM , MandrioliJ , BorellaP , MichalkeB , TsatsakisA , FinkelsteinY . Selenium neurotoxicity in humans: bridging laboratory and epidemiologic studies. Toxicology Letters2014; Vol. 230:295‐303. ">Vinceti 2014a</a>), along with a slightly increased risk of cancer, mainly due to excess risk of oropharyngeal cancer, melanoma, kidney cancer, and lymphoid malignancies (<a href="./references#CD005195-bbs2-0295" title="VincetiM , BallotariP , SteinmausC , MalagoliC , LubertoF , MalavoltiM , et al. Long‐term mortality patterns in a residential cohort exposed to inorganic selenium in drinking water. Environmental Research2016;150:348‐56. [PUBMED: 27344266] ">Vinceti 2016b</a>). </p> <p>An important issue is the possibility that participants with low baseline selenium status may experience an inverse association between selenium exposure and cancer risk, as suggested by some trial authors (<a href="./references#CD005195-bbs2-0219" title="LuJ , ZhangJ , JiangC , DengY , OztenN , BoslandMC . Cancer chemoprevention research with selenium in the post‐SELECT era: promises and challenges. Nutrition and Cancer2016;68(1):1‐17. [PUBMED: 26595411] ">Lu 2016</a>; <a href="./references#CD005195-bbs2-0252" title="RaymanMP , CombsGFJr , WatersDJ . Selenium and vitamin E supplementation for cancer prevention. JAMA2009; Vol. 301, issue 18:1876; author reply 1877. [PUBMED: 19436009] ">Rayman 2009</a>). This has been suggested to explain the different results of SELECT and the NPCT, and could also hypothetically explain, at least in part, the different relations found in experimental as compared with observational studies. NPCT found a strong beneficial effect of selenium supplementation among participants at the lowest tertiles of baseline selenium levels; however, the risk of cancer changed abruptly from an apparently protective effect in the two lower tertiles (HR 0.51 and 0.70) to an excess risk in the highest tertile of plasma selenium (HR 1.20, 95% CI 0.77 to 1.86). This occurred despite a difference of only 16.4 µg/L between lowest and highest tertiles, corresponding to a change in dietary selenium intake as low as around 10 µg. This would imply that such a small a change in selenium dietary intake would change a strongly protective effect of the element on cancer risk into a possibly detrimental effect ‐ an implausible scenario given the wide range of selenium intake (from about 20 to several hundred micrograms) characterising Western populations. Moreover, the intermediate tertile of baseline plasma selenium in the NPCT (105.6 to 122.0 µg/L) appeared to be associated not only with reduced overall cancer risk but also with an excess risk of squamous cell skin carcinoma (HR 1.49, 95% CI 1.05 to 2.12) and overall non‐melanoma skin cancer (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), as well as diabetes (RR 1.36, 95% CI 0.60 to 3.09), whose risk also considerably increased at the highest tertile of baseline selenium (<a href="./references#CD005195-bbs2-0274" title="StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">Stranges 2007</a>). Overall, this occurrence of both adverse and beneficial effects is unlikely if the selenium supplementation was serving to remedy a selenium deficiency. In addition, the strongest effect of selenium on overall cancer risk at lower levels of baseline selenium status was due to a considerable decrease in prostate cancer, but this finding was subject to detection bias because of a decreased biopsy rate in selenium‐supplemented participants, particularly in those with lowest baseline selenium status, as recognised by investigators of the NPCT (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). </p> <p>In addition, after NPCT, three of the four high‐quality RCTs on selenium supplementation for cancer prevention investigated the possible modifying effect of baseline selenium exposure and found no evidence of a beneficial effect of the intervention even in the lowest baseline exposure category. For instance, in NBT (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), the average baseline plasma selenium level at the lowest tertile of the study population was 101.1 µg/L ‐ much lower than the corresponding level at the middle tertile of NPCT (114.6 µg/L), in which the HR of prostate cancer had been as low as 0.33 (95% CI 0.13 to 0.82). However, in this ‘low’ NBT subgroup, investigators found no evidence of a beneficial effect of selenium supplementation on prostate cancer risk. In the SWOG S9917 trial (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>), data show no change in the null effect of selenium in the two lowest categories (quartiles) of selenium intake, whose boundaries were &lt; 106 and 106 to132 µg/L ‐ similar to cut points of the two bottom NPCT tertiles and of the bottom category of NBT. In these two subgroups of the SWOG population with the lowest baseline selenium status, the RR of prostate cancer was 0.82 (95% CI 0.40 to 1.69) and 1.38 (95% CI 0.68 to 2.78), and in the third upper quartile, the RR was 0.98 (95% CI 0.58 to 1.68), suggesting no consistent trend of an inverse relation between antecedent selenium exposure and effects of supplementation (as was also shown by analysis for trend in this study). Investigators in SELECT reported no reduction in cancer risk among selenium‐supplemented participants, although they did not provide specific RRs according to baseline selenium status. Calculation of blood selenium content distribution in SELECT, as well as in the three other RCTs (NPCT, NBT, SWOG), showed substantial overlap of plasma and serum selenium levels between this large trial population and the other study populations (<a href="#CD005195-fig-0007">Figure 7</a>). In addition, a more recent case‐cohort study carried out within SELECT assessed the effect of selenium supplementation on prostate cancer risk, taking into consideration baseline selenium exposure, as assessed through toenail selenium levels. The study, which involved 1739 prostate cancer cases and 3117 controls, was unable to find a beneficial effect of selenium supplementation in the lowest categories (quintiles) of baseline toenail selenium (<a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>). Actually, a dose‐response effect in that SELECT population emerged, but it favoured an increased risk of (high‐grade) prostate cancer induced by selenium supplementation among participants belonging to the two upper quintiles of baseline selenium exposure (<a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>). Therefore, it seems reasonable to agree with this SELECT statement: “The analysis of our data using lower cut points for baseline toenail Se categories, in an attempt to replicate findings from the NPCT, also showed no evidence of benefit from supplementation among men with low baseline Se status (data given in Results). Given these findings, we believe it reasonable to conclude that Se supplementation of men at the low range of Se intake common in USA men will not reduce PCa risk” (<a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a>). </p> <div class="figure" id="CD005195-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Baseline circulating selenium levels in the NPC trial (Duffield‐Lillico 2003b in: NPCT 2002), the NBT (Algotar 2013), SWOG trial (as plasma selenium) (Marshall 2011), and SELECT (as serum selenium) (Lippman 2009, in: SELECT 2009). When median and interquartile values were reported, we estimated mean and standard deviation according to Cochrane guidelines provided in Higgins 2011a." data-id="CD005195-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Baseline circulating selenium levels in the NPC trial (Duffield‐Lillico 2003b in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), the NBT (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), SWOG trial (as plasma selenium) (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>), and SELECT (as serum selenium) (Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). When median and interquartile values were reported, we estimated mean and standard deviation according to Cochrane guidelines provided in <a href="./references#CD005195-bbs2-0190" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>. </p> </div> </div> </div> <p>Overall, results of recent high‐quality RCTs do not support the hypothesis that differing baseline selenium status may explain conflicting results between NPCT and SELECT (<a href="./references#CD005195-bbs2-0219" title="LuJ , ZhangJ , JiangC , DengY , OztenN , BoslandMC . Cancer chemoprevention research with selenium in the post‐SELECT era: promises and challenges. Nutrition and Cancer2016;68(1):1‐17. [PUBMED: 26595411] ">Lu 2016</a>; <a href="./references#CD005195-bbs2-0252" title="RaymanMP , CombsGFJr , WatersDJ . Selenium and vitamin E supplementation for cancer prevention. JAMA2009; Vol. 301, issue 18:1876; author reply 1877. [PUBMED: 19436009] ">Rayman 2009</a>). Results of the most recent RCTs seem therefore to be applicable to populations with various degrees of background selenium exposure, with the exception of populations characterised by extremely low (&lt; 20 µg) or high selenium intake. </p> </section> <section id="CD005195-sec-0105"> <h4 class="title">Observational studies and aetiological association</h4> <p>We reviewed data from prospective observational studies in which investigators measured selenium exposure in populations without evidence of cancer, who were then followed up for a specified period of time. We limited our systematic review to cohort studies to avoid or decrease two major sources of bias in observational investigations, particularly in case‐control and cross‐sectional studies (i.e. selection bias and risk of reverse causality). Data continue to show important differences among included studies in terms of selenium exposure assessment, types of outcomes, and study populations, which may affect their interpretation. The small number of studies that examined most of the meta‐analysed types of cancers prevented a thorough investigation of sources of heterogeneity between study results. In particular, we had limited opportunity to explore the influence of specific sources of bias or the methodological quality of epidemiological studies on heterogeneity. </p> <p>Participants examined in this review update include more than 2,300,000 individuals, predominantly from Europe and North America, and, to a much lesser extent, from Asia and Australia. We were able to identify no prospective observational studies on selenium and cancer risk from Africa or South America. This regional distribution reflects the under representation of non‐Western and resource‐poor countries in epidemiological research (<a href="./references#CD005195-bbs2-0241" title="PearceN . The globalization of epidemiology: introductory remarks. International Journal of Epidemiology2004;33(5):1127‐31. ">Pearce 2004</a>). Differential regional representation in epidemiological studies is of special interest for this review, as selenium levels in humans around the world vary significantly. Selenium levels measured in the included cohorts reflect a broad range of naturally occurring selenium exposure, as documented by several epidemiological studies worldwide. However, some of the lowest and highest selenium levels in humans have been reported in populations in South America (<a href="./references#CD005195-bbs2-0201" title="JafféW . Selenio, un elemento esencial y toxico. Datos de Latinoamerica. Archivos Latinoamericanos de Nutrición1992;42(2):90‐3. ">Jaffé 1992</a>) ‐ a region not investigated by any of the reviewed observational studies. </p> <p>More than half of the included studies enrolled mixed‐sex populations, but most did not report sex‐disaggregated results. In available sex‐specific results, men are over represented ‐ a fact that could hamper potential assessment of the relation between selenium exposure and cancer risk in women. Despite this sex imbalance, we systematically saw stronger (inverse) associations with cancer risk among men than among women, for whom such associations with antecedent selenium status was nearly absent. This was true for stomach, colorectal, and lung cancer, and, when added to the inverse association for prostate cancer, led to an impact on overall cancer risk that was clearly lacking in women that could be due to potential confounders (such as smoking, occupational exposures, or other dietary factors) or to a real change in the association between selenium exposure and cancer risk in the two sexes. </p> <p>The range of selenium exposure experienced by members of cohorts investigated in the observational studies was generally lower than that experienced by participants in RCTs, who added supplemental selenium, generally 200 µg/d and in its organic forms, to their usual background intake, which ranged from about 70 to 90 µg/d as organic selenium, although some RCTs provided no estimate (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>). It is theoretically possible that a preventive effect of selenium against cancer exists only at low (&lt; 30 to 50 µg/d) intake of the element, and that it disappears at higher intakes, when ‘saturation’ or ‘maximisation’ of selenoprotein expression driven by selenium occurs. Investigations have frequently chosen this proteomic endpoint as a reference point for deriving dietary reference values for selenium (<a href="./references#CD005195-bbs2-0198" title="JablonskaE , VincetiM . Selenium and human health: witnessing a Copernican revolution?. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis &amp; Ecotoxicology Reviews2015;33(3):328‐68. [PUBMED: 26074278] ">Jablonska 2015a</a>; <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a>). Selenium exposure in the range of around 50 to 200 µg of daily selenium intake has not been tested by intervention studies, which have used larger amounts of supplemental selenium, and is unlikely to be tested in RCTs in the future, given the termination of past trials for futility or safety concerns. This possibility must be considered, but within the context of the two fundamental limitations of observational studies ‐ exposure misclassification and unmeasured confounding, which limit the reliability of the evidence they generate and its applicability in terms of cancer prevention. </p> <p>A few lines of evidence suggest that even at low levels of selenium exposure, it is unlikely that such an inverse association with cancer risk exists. First, inconsistencies in the results found in our meta‐analysis for most cancer sites and lack of a dose‐response relation between cancer risk and selenium at varying levels of background selenium exposure, or of a difference between highest and lowest exposure categories, argue against a real relation between selenium and cancer risk. Limited differences between highest and lowest categories of selenium intake, often amounting to a difference of only 20 to 30 µg per day, compared with large variations in selenium intake worldwide (from 10 to 15 µg in low‐selenium areas up to several hundred µg in seleniferous areas), also argue against a true relation. Finally, as previously described, some recent high‐quality RCTs investigated the effect of baseline selenium status on cancer risk associated with selenium supplementation and found no beneficial effect of selenium supplementation, even among participants with the lowest amounts of baseline exposure. Overall, these findings do not support an association between higher selenium status and lower cancer risk independently from factors such as sex, baseline selenium exposure, and cancer type. One additional observational cohort study, which could not be meta‐analysed in this review because it was released in PubMed in July 2017, appears to confirm these conclusions (<a href="./references#CD005195-bbs2-0262" title="SandsvedenM , ManjerJ . Selenium and breast cancer risk: a prospective nested case‐control study on serum selenium levels, smoking habits and overweight. International Journal of Cancer2017;141(8):1741‐50. [PUBMED: 28681438] ">Sandsveden 2017</a>). </p> </section> </section> <section id="CD005195-sec-0106"> <h3 class="title" id="CD005195-sec-0106">Quality of the evidence</h3> <section id="CD005195-sec-0107"> <h4 class="title">RCTs and preventive efficacy</h4> <p>SELECT (<a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), SWOG S9917 (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>), NBT (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), and ECOG 5597 (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>) were the only trials considered to have low risk of bias with adequate sequence generation, allocation concealment, blinding, and reporting of findings, and the consistency of their findings for prostate cancer, as well as for other cancer types for the two trials investigating them (SELECT and ECOG 5597), added to the statistical power of the major trial (SELECT), making their overall results highly reliable and suitable for yielding useful evidence to assess the relation between selenium supplementation and cancer prevention. These trials are also of major importance because (with one exception) they have provided information about baseline selenium exposure and its possible modifying role and about the effect of selenium supplementation on subsequent cancer incidence. Another important feature of these trials has been their ability to address the issue of selenium overexposure and related adverse effects owing to a systematic surveillance system for adverse effects, as well as their ability to extend the monitoring programme to additional effects, if suggested by new analyses targeting previously unplanned secondary endpoints, as was the case for diabetes (<a href="./references#CD005195-bbs2-0274" title="StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">Stranges 2007</a>). This is particularly relevant because all of these trials were planned under the hypothesis, later found to be erroneous but at that time endorsed by regulatory agencies, that the supplemental selenium dose administered to intervention arms (200 µg/d in almost all RCTs) was entirely safe and was well below the upper safe limit of the element, even with consideration of background selenium exposure. </p> <p>These trials may continue to yield important results. Secondary analysis of additional endpoints, or based on genetic and non‐genetic biomarkers of exposure to selenium and other factors, is still possible. For example, major contributions were yielded by SELECT in 2017, concerning outcomes such as prevention of colorectal adenoma and of Alzheimer’s disease by selenium supplementation, in both cases with null results (<a href="./references#CD005195-bbs2-0211" title="KryscioRJ , AbnerEL , Caban‐HoltA , LovellM , GoodmanP , DarkeAK , et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by vitamin E and selenium trial (preadvise). JAMA Neurology2017;74(5):567‐73. [PUBMED: 28319243] ">Kryscio 2017</a>; <a href="./references#CD005195-bbs2-0214" title="LanceP , AlbertsDS , ThompsonPA , FalesL , WangF , San JoseJ , et al. Colorectal adenomas in participants of the select randomized trial of selenium and vitamin E for prostate cancer prevention. Cancer Prevention Research2017;10(1):45‐54. [PUBMED: 27777235] ">Lance 2017</a>). </p> <p>We assessed the certainty of evidence from high‐quality RCTs using the GRADE approach (<a href="http://gdt.guidelinedevelopment.org/app/handbook/handbook.html#h.svwngs6pm0f2" target="_blank">http://gdt.guidelinedevelopment.org/app/handbook/handbook.html#h.svwngs6pm0f2</a>) and reported the results of this assessment in the 'Summary of findings' table (<a href="./full#CD005195-tbl-0001">summary of findings Table for the main comparison</a>). From preliminary assignment to a high level of certainty due to the experimental study design, we did not identify reasons to downgrade trial quality according to standard GRADE guidelines for risk of all cancers, for risk of cancer mortality, or for risk of colorectal, lung, bladder, or prostate cancer. In contrast, meta‐analysis for breast cancer risk yielded a statistically imprecise result mainly reflecting the small number of cases, and meta‐analysis for non‐melanoma skin cancer showed high statistical heterogeneity across studies. When addressing factors possibly increasing the certainty of evidence assessment, we considered as non‐applicable the GRADE item “<i>All plausible confounding would reduce the demonstrated effect or increase the effect if no effect was observed</i>”, neither could we evaluate possible dose‐response gradients because unfortunately they were not tested in these RCTs. We therefore rated the certainty of evidence as ‘high’ if it indicates no effect of selenium supplementation on all cancers overall, on cancer mortality, nor on colorectal, lung, bladder, and prostate cancer, and we considered certainty of the evidence as ‘moderate’ if it indicates no effect on non‐melanoma skin cancer and breast cancer, with downgrades due to heterogeneity and imprecision, respectively. However, stating that the evidence supporting no effect of selenium on cancer prevention at these sites is of moderate rather than high certainty does not mean that the only alternative hypothesis is necessarily that selenium decreases risk of cancer at these sites. Actually, the overall results of high‐quality RCTs, when available, suggest a slight to moderate although statistically imprecise increase in the risk of some of these specific cancers following selenium supplementation. </p> <p>Concerning the RCTs that we downgraded in our appraisal of risk of bias, we considered the quality of reporting to be an issue in the three trials on liver cancer prevention, thus leading to their classification as having unknown risk of bias. Several papers reported the individual trials, in some cases discrepantly, and essential questions regarding sequence generation, allocation concealment, handling of dropouts and withdrawals, and detection of outcomes remain unanswered. This might be due to inadequate reporting but might also hint at flaws in trial design and implementation. We were uncertain about whether the only trial that reported positive results for selenium supplements in liver cancer prevention randomly assigned participants individually. Cluster randomisation of participants who lived in the same area/village, which may have been the procedure used in this investigation, might have introduced additional bias to the study results (e.g. as the result of different environmental factors contributing to liver cancer development or detection) and might have led to an overestimation of the protective efficacy of selenium. Duplication of results of trials based on a rigorous study design would be necessary to assess the effects of sodium selenite on liver cancer incidence. With regard to the NPCT (<a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>) and the trial of <a href="./references#CD005195-bbs2-0014" title="DrenoB , EuvrardS , FrancesC , MoyseD , NandeuilA . Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. European Journal of Dermatology2007;17(2):140‐5. ">Dreno 2007</a>, indications of serious detection bias for the USA study and of unclear methodological details (such as blinding) for the French investigation led us to consider these experimental studies to be at unclear risk of bias, as discussed in greater detail elsewhere in this review. As far as the trial on breast cancer is concerned (<a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>), our downgrade of evidence certainty was based on incomplete information provided in the only report that we could retrieve (an abstract), although we acknowledge the relevance of that trial ‐ the only trial specifically targeting breast cancer and a genetically specific population ‐ and the fact that complete reporting of trial procedures may lead to reassessment of trial quality and its upgrade. </p> </section> <section id="CD005195-sec-0108"> <h4 class="title">Observational studies and aetiological association</h4> <p>The 70 observational studies were heterogeneous, not only in methodology, but also in the quality and level of detail of reporting and in their potential biases. We assessed our confidence in the evidence from these studies using the GRADE approach and reported our findings in <a href="./full#CD005195-tbl-0002">summary of findings Table 2</a>; we reported judgements only for those outcomes evaluated in the 'Summary of findings' table for RCTs with low risk of bias. </p> <section id="CD005195-sec-0109"> <h5 class="title">Confounding and other biases</h5> <section id="CD005195-sec-0110"> <h6 class="title">Selenium measurement and exposure misclassification</h6> <p>All studies on total cancer risk identified cases by using registry links or a combination of several methods, and losses to follow‐up were generally very low. One study on cancer incidence and two studies on cancer mortality analysed less than 80% of all identified cases (incidence: <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a>: 79%; mortality: <a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a>: 71%; <a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a>: 57%). The main reason for this loss of sample was missing selenium measurements. Not all studies that assessed mortality as a measure of cancer risk excluded people with cancer at study inception. This might have led to overestimation of a protective effect if selenium levels were lowered by the presence of cancer. We therefore consider the results for cancer incidence to be more valid than the cancer mortality results. </p> <p>Concerning the outcome most frequently investigated ‐ prostate cancer ‐ all but two of the included studies identified cases by using links to cancer registries or a combination of personal follow‐up interviews with PSA screening. Two studies with health professionals used self‐reporting for case identification, followed by confirmation through medical records. The number of people lost to follow‐up was low in all included studies. However, two studies included less than 80% of all identified cases in their analyses because samples were not available for selenium measurement, or diagnosis was not confirmed (<a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a>: 39%; van den Brandt 2003, in: <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a>: 77%). In <a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a>, bias might have been introduced to the results to some extent, as demographic variables differed between identified and analysed cases. </p> </section> <section id="CD005195-sec-0111"> <h6 class="title">Residual confounding and effect modification</h6> <p>Most of the included studies used controls for smoking and age by matching or using multi‐variate techniques. However, the control for self‐declared smoking habits may be inadequate, and this may occur particularly in people with a diagnosis of cancer (<a href="./references#CD005195-bbs2-0162" title="Connor GorberS , Schofield‐HurwitzS , HardtJ , LevasseurG , TremblayM . The accuracy of self‐reported smoking: a systematic review of the relationship between self‐reported and cotinine‐assessed smoking status. Nicotine &amp; Tobacco Research2009;11(1):12‐24. [PUBMED: 19246437] ">Connor Gorber 2009</a>; <a href="./references#CD005195-bbs2-0173" title="GerritsenM , BerndtN , LechnerL , deVriesH , MuddeA , BolmanC . Self‐reporting of smoking cessation in cardiac patients: how reliable is it and is reliability associated with patient characteristics?. Journal of Addiction Medicine2015;9(4):308‐16. [PUBMED: 26083956] ">Gerritsen 2015</a>; <a href="./references#CD005195-bbs2-0229" title="MoralesNA , RomanoMA , Michael CummingsK , MarshallJR , HylandAJ , HutsonA , et al. Accuracy of self‐reported tobacco use in newly diagnosed cancer patients. Cancer Causes and Control2013;24(6):1223‐30. [PUBMED: 23553611] ">Morales 2013</a>). Control for smoking as a known risk factor for several types of cancer is an important issue in epidemiological studies on cancer risk, and inadequate control for this cancer risk factor has been recognised as a major methodological issue affecting observational research on selenium and cancer (<a href="./references#CD005195-bbs2-0145" title="Beane FreemanLE , KaragasMR , BarisD , SchwennM , JohnsonAT , ColtJS , et al. Is the inverse association between selenium and bladder cancer due to confounding by smoking?. American Journal of Epidemiology2015;181(7):488‐95. [PUBMED: 25776013] ">Beane Freeman 2015</a>). This possible bias may be particularly relevant for research on selenium biomarkers and cancer. Cigarette smokers tend to have lower selenium biomarker levels, although cigarette smoking in itself is a source of selenium exposure. In addition to this source of non‐random exposure misclassification, it is well recognised that smoking is a powerful cancer risk factor, thus qualifying it also as a major confounder when the selenium and cancer relation is investigated. Therefore, an inverse association between low baseline selenium status and lung cancer risk might be the result of residual confounding and effect modification by smoking, and this may also be true for other cancer types (<a href="./references#CD005195-bbs2-0145" title="Beane FreemanLE , KaragasMR , BarisD , SchwennM , JohnsonAT , ColtJS , et al. Is the inverse association between selenium and bladder cancer due to confounding by smoking?. American Journal of Epidemiology2015;181(7):488‐95. [PUBMED: 25776013] ">Beane Freeman 2015</a>). Exposure to environmental and household smoking, which has been shown to be associated with increased risk of cancer (<a href="./references#CD005195-bbs2-0177" title="GorlovaOY , ZhangY , SchabathMB , LeiL , ZhangQ , AmosCI , et al. Never smokers and lung cancer risk: a case‐control study of epidemiological factors. International Journal of Cancer2006;118(7):1798‐804. ">Gorlova 2006</a>; <a href="./references#CD005195-bbs2-0235" title="NishinoY , TsubonoY , TsujiI , KomatsuS , KanemuraS , NakatsukaH , et al. Passive smoking at home and cancer risk: a population‐based prospective study in Japanese nonsmoking women. Cancer Causes and Control2001;12(9):797‐802. ">Nishino 2001</a>), might be associated with selenium status due to differential nutritional behaviours or other mechanisms. </p> <p>Several other factors may act as effect modifiers or confounders. Possible confounding factors could consist of another food nutrient or a certain behaviour that exhibits cancer protective effects and may be associated with higher intake of selenium‐rich foods. The number of candidates for such a role is so large that no observational study can measure all of these factors nor account for them. Furthermore, it is well known that intake of heavy metals (such as arsenic, cadmium, and mercury) and other dietary factors such as methionine may substantially modify selenium health effects or relations between selenium exposure and biomarkers (overview, in: <a href="./references#CD005195-bbs2-0285" title="VincetiM , RovestiS , BergomiM , VivoliG . The epidemiology of selenium and human cancer. Tumori2000;86(2):105‐18. ">Vinceti 2000</a>; <a href="./references#CD005195-bbs2-0309" title="ZengH , UthusEO , CombsGFJr . Mechanistic aspects of the interaction between selenium and arsenic. Journal of Inorganic Biochemistry2005;99(6):1269‐74. ">Zeng 2005</a>; <a href="./references#CD005195-bbs2-0311" title="ZwolakI , ZaporowskaH . Selenium interactions and toxicity: a review. Cell Biology and Toxicology2012;28(1):31‐46. ">Zwolak 2012</a>), and may potentially confound the association between selenium and cancer. </p> <p>Some potential confounders cluster in population groups according to socioeconomic position (SEP), and this factor has been shown to vary together with selenium status in both men and women (<a href="./references#CD005195-bbs2-0182" title="GundackerC , KomarnickiG , ZodlB , ForsterC , SchusterE , WittmannK . Whole blood mercury and selenium concentrations in a selected Austrian population: does gender matter?. Science of the Total Environment2006;372(1):76‐86. ">Gundacker 2006</a>; <a href="./references#CD005195-bbs2-0236" title="NiskarAS , PaschalDC , KieszakSM , FlegalKM , BowmanB , GunterEW , et al. Serum selenium levels in the US population: Third National Health and Nutrition Examination Survey, 1988‐1994. Biological Trace Element Research2003;91(1):1‐10. ">Niskar 2003</a>). Only a few studies attempted to control for indicators of adult SEP as potential confounders (e.g. education, occupation, income). None used a composite index of indicators or considered childhood SEP. Some studies restricted their cohorts to certain subgroups of a population, such as occupational groups, and were likely to include only people of a similar adult socioeconomic background.<br/> <br/> It has been claimed that associations between vitamins and diseases are the result of confounding by social and behavioural factors acting over the course of a lifetime (<a href="./references#CD005195-bbs2-0216" title="LawlorDA , DaveySG , KunduD , BruckdorferKR , EbrahimS . Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet2004;363(9422):1724‐7. ">Lawlor 2004</a>). <a href="./references#CD005195-bbs2-0216" title="LawlorDA , DaveySG , KunduD , BruckdorferKR , EbrahimS . Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet2004;363(9422):1724‐7. ">Lawlor 2004</a> argued that divergent results from epidemiological and randomised controlled studies on prevention of cardiovascular disease can be explained by unmeasured confounding due to SEP. Risk of most cancers is known to decrease with higher SEP. Research also indicates a positive association between higher SEP and selenium biomarkers (<a href="./references#CD005195-bbs2-0144" title="BaranyE , BergdahlIA , BrattebyLE , LundhT , SamuelsonG , SchutzA , et al. Trace elements in blood and serum of Swedish adolescents: relation to gender, age, residential area, and socioeconomic status. Environmental Research2002;89(1):72‐84. ">Barany 2002</a>; <a href="./references#CD005195-bbs2-0236" title="NiskarAS , PaschalDC , KieszakSM , FlegalKM , BowmanB , GunterEW , et al. Serum selenium levels in the US population: Third National Health and Nutrition Examination Survey, 1988‐1994. Biological Trace Element Research2003;91(1):1‐10. ">Niskar 2003</a>). However, other investigations have not confirmed these findings: <a href="./references#CD005195-bbs2-0206" title="KantAK , GraubardBI . Ethnicity is an independent correlate of biomarkers of micronutrient intake and status in American adults. Journal of Nutrition2007;137(11):2456‐63. ">Kant 2007</a>, for example, did not find an association between a measure of household poverty and selenium status.<br/> <br/> The hypothesis of possible confounding due to SEP leading to an indirect association between selenium and cancer would be consistent with results of observational studies for all types of cancers in this review, with the exception of prostate cancer. <a href="./references#CD005195-bbs2-0166" title="DaltonSO , SchuzJ , EngholmG , JohansenC , KjaerSK , Steding‐JessenM , et al. Social inequality in incidence of and survival from cancer in a population‐based study in Denmark, 1994‐2003: summary of findings. European Journal of Cancer2008;44(14):2074‐85. ">Dalton 2008</a> found that prostate cancer has been diagnosed more often in men of a higher SEP, and we saw a protective association of higher selenium exposure with this cancer type. It remains unclear whether the more frequent diagnosis of prostate cancer in men with a higher SEP actually reflects an excess of prostate cancer incidence in this population. It might also result from differential health and screening behaviours leading to detection of otherwise symptom‐free cases, while men with a lower SEP tend to be over represented in diagnoses of the disease at advanced stages (<a href="./references#CD005195-bbs2-0248" title="RapitiE , FiorettaG , SchaffarR , Neyroud‐CasparI , VerkooijenHM , SchmidlinF , et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer2009;115(23):5556‐65. ">Rapiti 2009</a>). More information on screening and diagnostic behaviours of male cohort participants would be necessary to further elucidate these issues. </p> <p>Another consideration is genetic factors, which may both confound and modify the role of selenium in cancer prevention and causation. Recent observational studies examining selenoprotein‐related single‐nucleotide polymorphisms have suggested a role for genetic variants in genes coding for selenoproteins or other proteins in modifying cancer risk, or even the relation itself between selenium and cancer risk, although results have not been consistent (<a href="./references#CD005195-bbs2-0174" title="GerstenbergerJP , BauerSR , VanBlariganEL , SosaE , SongX , WitteJS , et al. Selenoprotein and antioxidant genes and the risk of high‐grade prostate cancer and prostate cancer recurrence. The Prostate2015;75(1):60‐9. [PUBMED: 25284284] ">Gerstenberger 2015</a>; <a href="./references#CD005195-bbs2-0097" title="GeybelsMS , VerhageBA , vanSchootenFJ , GoldbohmRA , van denBrandtPA . Advanced prostate cancer risk in relation to toenail selenium levels. Journal of the National Cancer Institute2013;105(18):1394‐401. [PUBMED: 23878355] ">Geybels 2013</a>; <a href="./references#CD005195-bbs2-0199" title="JablonskaE , GromadzinskaJ , PeplonskaB , FendlerW , ReszkaE , KrolMB , et al. Lipid peroxidation and glutathione peroxidase activity relationship in breast cancer depends on functional polymorphism of GPX1. BMC Cancer2015;15:657. [PUBMED: 26446998] ">Jablonska 2015b</a>; <a href="./references#CD005195-bbs2-0226" title="MeplanC . Selenium and chronic diseases: a nutritional genomics perspective. Nutrients2015;7(5):3621‐51. [PUBMED: 25988760] ">Meplan 2015</a>). Null results of the most recent low‐bias RCTs do not suggest that at least the most frequent genotypes strongly influence the selenium and cancer relation (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>; <a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>; <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>), although such hypotheses cannot be ruled out for more rare genetic variants of selenoproteins or other proteins. Hypothetically, different genetic factors could increase and decrease the risk of cancer associated with selenium exposure, cancelling each other out and resulting in an overall null effect. Additional data from SELECT based on genotyping of study participants, if available, might be extremely useful for assessing hypotheses regarding genetic variants of selenoenzymes and their interaction with selenium status. So far, the only evidence derived from SELECT indicates that single‐nucleotide polymorphisms related to the prostate tumour suppressor protein <i>NKX3.1</i> gene (CC genotype at rs11781886) may increase cancer risk following selenium supplementation (<a href="./references#CD005195-bbs2-0120" title="MartinezEE , DarkeAK , TangenCM , GoodmanPJ , FowkeJH , KleinEA , et al. A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research2014;7(9):950‐7. [PUBMED: 24894197] ">Martinez 2014</a>). Recent observational evidence also suggests that polymorphisms of selenoproteins and other antioxidant proteins in men with non‐metastatic prostate cancer may be associated with increased risk of high‐grade disease and subsequent prostate cancer recurrence (<a href="./references#CD005195-bbs2-0174" title="GerstenbergerJP , BauerSR , VanBlariganEL , SosaE , SongX , WitteJS , et al. Selenoprotein and antioxidant genes and the risk of high‐grade prostate cancer and prostate cancer recurrence. The Prostate2015;75(1):60‐9. [PUBMED: 25284284] ">Gerstenberger 2015</a>). </p> </section> </section> <section id="CD005195-sec-0112"> <h5 class="title">Summary</h5> <p>In observational studies, factors that may have accounted for inter‐study heterogeneity and that may have biased study results include type of outcome measure, exposure assessment, sex, incomplete control for confounding (smoking and socioeconomic position), and unmeasured confounding, linked to both dietary and non‐dietary factors. Given the high risk of bias due to these factors, particularly to the unmeasured confounding inherent in observational studies, along with conflicting results of several studies and lack of any modification of the selenium and cancer relation by level of baseline selenium exposure and by the difference between highest and lowest selenium categories, we consider the evidence provided by observational studies to have very low certainty (<a href="./full#CD005195-tbl-0002">summary of findings Table 2</a>); therefore these results must be interpreted with great caution and do not allow firm conclusions about a possible cancer‐preventive effect of selenium intake. Meta‐analyses of spurious findings in observational studies enhance the precision of a summary risk estimate, which does not itself get nearer to the true value and may suggest a non‐existent association (<a href="./references#CD005195-bbs2-0167" title="EggerM , SchneiderM , Davey SmithG . Spurious precision? Meta‐analysis of observational studies. British Medical Journal1998;316(7125):140‐4. ">Egger 1998</a>). </p> </section> </section> </section> <section id="CD005195-sec-0113"> <h3 class="title" id="CD005195-sec-0113">Potential biases in the review process</h3> <section id="CD005195-sec-0114"> <h4 class="title">RCTs and preventive efficacy and observational studies and aetiological association</h4> <p>The literature search included major international databases in the English and German languages, and we applied a broad search strategy supplemented by handsearching for references. We assume that we identified all randomised controlled studies and prospective observational studies relevant to our review questions. As we did not search databases in other languages (e.g. Chinese, Russian), we cannot rule out that we might have missed smaller studies that were not published in international journals. However, we consider it unlikely that we could have missed major sources of evidence through our approach. We also might have missed observational studies whose results on selenium exposure and cancer were reported in the body of a paper but were not mentioned in the paper's title or abstract, even if the paper is indexed in the searched databases. However, our systematic use of backward and forward citation chasing and our search for relevant abstracts in conference proceedings or related material should have substantially decreased the risk of missing literature that could have been relevant for our assessment. </p> <p>When needed because of lack of complete or appropriate participant data (e.g. when cohorts including cancer and non‐cancer participants were mixed in data analysis), we contacted study investigators to ask for data missing from their studies. We also did this when we did not have enough data from published reports to adequately appraise study risk of bias. Sometimes we were unable to obtain answers to questions that we had regarding methods or outcomes, but frequently investigators kindly gave us the information we needed. We were sometimes unable to obtain answers, particularly for earlier epidemiological studies from which primary investigators may have relocated or died, or we found that data were not available in a current electronic format. Similarly, we could not make contact with primary investigators of Chinese RCTs. </p> <p>We based our risk of bias assessment on information included in the original publications, unless the trial authors that we contacted gave us additional details. This means that in some instances, we may have overestimated the true risk of bias of studies that did not adequately describe their design in the original publications, such as <a href="./references#CD005195-bbs2-0043" title="LubinskiJ , JaworskaK , DurdaK , JakubowskaA , HuzarskiT , ByrskiT , et al. Selenium and the risk of cancer in BRCA1 carriers. Hereditary Cancer in Clinical Practice2011;9(Suppl 2):A5. ">Lubinski 2011</a>. </p> <p>Another concern, especially with epidemiological studies, is publication bias. Cohort and nested case‐control studies often are not exclusively designed to test for a specific exposure‐outcome association but enable investigators to investigate a range of questions. It is conceivable that unfavourable results were less likely to be published, although we could not find evidence supporting such a hypothesis. Our analysis of this issue through use of a funnel plot gave some support to publication bias for prostate cancer. </p> <p>We systematically meta‐analysed RCTs even when only two studies were available (<a href="./references#CD005195-bbs2-0034" title="KarpDD , LeeSJ , KellerSM , WrightGS , AisnerS , BelinskySA , et al. Randomized, double‐blind, placebo‐controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non‐small‐cell lung cancer: ECOG 5597. Journal of Clinical Oncology2013;31(33):4179‐87. [PUBMED: 24002495] PillaiRN , LeeSJ , KarpDD , AisnerSC , RuckdeschelJC , RamalingamSS , KhuriFR . Second primary lung cancers: analysis of E5597 selenium chemoprevention study. Journal of Clinical Oncology2014;32(15):7518. ">Karp 2013</a>; <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>). Finally, we carried out two meta‐analyses of intervention studies ‐ one on all studies, and another on RCTs assessed through a standard appraisal tool as being at low risk of bias ‐ and we emphasised results of the latter, as derived from high‐quality experimental studies. For observational studies, we decided a priori to conduct meta‐analyses only when five or more studies were available for a study outcome, thus excluding from meta‐analysis the few endpoints for which up to four studies were available (<a href="#CD005195-tbl-0003">Table 1</a>). Our primary intention was to facilitate the investigation of heterogeneity between studies included in meta‐analyses, to avoid producing more precise, but still unexplainably biased, results. However, our emphasis was clearly given to experimental studies because this trial design is widely recognised as the only one that may provide convincing evidence of an association between a factor and disease risk, or more generally biological endpoints, and this may be particularly true in nutritional epidemiology (<a href="./references#CD005195-bbs2-0294" title="VincetiM , RothmanKJ . More results but no clear conclusion on selenium and cancer. American Journal of Clinical Nutrition2016;104(2):245‐6. [PUBMED: 27413135] ">Vinceti 2016a</a>). </p> <p>Finally, the authors of this review, as already noted in the previous version of the review, came from different disciplines and have different areas of focus (e.g. epidemiology, biostatistics, clinical medicine, nutrition). We continue to consider such variety of expertise to be a strength of this review, and we made use of it by applying multiple checking procedures during the entire review process whenever possible. </p> </section> </section> <section id="CD005195-sec-0115"> <h3 class="title" id="CD005195-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>Recent reviews that have investigated the relation between selenium and cancer prevention have generally concluded that this trace element has no clear beneficial effect(<a href="./references#CD005195-bbs2-0149" title="BjelakovicG , NikolovaD , GluudLL , SimonettiRG , GluudC . Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD007176] ">Bjelakovic 2012</a>; <a href="./references#CD005195-bbs2-0163" title="Cortes‐JofreM , RuedaJR , Corsini‐MunozG , Fonseca‐CortesC , CaraballosoM , Bonfill CospX . Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD002141.pub2] ">Cortes‐Jofre 2012</a>; <a href="./references#CD005195-bbs2-0164" title="CuiK , LiX , DuY , TangX , AraiS , GengY , et al. Chemoprevention of prostate cancer in men with high‐grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison. Oncotarget2017; Vol. 8, issue 22:36674‐84. [PUBMED: 28415774] ">Cui 2017a</a>; <a href="./references#CD005195-bbs2-0170" title="FortmannSP , BurdaBU , SengerCA , LinJS , WhitlockEP . Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine2013;159(12):824‐34. ">Fortmann 2013</a>; <a href="./references#CD005195-bbs2-0212" title="KushiLH , DoyleC , McCulloughM , RockCL , Demark‐WahnefriedW , BanderaEV , et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA: a Cancer Journal for Clinicians2012;62(1):30‐67. [PUBMED: 22237782] ">Kushi 2012</a>; <a href="./references#CD005195-bbs2-0232" title="MoyerVA . Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine2014;160(8):558‐64. [PUBMED: 24566474] ">Moyer 2014</a>; <a href="./references#CD005195-bbs2-0246" title="PosadzkiP , LeeMS , OnakpoyaI , LeeHW , KoBS , ErnstE . Dietary supplements and prostate cancer: a systematic review of double‐blind, placebo‐controlled randomised clinical trials. Maturitas2013;75(2):125‐30. [PUBMED: 23567264] ">Posadzki 2013</a>; <a href="./references#CD005195-bbs2-0265" title="SchwingshacklL , SchwedhelmC , HoffmannG , LampousiAM , KnuppelS , IqbalK , et al. Food groups and risk of all‐cause mortality: a systematic review and meta‐analysis of prospective studies. American Journal of Clinical Nutrition2017;105(6):1462‐73. [PUBMED: 28446499] ">Schwingshackl 2017</a>), although updated systematic reviews and meta‐analyses on selenium encompassing all of the most recent intervention studies are lacking. These results are true for both all cancers and prostate cancer, and for other specific cancers, such as lung cancer. The turning point in the evaluation of the effect of selenium on cancer risk is generally acknowledged to have been SELECT, and the other trials, although their findings are consistent with SELECT, have received less attention, probably mainly because of their smaller size. It is understandable that most of the selenium trials under way during the 2000s and the 2010s and originally implemented mainly as the result of the promising results of the original NPCT, particularly its ad interim 1996 report, were eventually discontinued owing to the results of SELECT (which was discontinued too) and the null results of ad interim futility analyses (<a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). This seems also to be true for <a href="./references#CD005195-bbs2-0155" title="BrodinO , EksborgS , WallenbergM , Asker‐HagelbergC , LarsenEH , MohlkertD , et al. Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: the SECAR study. Nutrients2015;7(6):4978‐94. [PUBMED: 26102212] ">Brodin 2015</a>, <a href="./references#CD005195-bbs2-0160" title="ChenYC , PrabhuKS , MastroAM . Is selenium a potential treatment for cancer metastasis?. Nutrients2013;5(4):1149‐68. [PUBMED: 23567478] ">Chen 2013</a>, and <a href="./references#CD005195-bbs2-0296" title="VincetiM , FilippiniT , CilloniS , BargelliniA , VergoniAV , TsatsakisA , et al. Health risk assessment of environmental selenium: emerging evidence and challenges (Review). Molecular Medicine Reports2017;15:3323‐35. [PUBMED: 28339083] ">Vinceti 2017a</a> ‐ planned RCTs on the possible utility of selenium for cancer therapy ‐ and is an issue of considerable interest that has been investigated so far in very few phase 2 and phase 3 trials (<a href="./references#CD005195-bbs2-0176" title="GoossensME , ZeegersMP , vanPoppelH , JoniauS , AckaertK , AmeyeF , et al. Phase III randomised chemoprevention study with selenium on the recurrence of non‐invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. European Journal of Cancer2016;69:9‐18. [PUBMED: 27814472] ">Goossens 2016</a>; <a href="./references#CD005195-bbs2-0207" title="KaramaliM , NourgostarS , ZamaniA , VahedpoorZ , AsemiZ . The favourable effects of long‐term selenium supplementation on regression of cervical tissues and metabolic profiles of patients with cervical intraepithelial neoplasia: a randomised, double‐blind, placebo‐controlled trial. British Journal of Nutrition2015;114(12):2039‐45. [PUBMED: 26439877] ">Karamali 2015</a>; <a href="./references#CD005195-bbs2-0233" title="MueckeR , MickeO , SchomburgL , GlatzelM , ReichlB , KistersK , et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow‐up analysis of the survival data 6 years after cessation of randomization. Integrative Cancer Therapies2014;13(6):463‐7. [PUBMED: 25015649] ">Muecke 2014</a>; <a href="./references#CD005195-bbs2-0276" title="StrattonMS , AlgotarAM , Ranger‐MooreJ , StrattonSP , SlateEH , HsuCH , et al. Oral selenium supplementation has no effect on prostate‐specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prevention Research (Philadelphia, Pa.)2010;3(8):1035‐43. [PUBMED: 20647337] ">Stratton 2010</a>) (although other trials appear to be under way such as <a href="./references#CD005195-bbs2-0297" title="VincetiM , FilippiniT , CilloniS , CrespiCM . The epidemiology of selenium and human cancer. Advances in Cancer Research2017;136:1‐48. ">Vinceti 2017b</a>). </p> <p>Concerning observational studies, very few recent reviews have investigated the selenium and cancer relation, and they have focused on only a few cancer sites. These reviews have generally yielded results consistent with ours. For prostate cancer, a recent review found no association between baseline serum selenium and risk in cohort studies (<a href="./references#CD005195-bbs2-0165" title="CuiZ , LiuD , LiuC , LiuG . Serum selenium levels and prostate cancer risk: a MOOSE‐compliant meta‐analysis. Medicine2017;96(5):e5944. [PUBMED: 28151881] ">Cui 2017b</a>), as was reported by <a href="./references#CD005195-bbs2-0140" title="AllenNE , TravisRC , ApplebyPN , AlbanesD , BarnettMJ , BlackA , et al. Selenium and prostate cancer: analysis of individual participant data from fifteen prospective studies. Journal of the National Cancer Institute2016;108(11):djw153. [PUBMED: 27385803] ">Allen 2016</a>, which conducted a pooled analysis using individual data from 15 cohort studies. However, in the latter review, baseline serum selenium status was determined to be inversely associated with high‐grade prostate cancer risk, as was toenail selenium and subsequent prostate cancer incidence. <a href="./references#CD005195-bbs2-0175" title="GongHY , HeJG , LiBS . Meta‐analysis of the association between selenium and gastric cancer risk. Oncotarget2016;7(13):15600‐5. [PUBMED: 26862854] ">Gong 2016</a> also found reduced risk of gastric cancer among participants in the highest baseline selenium exposure category. Other reviews and meta‐analyses considered other cancer types such as liver, pancreatic, lung, and breast cancer, but these reviews generally incorporated case‐control and cross‐sectional studies in addition to cohort studies, further increasing the risk of bias due to heterogeneity of study designs. Most reviews on observational studies have acknowledged the key methodological issues noted in this type of study, namely, risk of unmeasured confounding and potential biases associated with this limitation. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005195-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart." data-id="CD005195-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Review authors’ judgements about each risk of bias item presented as percentages across all included RCTs and summary of review authors’ judgements about each risk of bias item for the included RCTs." data-id="CD005195-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Review authors’ judgements about each risk of bias item presented as percentages across all included RCTs and summary of review authors’ judgements about each risk of bias item for the included RCTs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.1 Total cancer incidence and mortality." data-id="CD005195-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.1 Total cancer incidence and mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.8 Colorectal cancer risk." data-id="CD005195-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.8 Colorectal cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.12 Lung cancer risk incidence and mortality" data-id="CD005195-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure, outcome: 2.12 Lung cancer risk incidence and mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.19 Prostate cancer risk." data-id="CD005195-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.19 Prostate cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Baseline circulating selenium levels in the NPC trial (Duffield‐Lillico 2003b in: NPCT 2002), the NBT (Algotar 2013), SWOG trial (as plasma selenium) (Marshall 2011), and SELECT (as serum selenium) (Lippman 2009, in: SELECT 2009). When median and interquartile values were reported, we estimated mean and standard deviation according to Cochrane guidelines provided in Higgins 2011a." data-id="CD005195-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Baseline circulating selenium levels in the NPC trial (Duffield‐Lillico 2003b in: <a href="./references#CD005195-bbs2-0053" title="ClarkL , KrongradA , DalkinB , WitheringtonR , HerlongH , CarpenterD . Decreased incidence of prostate cancer with selenium supplementation: 1983‐96 results of a double‐blind cancer prevention trial. European Journal of Cancer Prevention1997; Vol. 6, issue 5:497‐8. ClarkLC , CombsGFJr , TurnbullBW , SlateEH , ChalkerDK , ChowJ , et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA1996;276(24):1957‐63. ClarkLC , DalkinB , KrongradA , CombsGF , TurnbullBW , SlateEH , et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trial. British Journal of Urology1998;81(5):730‐4. ClarkLC , UARIZ‐CA49764NCI‐P89‐0003 . Double‐blind, randomized trial of selenium‐enriched brewer's yeast vs brewer's yeast placebo for the prevention of skin cancer in patients with a history of squamous or basal cell skin cancer (Summary Last Modified 05/91). http://www.cancer.gov. National Cancer Institute, (accessed 1 March 2004). CombsGF , ClarkLC , TurnbullBW . Reduction of cancer mortality and incidence by selenium supplementation. Medizinische Klinik1997;92(Suppl 3):42‐5. CombsGFJr , ClarkLC , TurnbullBW . Reduction of cancer risk with an oral supplement of selenium. Biomedical and Environmental Sciences1997;10(2‐3):227‐34. Duffield‐LillicoAJ , DalkinBL , ReidME , TurnbullBW , SlateEH , JacobsET , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International2003b;91(7):608‐12. Duffield‐LillicoAJ , ReidME , TurnbullBW , CombsGFJr , SlateEH , FischbachLA , et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(7):630‐9. Duffield‐LillicoAJ , SlateEH , ReidME , TurnbullBW , WilkinsPA , CombsGFJr , et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute2003a;95(19):1477‐81. MarshallJR , 5R01CA049764‐15 . Nutritional Prevention of Cancer. http://crisp.cit.nih.gov (accessed 1 March 2004). ReidME , Duffield‐LillicoAJ , GarlandL , TurnbullBW , ClarkLC , MarshallJR . Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1285‐91. ReidME , Duffield‐LillicoAJ , SlateE , NatarajanN , TurnbullB , JacobsE , et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutrition and Cancer2008;60(2):155‐63. StrangesS , MarshallJR , NatarajanR , DonahueRP , TrevisanM , CombsGF , et al. Effects of long‐term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Internal Medicine2007;147(4):217‐23. ">NPCT 2002</a>), the NBT (<a href="./references#CD005195-bbs2-0003" title="AlgotarAM , StrattonMS , AhmannFR , Ranger‐MooreJ , NagleRB , ThompsonPA , et al. Phase III clinical trial investigating the effect of selenium supplementation in men at high‐risk for prostate cancer. The Prostate2013;73(3):328‐35. ">Algotar 2013</a>), SWOG trial (as plasma selenium) (<a href="./references#CD005195-bbs2-0045" title="MarshallJR , TangenCM , SakrWA , WoodDPJr , BerryDL , KleinEA , et al. Phase III trial of selenium to prevent prostate cancer in men with high‐grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research2011;4:1761‐9. ">Marshall 2011</a>), and SELECT (as serum selenium) (Lippman 2009, in: <a href="./references#CD005195-bbs2-0068" title="CookED . Selenium and Vitamin E Cancer Prevention Trial ‐ this one's for us. Journal of the National Medical Association2002;94(9):856‐8. CookED , Moody‐ThomasS , AndersonKB , CampbellR , HamiltonSJ , HarringtonJM , et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clinical Trials2005;2(5):436‐42. DeFrancescoL . Prostate cancer prevention trial launched. Nature Medicine2001;7(10):1076. DunnBK , RyanA , FordLG . Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results in Cancer Research2009;181:183‐93. FDA . Largest‐ever prostate cancer prevention trial. FDA Consumer2001;35(5):8. FordLG , MinasianLM , McCaskill‐StevensW , PisanoED , SullivanD , SmithRA . Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians2003;53(2):82‐101. HoqueA , AlbanesD , LippmanSM , SpitzMR , TaylorPR , KleinEA , et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control2001;12(7):627‐33. KardinalC , BrooksJ . Ochsner Cancer Institute studies vitamin E and selenium as prostate cancer prevention agents. Ochsner Journal2003;5(2):51. KleinEA . Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Recent Results in Cancer Research2003;163:212‐25. KleinEA . Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences2004;1031:234‐41. KleinEA , AtkinsMB , WaltherP , KlotzL , SWOG‐S000 . Phase III randomized study of selenium and vitamin E for the prevention of prostate cancer (SELECT trial). http://clinicaltrials.gov/ (accessed 12 January 2004). KleinEA , LippmanSM , ThompsonIM , GoodmanPJ , AlbanesD , TaylorPR , et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology2003;21(1):21‐7. KleinEA , ThompsonIMJr , TangenCM , CrowleyJJ , LuciaMS , GoodmanPJ , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2011;306(14):1549‐56. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial. Urologic Oncology2003;21(1):59‐65. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer and Prostatic Diseases2000;3(3):145‐51. KleinEA , ThompsonIM , LippmanSM , GoodmanPJ , AlbanesD , TaylorPR , et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. Journal of Urology2001;166(4):1311‐5. LippmanSM , GoodmanPJ , KleinEA , ParnesHL , ThompsonIMJr , KristalAR , et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute2005;97(2):94‐102. LippmanSM , KleinEA , GoodmanPJ , LuciaMS , ThompsonIM , FordLG , et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA2009;301(1):39‐51. LotanY , GoodmanPJ , YoussefRF , SvatekRS , ShariatSF , TangenCM , et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. Journal of Urology2012;187(6):205‐10. MillerM . Enrollment begins for largest‐ever prostate cancer prevention trial. Journal of the National Cancer Institute2001;93(15):1132. PakRW , LanteriVJ , ScheuchJR , SawczukIS . Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integrative Cancer Therapies2002;1(4):338‐44. South West Oncology Group. Selenium and Vitamin E Cancer Prevention Trial (SELECT). http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/42795.html (accessed 16 April 2004). South West Oncology Group. Selenium and Vitamin E in preventing prostate cancer. http://www.controlled‐trials.com/mrct/trial/SELENIUM/1059/32859.html. Southwest Oncology Group, (accessed 16 April 2004). TangenCM , GoodmanPJ , CrowleyJJ , ThompsonIM . Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology2004;171(2 Pt 2):S64‐7. TomJ . SELECT (opportunity for prostate cancer prevention). Hawaii Medical Journal2002;61(6):126‐9. ">SELECT 2009</a>). When median and interquartile values were reported, we estimated mean and standard deviation according to Cochrane guidelines provided in <a href="./references#CD005195-bbs2-0190" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 1 Any cancer risk." data-id="CD005195-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 1 Any cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 2 Cancer mortality." data-id="CD005195-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 2 Cancer mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 3 Head and neck cancer risk." data-id="CD005195-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 3 Head and neck cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 4 Oesophageal cancer risk." data-id="CD005195-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 4 Oesophageal cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 5 Colorectal cancer risk." data-id="CD005195-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 5 Colorectal cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 6 Liver cancer risk." data-id="CD005195-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 6 Liver cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 7 Melanoma risk." data-id="CD005195-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 7 Melanoma risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 8 Non‐melanoma skin cancer risk." data-id="CD005195-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 8 Non‐melanoma skin cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 9 Lung cancer risk." data-id="CD005195-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 9 Lung cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 10 Breast cancer risk." data-id="CD005195-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 10 Breast cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 11 Bladder cancer risk." data-id="CD005195-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 11 Bladder cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 12 Prostate cancer risk." data-id="CD005195-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 12 Prostate cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 13 Leukaemia and lymphoma risk." data-id="CD005195-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure, Outcome 13 Leukaemia and lymphoma risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 1 Total cancer incidence and mortality." data-id="CD005195-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 1 Total cancer incidence and mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 2 Total cancer incidence and mortality (men)." data-id="CD005195-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 2 Total cancer incidence and mortality (men). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 3 Total cancer incidence and mortality (women)." data-id="CD005195-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 3 Total cancer incidence and mortality (women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 4 Total cancer incidence and mortality (ascending order of selenium levels)." data-id="CD005195-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 4 Total cancer incidence and mortality (ascending order of selenium levels). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 5 Total cancer incidence and mortality (ascending order of differences in selenium levels)." data-id="CD005195-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 5 Total cancer incidence and mortality (ascending order of differences in selenium levels). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 6 Stomach cancer risk." data-id="CD005195-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 6 Stomach cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 7 Stomach cancer risk (by sex)." data-id="CD005195-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 7 Stomach cancer risk (by sex). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 8 Colorectal cancer risk." data-id="CD005195-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 8 Colorectal cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 9 Colorectal cancer risk (by sex)." data-id="CD005195-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 9 Colorectal cancer risk (by sex). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 10 Colon cancer risk." data-id="CD005195-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 10 Colon cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 11 Colon cancer risk (by sex)." data-id="CD005195-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 11 Colon cancer risk (by sex). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-12.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 12 Lung cancer incidence and mortality." data-id="CD005195-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 12 Lung cancer incidence and mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 13 Lung cancer risk (sex‐disaggregated data)." data-id="CD005195-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 13 Lung cancer risk (sex‐disaggregated data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 14 Lung cancer risk (by exposure assessment)." data-id="CD005195-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 14 Lung cancer risk (by exposure assessment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 15 Lung cancer risk (ascending order of selenium levels)." data-id="CD005195-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 15 Lung cancer risk (ascending order of selenium levels). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 16 Lung cancer risk (ascending order of differences in selenium levels)." data-id="CD005195-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 16 Lung cancer risk (ascending order of differences in selenium levels). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 17 Breast cancer risk (women)." data-id="CD005195-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 17 Breast cancer risk (women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 18 Bladder cancer risk." data-id="CD005195-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 18 Bladder cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-19.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 19 Prostate cancer risk." data-id="CD005195-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 19 Prostate cancer risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 20 Prostate cancer risk (by exposure assessment)." data-id="CD005195-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 20 Prostate cancer risk (by exposure assessment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 21 Prostate cancer risk (ascending order of selenium levels)." data-id="CD005195-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 21 Prostate cancer risk (ascending order of selenium levels). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005195-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/urn:x-wiley:14651858:media:CD005195:CD005195-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_t/tCD005195-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 22 Prostate cancer risk (ascending order of differences in selenium levels)." data-id="CD005195-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 22 Prostate cancer risk (ascending order of differences in selenium levels). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/media/CDSR/CD005195/image_n/nCD005195-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005195-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Participants in trials with low risk of bias<br/> <b>Setting:</b> out‐patient<br/> <b>Intervention:</b> highest selenium exposure<br/> <b>Comparison:</b> lowest selenium exposure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Without highest</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With highest</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any cancer risk<br/> No. of participants: 19,475<br/> (3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.93 to 1.10) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 0.99 (95% CI 0.86 to 1.14). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1%<br/> (9.3 to 11.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1% more<br/> (0.7 fewer to 1 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cancer mortality risk<br/> No. of participants: 17,448<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.80 to 1.30) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The effect is led from the study SELECT. The RR in all RCTs is 0.81 (95% CI 0.49 to 1.32). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%<br/> (1.1 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% more<br/> (0.3 fewer to 0.4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Colorectal cancer risk<br/> No. of participants: 19,009<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/> (0.69 to 1.43) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 0.74 (95% CI 0.41 to 1.33). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7%<br/> (0.5 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/> (0.2 fewer to 0.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐melanoma skin cancer risk<br/> No. of participants: 2027<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.30 to 4.42) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pooled estimate is imprecise owing to high heterogeneity. The RR in all RCTs is 1.23 (95% CI 0.73 to 2.08). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%<br/> (0.9 to 12.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% more<br/> (2 fewer to 10 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lung cancer risk<br/> No. of participants: 19,009<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.89 to 1.50) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The RR in all RCTs is 1.03 (95% CI 0.78 to 1.37).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2%<br/> (0.9 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2% more<br/> (0.1 fewer to 0.5 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Breast cancer risk<br/> No. of participants: 802<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 2.04<br/> (0.44 to 9.55) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The RR in all RCTs is 1.44 (95% CI 0.96 to 2.17).</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%<br/> (0.3 to 7.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8% more<br/> (0.4 fewer to 6.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bladder cancer risk<br/> No. of participants: 19,009<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.76 to 1.52) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 1.10 (95% CI 0.79 to 1.52). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7%<br/> (0.5 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0% fewer<br/> (0.2 fewer to 0.3 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate cancer risk<br/> No. of participants: 18,942<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.90 to 1.14) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SELECT study had the strongest influence on the effect estimate. The RR in all RCTs is 0.91 (95% CI 0.75 to 1.12). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4%<br/> (4.8 to 6.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1% more<br/> (0.5 fewer to 0.8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SELECT: Selenium and Vitamin E Cancer Prevention Trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for moderate heterogeneity (tau² = 0.69, I² = 72%, P = 0.06) not explained.<br/> <sup>b</sup>Downgraded one level owing to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005195-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Highest compared with lowest selenium exposure for preventing cancer in observational studies</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Highest compared with lowest selenium exposure for preventing cancer in observational studies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Patient or population:</b> Participants in non experimental cohort studies on selenium and cancer<br/> <b>Setting:</b> out‐patient<br/> <b>Intervention:</b> highest selenium exposure<br/> <b>Comparison:</b> lowest selenium exposure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any cancer risk</p> <p>No. of participants: 76,239<br/> (7 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.72<br/> (0.55 to 0.93) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer mortality risk</p> <p>No. of participants: 183,863<br/> (7 observational studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>OR 0.76</p> <p>(0.59 to 0.97)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colorectal cancer risk</p> <p>No. of participants: 712,746<br/> (6 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.82<br/> (0.72 to 0.94) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung cancer risk</p> <p>No. of participants: 371,067<br/> (11 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.82<br/> (0.59 to 1.14) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast cancer risk (women)</p> <p>No. of participants: 169,028<br/> (8 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 1.09<br/> (0.87 to 1.37) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bladder cancer risk</p> <p>No. of participants: 279,100<br/> (5 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.67<br/> (0.46 to 0.97) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate cancer risk</p> <p>No. of participants: 576,667<br/> (21 observational studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.84<br/> (0.75 to 0.95) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>CI: confidence interval; OR: odds ratio.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level owing to risk of bias, which we deemed as serious because of inability to rule out unmeasured confounding, particularly from lifestyle or nutritional factors that might covary with selenium exposure beyond those factors taken into account in the multi‐variable analyses.<br/> <sup>b</sup>Downgraded one level for moderate heterogeneity (tau² = 0.19, I² = 66%, P = 0.0008) not explained.<br/> <sup>c</sup>Downgraded one level owing to imprecision.<br/> <sup>d</sup>Downgraded one level owing to potential presence of publication bias suggested by the funnel plot. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Highest compared with lowest selenium exposure for preventing cancer in observational studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005195-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included observational studies by outcome</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Organ system</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies/case definitions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Meta‐</b> <br/> <b>analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Countries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of cases</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selenium assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reporting study</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 16</p> <p>incidence: 7<br/> mortality: 7<br/> incidence and mortality combined: 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland<br/> Netherlands<br/> Sweden<br/> Norway<br/> Belgium<br/> France </p> <p>China</p> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 276,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6488</p> <p>male: 3196</p> <p>female: 1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 12</p> <p>plasma: 2</p> <p>serum + plasma: 1</p> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0079" title="WillettWC , PolkBF , MorrisJS , StampferMJ , PresselS , RosnerB , et al. Prediagnostic serum selenium and risk of cancer. Lancet1983;2(8342):130‐4. ">Willett 1983</a> </p> <p><a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> </p> <p><a href="./references#CD005195-bbs2-0059" title="PelegI , MorrisS , HamesCG . Is serum selenium a risk factor for cancer?. Medical Oncology and Tumor Pharmacotherapy1985;2(3):157‐63. ">Peleg 1985</a> </p> <p><a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a><br/> <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a><br/> <a href="./references#CD005195-bbs2-0076" title="VirtamoJ , ValkeilaE , AlfthanG , PunsarS , HuttunenJK , KarvonenMJ . Serum selenium and risk of cancer. A prospective follow‐up of nine years. Cancer1987;60(2):145‐8. ">Virtamo 1987</a> </p> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a><br/> <a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a> </p> <p><a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a><br/> <a href="./references#CD005195-bbs2-0064" title="RingstadJ , JacobsenBK , TretliS , ThomassenY . Serum selenium concentration associated with risk of cancer. Journal of Clinical Pathology1988;41(4):454‐7. ">Ringstad 1988</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a><br/> <a href="./references#CD005195-bbs2-0002" title="AkbaralyNT , ArnaudJ , Hininger‐FavierI , GourletV , RousselAM , BerrC . Selenium and mortality in the elderly: results from the EVA study. Clinical Chemistry2005;51(11):2117‐23. ">Akbaraly 2005</a><br/> <a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a> </p> <p><a href="./references#CD005195-bbs2-0017" title="FujishimaY , OhsawaM , ItaiK , KatoK , TannoK , TurinTC , et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrology, Dialysis, Transplantation2011;26(10):3331‐8. ">Fujishima 2011</a> </p> <p><a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Gynaecological cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female breast cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 8</p> <p>incidence: 8<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland<br/> Netherlands<br/> Channel Islands </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 169,028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 1277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>plasma: 1</p> <p>serum + plasma: 1</p> <p>toenail: 3</p> <p>intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0075" title="vanNoordPAH , ColletteHJA , MaasMJ , deWaardF . Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort‐nested case‐referent study among women screened in the DOM project. International Journal of Epidemiology1987;16(2):318‐22. ">van Noord 1987</a><br/> <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0056" title="OvervadK , WangDY , OlsenJ , AllenDS , ThorlingEB , BulbrookRD , HaywardJL . Selenium in human mammary carcinogenesis: a case‐cohort study. European Journal of Cancer1991;27(7):900‐2. ">Overvad 1991</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0013" title="DorganJF , SowellA , SwansonCA , PotischmanN , MillerR , SchusslerN , et al. Relationships of serum carotenoids, retinol, alpha‐tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). Cancer Causes and Control1998;9(1):89‐97. ">Dorgan 1998</a> </p> <p><a href="./references#CD005195-bbs2-0057" title="PantavosA , RuiterR , FeskensEF , deKeyserCE , HofmanA , StrickerBH , et al. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: the Rotterdam Study. International Journal of Cancer2015;136(9):2178‐86. [PUBMED: 25284450] ">Pantavos 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cervical cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2</p> <p>incidence: 2<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: &gt; 15,161</p> <p>(1 study did not report cohort size by sex)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uterine cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 62,641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ovarian cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: ˜ 214,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>toenail: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a><br/> <a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecological cancer (without breast cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 18,096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/female: 86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Urological cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kindom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 23,658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary bladder cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6</p> <p>incidence: 6<br/> mortality: 0<br/> incidence &amp; mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii<br/> Finland<br/> Netherlands </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 279,100</p> <p>female: 130,786</p> <p>male: 128,009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1295</p> <p>female: 175</p> <p>male 755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>toenail: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a> </p> <p><a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> </p> <p><a href="./references#CD005195-bbs2-0029" title="HotalingJM , WrightJL , PocobelliG , BhattiP , PorterMP , WhiteE . Long‐term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. The Journal of Urology2011;185(4):1210‐5. ">Hotaling 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary tract cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence &amp; mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 38,500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 47</p> <p>male: 34</p> <p>female: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Respiratory tract cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 15</p> <p>incidence: 13<br/> mortality: 2<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> Japan<br/> USA<br/> Finland<br/> Netherlands </p> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 371,067</p> <p>male: 125,341</p> <p>female: 181,895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2223</p> <p>male: 1384</p> <p>female: 416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 9</p> <p>serum + plasma: 2</p> <p>toenail: 2</p> <p>dietary intake: 2</p> <p>(1 study reported both serum levels and food intake)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0040" title="KromhoutD . Essential micronutrients in relation to carcinogenesis. American Journal of Clinical Nutrition1987;45(5 Suppl):1361‐7. ">Kromhout 1987</a><br/> <a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a><br/> <a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a><br/> <a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> </p> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a><br/> <a href="./references#CD005195-bbs2-0062" title="RatnasingheD , TangreaJA , FormanMR , HartmanT , GunterEW , QiaoYL , et al. Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes and Control2000;11(2):129‐35. ">Ratnasinghe 2000</a> </p> <p><a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a><br/> <a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> <p><a href="./references#CD005195-bbs2-0071" title="SuadicaniP , HeinHO , GyntelbergF . Serum selenium level and risk of lung cancer mortality: a 16‐year follow‐up of the Copenhagen Male Study. European Respiratory Journal2012;39(6):1443‐8. ">Suadicani 2012</a> </p> <p><a href="./references#CD005195-bbs2-0050" title="MukaT , KrajaB , RuiterR , LahousseL , deKeyserCE , HofmanA , et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition2017;56(4):1637‐46. [PUBMED: 27073037] ">Muka 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral/pharyngeal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 20,305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Andrological cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 21</p> <p>incidence: 21<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> <p>Canada</p> <p>Puerto Rico<br/> Europe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/male: 576,667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total/male: 14,950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 8</p> <p>plasma: 5</p> <p>toenail: 4</p> <p>dietary intake: 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0026" title="HartmanTJ , AlbanesD , PietinenP , HartmanAM , RautalahtiM , TangreaJA , et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha‐tocopherol, beta‐carotene cancer prevention study. Cancer Epidemiology, Biomarkers &amp; Prevention1998;7(4):335‐40. ">Hartman 1998</a> </p> <p><a href="./references#CD005195-bbs2-0080" title="YoshizawaK , WillettWC , MorrisSJ , StampferMJ , SpiegelmanD , RimmEB , et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Journal of the National Cancer Institute1998;90(16):1219‐24. ">Yoshizawa 1998</a> </p> <p><a href="./references#CD005195-bbs2-0028" title="HelzlsouerKJ , HuangHY , AlbergAJ , HoffmanS , BurkeA , NorkusEP , et al. Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer. Journal of the National Cancer Institute2000;92(24):2018‐23. ">Helzlsouer 2000</a><br/> <a href="./references#CD005195-bbs2-0052" title="NomuraAMY , LeeJ , StemmermannGN , CombsGFJr . Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2000;9(9):883‐7. ">Nomura 2000</a> </p> <p><a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a><br/> <a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a><br/> <a href="./references#CD005195-bbs2-0042" title="LiH , KantoffPW , GiovannucciE , LeitzmannMF , GazianoJM , StampferMJ , et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research2005a;65(6):2498‐504. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute2004;96(9):696‐703. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. Plasma selenium levels associated with subsequent risk of prostate cancer. American Journal of Urology Review2005b;3(1):28‐34. ">Li 2004a</a><br/> <a href="./references#CD005195-bbs2-0060" title="PetersU , FosterCB , ChatterjeeN , SchatzkinA , RedingD , AndrioleGL , et al. Serum selenium and risk of prostate cancer ‐ a nested case‐control study. American Journal of Clinical Nutrition2007;85(1):209‐17. ">Peters 2007</a> </p> <p><a href="./references#CD005195-bbs2-0004" title="AllenNE . Reply to B Bekaert and MP Rayman. American Journal of Clinical Nutrition2009;89(4):1277. AllenNE , ApplebyPN , RoddamAW , TjønnelandA , JohnsenNF , OvervadK , et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Clinical Nutrition2008;88(6):1567‐75. ">Allen 2008</a><br/> <a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a><br/> <a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> <p><a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> </p> <p><a href="./references#CD005195-bbs2-0058" title="ParkSY , HaimanCA , ChengI , ParkSL , WilkensLR , KolonelLN , et al. Racial/ethnic differences in lifestyle‐related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes &amp; Control2015;26(10):1507‐15. [PUBMED: 26243447] ">Park 2015</a> </p> <p><a href="./references#CD005195-bbs2-0055" title="OutzenM , TjonnelandA , LarsenEH , FriisS , LarsenSB , ChristensenJ , et al. Selenium status and risk of prostate cancer in a Danish population. British Journal of Nutrition2016;115(9):1669‐77. [PUBMED: 26971676] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Outzen 2016</a> </p> <p><a href="./references#CD005195-bbs2-0022" title="GraffRE , JudsonG , AhearnTU , FiorentinoM , LodaM , GiovannucciEL , et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. The Prostate2017;77(6):647‐53. [PUBMED: 28102015] ">Graff 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><b>Gastrointestinal cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2</p> <p>incidence: 2<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> USA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 29,923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: &gt; 959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a><br/> <a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:<i>2</i> </p> <p>incidence: 2<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 168,257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> <p>intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:<i>1</i> </p> <p>incidence:<i>1</i> <br/> mortality:<i>0</i><br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 120,852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal/stomach cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 36,265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 86</p> <p>male: 51</p> <p>female: 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastric cardia adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:<i>1</i> </p> <p>incidence:<i>1</i> <br/> mortality:<i>0</i><br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 120,852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total:114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 5</p> <p>incidence: 5<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> Japan<br/> USA/Hawaii<br/> Finland<br/> Netherlands </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 197,000</p> <p>male: 86,311</p> <p>female: 80,669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 955</p> <p>male: 626</p> <p>female: 329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 4</p> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a><br/> <a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a><br/> <a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary liver cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 3<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> <p>Europe</p> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 701,809</p> <p>male: 61,470</p> <p>female: 74,941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 877</p> <p>male: 567</p> <p>female: 204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma: 1</p> <p>serum: 1</p> <p>toenail: 1</p> <p>intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a><br/> <a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pancreatic cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA<br/> Finland </p> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 159,062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 311</p> <p>male: 69</p> <p>female: 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>intake: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a><br/> <a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colorectal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6</p> <p>incidence: 6<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii<br/> Europe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 712,746</p> <p>male: 216,272</p> <p>female: 442,266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2627</p> <p>male: 810</p> <p>female: 797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>toenail: 2</p> <p>supplement use: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colon cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 5</p> <p>incidence: 5<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii</p> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 636,641</p> <p>male: 195,100</p> <p>female: 361,529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1677</p> <p>male: 525</p> <p>female: 510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>toenail: 1</p> <p>supplement use: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rectal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA/Hawaii<br/> Europe </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 610,837</p> <p>male: 195,100</p> <p>female: 361,529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 861</p> <p>male: 303</p> <p>female: 210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>toenail: 1</p> <p>supplement use:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All gastrointestinal cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6,167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma and serum: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Skin cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 3</p> <p>incidence: 3<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 158,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> <p>toenail: 1</p> <p>supplemental intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Basal cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 3</p> <p>incidence: 3<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia<br/> USA<br/> Finland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: &gt; 66,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 3</p> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a><br/> <a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 4<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia<br/> USA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: ˜ 30,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>plasma: 1</p> <p>dietary intake: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a><br/> <a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a><br/> <a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total non‐melanoma skin cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Rare and other cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haematological cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 1</p> <p>incidence: 1<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 6167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum + plasma: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thyroid cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 2</p> <p>incidence: 2<br/> mortality: 0<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 582,807</p> <p>male: 287,944</p> <p>female: 194,863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 635</p> <p>male: 269</p> <p>female: 366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 1</p> <p>intake:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 4</p> <p>incidence: 3<br/> mortality: 1<br/> incidence and mortality combined: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✗ no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China<br/> USA<br/> Finland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 109,179</p> <p>male: 21,172</p> <p>female: 80,737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total: 512</p> <p>male: 169</p> <p>female: 285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum: 2</p> <p>serum + plasma: 1</p> <p>toenail: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a><br/> <a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Some studies did not report the sex of participants or cancer cases; consequently, figures for women and men do not always sum up to the total number of participants or cancer cases. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included observational studies by outcome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005195-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias: observational studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Publication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Newcastle‐Ottawa Scale (cohort)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Newcastle‐Ottawa Scale (case‐control)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exposure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0001" title="AgalliuI , KirshVA , KreigerN , SoskolneCL , RohanTE . Oxidative balance score and risk of prostate cancer: results from a case‐cohort study. Cancer Epidemiology2011;35(4):353‐61. ">Agalliu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0001" title="AgalliuI , KirshVA , KreigerN , SoskolneCL , RohanTE . Oxidative balance score and risk of prostate cancer: results from a case‐cohort study. Cancer Epidemiology2011;35(4):353‐61. ">Agalliu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0002" title="AkbaralyNT , ArnaudJ , Hininger‐FavierI , GourletV , RousselAM , BerrC . Selenium and mortality in the elderly: results from the EVA study. Clinical Chemistry2005;51(11):2117‐23. ">Akbaraly 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0002" title="AkbaralyNT , ArnaudJ , Hininger‐FavierI , GourletV , RousselAM , BerrC . Selenium and mortality in the elderly: results from the EVA study. Clinical Chemistry2005;51(11):2117‐23. ">Akbaraly 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0004" title="AllenNE . Reply to B Bekaert and MP Rayman. American Journal of Clinical Nutrition2009;89(4):1277. AllenNE , ApplebyPN , RoddamAW , TjønnelandA , JohnsenNF , OvervadK , et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Clinical Nutrition2008;88(6):1567‐75. ">Allen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0004" title="AllenNE . Reply to B Bekaert and MP Rayman. American Journal of Clinical Nutrition2009;89(4):1277. AllenNE , ApplebyPN , RoddamAW , TjønnelandA , JohnsenNF , OvervadK , et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). American Journal of Clinical Nutrition2008;88(6):1567‐75. ">Allen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrass 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0006" title="BleysJ , Navas‐AcienA , GuallarE . Serum selenium levels and all‐cause, cancer, and cardiovascular mortality among US adults. Archives of Internal Medicine2008;168(4):404‐10. ">Bleys 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0021" title="GoyalA , TerryMB , SiegelAB . Serum antioxidant nutrients, vitamin A, and mortality in US adults. Cancer Epidemiology, Biomarkers &amp; Prevention2013;22(12):2202‐11. [PUBMED: 23897583] ">Goyal 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0007" title="BrooksJD , MetterEJ , ChanDW , SokollLJ , LandisP , NelsonWG , et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology2001;166(6):2034‐8. ">Brooks 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coates 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0011" title="ComstockGW , AlbergAJ , HuangHY , WuK , BurkeAE , HoffmanSC , et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha‐tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(11):907‐16. ">Comstock 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0013" title="DorganJF , SowellA , SwansonCA , PotischmanN , MillerR , SchusslerN , et al. Relationships of serum carotenoids, retinol, alpha‐tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). Cancer Causes and Control1998;9(1):89‐97. ">Dorgan 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0013" title="DorganJF , SowellA , SwansonCA , PotischmanN , MillerR , SchusslerN , et al. Relationships of serum carotenoids, retinol, alpha‐tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). Cancer Causes and Control1998;9(1):89‐97. ">Dorgan 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0015" title="EppleinM , FrankeAA , CooneyRV , MorrisJS , WilkensLR , GoodmanMT , et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(7):1962‐70. GillJK , FrankeAA , StevenMJ , CooneyRV , WilkensLR , LeMarchandL , et al. Association of selenium, tocopherols, carotenoids, retinol, and 15‐isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control2009;20(7):1161‐71. KolonelLN , 5P01CA033619‐20 . Epidemiologic studies of diet and cancer in Hawaii. http://cancercontrol.cancer.gov/grants/abstract.asp?ApplID=6805844 (accessed 6 April 2011). ">Epplein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gill 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0016" title="FexG , PetterssonB , AkessonB . Low plasma selenium as a risk factor for cancer death in middle‐aged men. Nutrition and Cancer1987;10(4):221‐9. ">Fex 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0017" title="FujishimaY , OhsawaM , ItaiK , KatoK , TannoK , TurinTC , et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrology, Dialysis, Transplantation2011;26(10):3331‐8. ">Fujishima 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0017" title="FujishimaY , OhsawaM , ItaiK , KatoK , TannoK , TurinTC , et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrology, Dialysis, Transplantation2011;26(10):3331‐8. ">Fujishima 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0192" title="HunterDJ , MorrisJS , ChuteCG , KushnerE , ColditzGA , StampferMJ , et al. Predictors of selenium concentration in human toenails. American Journal of Epidemiology1990;132(1):114‐22. ">Hunter 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0020" title="GoodmanGE , SchafferS , BanksonDD , HughesMP , OmennGS , The Carotene and Retinol Efficacy Trial (CARET) Co‐Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2001;10(10):1069‐76. OmennGS , GoodmanG , ThornquistM , GrizzleJ , RosenstockL , BarnhartS , et al. The beta‐carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos‐exposed workers. Cancer Research1994;54(7 Suppl):2038s‐43s. [PUBMED: 8137335] ">Goodman 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0022" title="GraffRE , JudsonG , AhearnTU , FiorentinoM , LodaM , GiovannucciEL , et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. The Prostate2017;77(6):647‐53. [PUBMED: 28102015] ">Graff 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0022" title="GraffRE , JudsonG , AhearnTU , FiorentinoM , LodaM , GiovannucciEL , et al. Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG. The Prostate2017;77(6):647‐53. [PUBMED: 28102015] ">Graff 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0023" title="GrundmarkB , ZetheliusB , GarmoH , HolmbergL . Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow‐up. BMC Cancer2011;11:431. [EPI_EU_Grundmark 2011] ">Grundmark 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0023" title="GrundmarkB , ZetheliusB , GarmoH , HolmbergL . Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow‐up. BMC Cancer2011;11:431. [EPI_EU_Grundmark 2011] ">Grundmark 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0026" title="HartmanTJ , AlbanesD , PietinenP , HartmanAM , RautalahtiM , TangreaJA , et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha‐tocopherol, beta‐carotene cancer prevention study. Cancer Epidemiology, Biomarkers &amp; Prevention1998;7(4):335‐40. ">Hartman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0026" title="HartmanTJ , AlbanesD , PietinenP , HartmanAM , RautalahtiM , TangreaJA , et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha‐tocopherol, beta‐carotene cancer prevention study. Cancer Epidemiology, Biomarkers &amp; Prevention1998;7(4):335‐40. ">Hartman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0028" title="HelzlsouerKJ , HuangHY , AlbergAJ , HoffmanS , BurkeA , NorkusEP , et al. Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer. Journal of the National Cancer Institute2000;92(24):2018‐23. ">Helzlsouer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0028" title="HelzlsouerKJ , HuangHY , AlbergAJ , HoffmanS , BurkeA , NorkusEP , et al. Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer. Journal of the National Cancer Institute2000;92(24):2018‐23. ">Helzlsouer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0032" title="KabutoM , ImaiH , YonezawaC , NeriishiK , AkibaS , KatoH , et al. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiology, Biomarkers &amp; Prevention1994;3(6):465‐9. ">Kabuto 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hakama 1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knekt 1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knekt 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0109" title="KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , NikkariT , et al. Serum micronutrients and risk of cancers of low incidence in Finland. American Journal of Epidemiology1991;134(4):356‐61. ">Knekt 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0036" title="KnektP , MarniemiJ , TeppoL , HeliovaaraM , AromaaA . Is low selenium status a risk factor for lung cancer?. American Journal of Epidemiology1998;148(10):975‐82. ">Knekt 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0110" title="KokFJ , vanDuijnCM , HofmanA , VermeerenR , DeBruijnAM , ValkenburgHA . Micronutrients and the risk of lung cancer (letter). New England Journal of Medicine1987c;316:1416. ">Kok 1987b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0037" title="KokFJ , DeBruijnAM , HofmanA , ValkenburgHA . Selenium status and chronic disease mortality: Dutch epidemiological findings. International Journal of Epidemiology1987a;16(2):329‐32. KokFJ , DeBruijnAM , HofmanA , VermeerenR , ValkenburgHA . Is serum selenium a risk factor for cancer in men only?. American Journal of Epidemiology1987b;125(1):12‐6. ">Kok 1987a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0038" title="KornitzerM , ValenteF , DeBacquerD , NeveJ , DeBackerG . Serum selenium and cancer mortality: a nested case‐control study within an age‐ and sex‐stratified sample of the Belgian adult population. European Journal of Clinical Nutrition2004;58(1):98‐104. ">Kornitzer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0039" title="KristalAR , DarkeAK , MorrisJS , TangenCM , GoodmanPJ , ThompsonIM , et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. Journal of the National Cancer Institute2014;106(3):djt456. [PUBMED: 24563519] ">Kristal 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0040" title="KromhoutD . Essential micronutrients in relation to carcinogenesis. American Journal of Clinical Nutrition1987;45(5 Suppl):1361‐7. ">Kromhout 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0040" title="KromhoutD . Essential micronutrients in relation to carcinogenesis. American Journal of Clinical Nutrition1987;45(5 Suppl):1361‐7. ">Kromhout 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0042" title="LiH , KantoffPW , GiovannucciE , LeitzmannMF , GazianoJM , StampferMJ , et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research2005a;65(6):2498‐504. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute2004;96(9):696‐703. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. Plasma selenium levels associated with subsequent risk of prostate cancer. American Journal of Urology Review2005b;3(1):28‐34. ">Li 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0042" title="LiH , KantoffPW , GiovannucciE , LeitzmannMF , GazianoJM , StampferMJ , et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Research2005a;65(6):2498‐504. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute2004;96(9):696‐703. LiH , StampferMJ , GiovannucciEL , MorrisJS , WillettWC , GazianoJM , et al. Plasma selenium levels associated with subsequent risk of prostate cancer. American Journal of Urology Review2005b;3(1):28‐34. ">Li 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heinen 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van der Pols 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Batieha 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Breslow 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burney 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helzlsouer 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helzlsouer 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ko 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schober 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schober 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0048" title="MichaudDS , HartmanTJ , TaylorPR , PietinenP , AlfthanG , VirtamoJ , et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1505‐6. ">Michaud 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0049" title="MichaudDS , DeVivoI , MorrisJS , GiovannucciE . Toenail selenium concentrations and bladder cancer risk in women and men. British Journal of Cancer2005;93(7):804‐6. ">Michaud 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0050" title="MukaT , KrajaB , RuiterR , LahousseL , deKeyserCE , HofmanA , et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition2017;56(4):1637‐46. [PUBMED: 27073037] ">Muka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0050" title="MukaT , KrajaB , RuiterR , LahousseL , deKeyserCE , HofmanA , et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition2017;56(4):1637‐46. [PUBMED: 27073037] ">Muka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0052" title="NomuraAMY , LeeJ , StemmermannGN , CombsGFJr . Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2000;9(9):883‐7. ">Nomura 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0052" title="NomuraAMY , LeeJ , StemmermannGN , CombsGFJr . Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2000;9(9):883‐7. ">Nomura 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0055" title="OutzenM , TjonnelandA , LarsenEH , FriisS , LarsenSB , ChristensenJ , et al. Selenium status and risk of prostate cancer in a Danish population. British Journal of Nutrition2016;115(9):1669‐77. [PUBMED: 26971676] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Outzen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0055" title="OutzenM , TjonnelandA , LarsenEH , FriisS , LarsenSB , ChristensenJ , et al. Selenium status and risk of prostate cancer in a Danish population. British Journal of Nutrition2016;115(9):1669‐77. [PUBMED: 26971676] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Outzen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0056" title="OvervadK , WangDY , OlsenJ , AllenDS , ThorlingEB , BulbrookRD , HaywardJL . Selenium in human mammary carcinogenesis: a case‐cohort study. European Journal of Cancer1991;27(7):900‐2. ">Overvad 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0056" title="OvervadK , WangDY , OlsenJ , AllenDS , ThorlingEB , BulbrookRD , HaywardJL . Selenium in human mammary carcinogenesis: a case‐cohort study. European Journal of Cancer1991;27(7):900‐2. ">Overvad 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0057" title="PantavosA , RuiterR , FeskensEF , deKeyserCE , HofmanA , StrickerBH , et al. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: the Rotterdam Study. International Journal of Cancer2015;136(9):2178‐86. [PUBMED: 25284450] ">Pantavos 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0057" title="PantavosA , RuiterR , FeskensEF , deKeyserCE , HofmanA , StrickerBH , et al. Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: the Rotterdam Study. International Journal of Cancer2015;136(9):2178‐86. [PUBMED: 25284450] ">Pantavos 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0058" title="ParkSY , HaimanCA , ChengI , ParkSL , WilkensLR , KolonelLN , et al. Racial/ethnic differences in lifestyle‐related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes &amp; Control2015;26(10):1507‐15. [PUBMED: 26243447] ">Park 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0058" title="ParkSY , HaimanCA , ChengI , ParkSL , WilkensLR , KolonelLN , et al. Racial/ethnic differences in lifestyle‐related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes &amp; Control2015;26(10):1507‐15. [PUBMED: 26243447] ">Park 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0059" title="PelegI , MorrisS , HamesCG . Is serum selenium a risk factor for cancer?. Medical Oncology and Tumor Pharmacotherapy1985;2(3):157‐63. ">Peleg 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0059" title="PelegI , MorrisS , HamesCG . Is serum selenium a risk factor for cancer?. Medical Oncology and Tumor Pharmacotherapy1985;2(3):157‐63. ">Peleg 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0060" title="PetersU , FosterCB , ChatterjeeN , SchatzkinA , RedingD , AndrioleGL , et al. Serum selenium and risk of prostate cancer ‐ a nested case‐control study. American Journal of Clinical Nutrition2007;85(1):209‐17. ">Peters 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0060" title="PetersU , FosterCB , ChatterjeeN , SchatzkinA , RedingD , AndrioleGL , et al. Serum selenium and risk of prostate cancer ‐ a nested case‐control study. American Journal of Clinical Nutrition2007;85(1):209‐17. ">Peters 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asgari 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0029" title="HotalingJM , WrightJL , PocobelliG , BhattiP , PorterMP , WhiteE . Long‐term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. The Journal of Urology2011;185(4):1210‐5. ">Hotaling 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0077" title="WalterRB , BraskyTM , MilanoF , WhiteE . Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(10):2298‐308. ">Walter 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0062" title="RatnasingheD , TangreaJA , FormanMR , HartmanT , GunterEW , QiaoYL , et al. Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes and Control2000;11(2):129‐35. ">Ratnasinghe 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0062" title="RatnasingheD , TangreaJA , FormanMR , HartmanT , GunterEW , QiaoYL , et al. Serum tocopherols, selenium and lung cancer risk among tin miners in China. Cancer Causes and Control2000;11(2):129‐35. ">Ratnasinghe 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0064" title="RingstadJ , JacobsenBK , TretliS , ThomassenY . Serum selenium concentration associated with risk of cancer. Journal of Clinical Pathology1988;41(4):454‐7. ">Ringstad 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0064" title="RingstadJ , JacobsenBK , TretliS , ThomassenY . Serum selenium concentration associated with risk of cancer. Journal of Clinical Pathology1988;41(4):454‐7. ">Ringstad 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0066" title="SalonenJT , AlfthanG , HuttunenJK , PuskaP . Association between serum selenium and the risk of cancer. American Journal of Epidemiology1984;120(3):342‐9. ">Salonen 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0067" title="SalonenJT , SalonenR , LappetelainenR , MaenpaaPH , AlfthanG , PuskaP . Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case‐control analysis of prospective data. British Medical Journal (Clinical Research Edition)1985;290(6466):417‐20. ">Salonen 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0070" title="SteinbrecherA , MeplanC , HeskethJ , SchomburgL , EndermannT , JansenE , et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology, Biomarkers &amp; Prevention. 19. American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106‐3483, United States), 2010; Vol. 19, issue 11:2958‐68. ">Steinbrecher 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0071" title="SuadicaniP , HeinHO , GyntelbergF . Serum selenium level and risk of lung cancer mortality: a 16‐year follow‐up of the Copenhagen Male Study. European Respiratory Journal2012;39(6):1443‐8. ">Suadicani 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0071" title="SuadicaniP , HeinHO , GyntelbergF . Serum selenium level and risk of lung cancer mortality: a 16‐year follow‐up of the Copenhagen Male Study. European Respiratory Journal2012;39(6):1443‐8. ">Suadicani 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0072" title="SunJW , ShuXO , LiHL , ZhangW , GaoJ , ZhaoLG , et al. Dietary selenium intake and mortality in two population‐based cohort studies of 133 957 Chinese men and women. Public Health Nutrition2016;19(16):2991‐8. [PUBMED: 27197889] ">Sun 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van den Brandt 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van den Brandt 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zeegers 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0075" title="vanNoordPAH , ColletteHJA , MaasMJ , deWaardF . Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort‐nested case‐referent study among women screened in the DOM project. International Journal of Epidemiology1987;16(2):318‐22. ">van Noord 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0075" title="vanNoordPAH , ColletteHJA , MaasMJ , deWaardF . Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort‐nested case‐referent study among women screened in the DOM project. International Journal of Epidemiology1987;16(2):318‐22. ">van Noord 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0076" title="VirtamoJ , ValkeilaE , AlfthanG , PunsarS , HuttunenJK , KarvonenMJ . Serum selenium and risk of cancer. A prospective follow‐up of nine years. Cancer1987;60(2):145‐8. ">Virtamo 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0076" title="VirtamoJ , ValkeilaE , AlfthanG , PunsarS , HuttunenJK , KarvonenMJ . Serum selenium and risk of cancer. A prospective follow‐up of nine years. Cancer1987;60(2):145‐8. ">Virtamo 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mark 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.‐.‐.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0079" title="WillettWC , PolkBF , MorrisJS , StampferMJ , PresselS , RosnerB , et al. Prediagnostic serum selenium and risk of cancer. Lancet1983;2(8342):130‐4. ">Willett 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0079" title="WillettWC , PolkBF , MorrisJS , StampferMJ , PresselS , RosnerB , et al. Prediagnostic serum selenium and risk of cancer. Lancet1983;2(8342):130‐4. ">Willett 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0080" title="YoshizawaK , WillettWC , MorrisSJ , StampferMJ , SpiegelmanD , RimmEB , et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Journal of the National Cancer Institute1998;90(16):1219‐24. ">Yoshizawa 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0080" title="YoshizawaK , WillettWC , MorrisSJ , StampferMJ , SpiegelmanD , RimmEB , et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Journal of the National Cancer Institute1998;90(16):1219‐24. ">Yoshizawa 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐0‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐1‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias: observational studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005195-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of observational studies not included in meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Organ system</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cancer</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Case definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio estimate (highest vs lowest exposure category)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selenium marker</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sex</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Gynaecological</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cervix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 2.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Batieha 1993) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecological (without breast)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 to 5.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> (Knekt 1996) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 3.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 to 1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Helzlsour 1996) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 to 1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0073" title="ThomsonCA , NeuhouserML , ShikanyJM , CaanBJ , MonkBJ , Mossavar‐RahmaniY , et al. The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. Nutrition and Cancer2008;60(6):710‐9. ">Thomson 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uterus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 to 3.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="33" valign=""> <p><b>Gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal tract (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum/plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oesophageal squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 to 0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 to 1.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0027" title="HashemianM , PoustchiH , AbnetCC , BoffettaP , DawseySM , BrennanPJ , et al. Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. American Journal of Clinical Nutrition2015;102(1):102‐8. [PUBMED: 26016858] PourshamsA , KhademiH , MalekshahAF , IslamiF , NouraeiM , SadjadiAR , et al. Cohort Profile: The Golestan Cohort Study ‐ a prospective study of oesophageal cancer in Northern Iran. International Journal of Epidemiology2010;39(1):52‐9. [PUBMED: 19332502] ">Hashemian 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oesophageal adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 to 1.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Oesophagus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> (Mark 2000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 to 0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a> (<a href="./references#CD005195-bbs2-0078" title="MarkSD , QiaoYL , DawseySM , WuYP , KatkiH , GunterEW , et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. Journal of the National Cancer Institute2000;92(21):1753‐63. WeiWQ , AbnetCC , QiaoYL , DawseySM , DongZW , SunXD , et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. American Journal of Clinical Nutrition2004;79(1):80‐5. ">Wei 2004</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 to 2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0012" title="DongLM , KristalAR , PetersU , SchenkJM , SanchezCA , RabinovitchPS , et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutrition and Cancer2008;60(1):39‐48. ">Dong 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastric cardio adenocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 to 1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0069" title="SteevensJ , Van denBrandtPA , GoldbohmRA , SchoutenLJ . Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 138. W.B. Saunders (Independence Square West, Philadelphia PA 19106‐3399, United States), 2010; Vol. 138, issue 5:1704‐13. ">Steevens 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oesophagus and stomach</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> (Knekt 1988) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 to 1.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0083" title="YuMW , HorngIS , HsuKH , ChiangYC , LiawYF , ChenCJ . Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. American Journal of Epidemiology1999;150(4):367‐74. ">Yu 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 to 0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0031" title="HughesDJ , Duarte‐SallesT , HybsierS , TrichopoulouA , StepienM , AleksandrovaK , et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition2016;104(2):406‐14. [PUBMED: 27357089] ">Hughes 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 to to 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0044" title="MaX , YangY , LiHL , ZhengW , GaoJ , ZhangW , et al. Dietary trace element intake and liver cancer risk: results from two population‐based cohorts in China. International Journal of Cancer2017;140(5):1050‐9. [PUBMED: 27859272] ">Ma 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 to 1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 to 1.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 to 0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0065" title="SakodaLC , GraubardBI , EvansAA , LondonWT , LinWY , ShenFM , et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. International Journal of Cancer2005;115(4):618‐24. ">Sakoda 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 to 1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 to 1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Pancreas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 to 0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Burney 1989) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 1.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 to 1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 to 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>supplemental intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0024" title="HanX , LiJ , BraskyTM , XunP , StevensJ , WhiteE , et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer2013;119(7):1314‐20. [PUBMED: 23280534] ">Han 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Rectum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0051" title="NomuraA , HeilbrunLK , MorrisJS , StemmermannGN . Serum selenium and the risk of cancer, by specific sites: case‐control analysis of prospective data. Journal of the National Cancer Institute1987;79(1):103‐8. ">Nomura 1987</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 to 2.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0074" title="ZeegersMPA , GoldbohmRA , BodeP , van denBrandtPA . Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2002;11(11):1292‐7. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Research1993a;53(20):4860‐5. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. Journal of the National Cancer Institute1993b;85(3):224‐9. van denBrandtPA , GoldbohmRA , van't VeerP , BodeP , DorantE , HermusRJ , et al. Toenail selenium levels and the risk of breast cancer. American Journal of Epidemiology1994;140(1):20‐6. van denBrandtPA , ZeegersMPA , BodeP , GoldbohmRA . Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiology, Biomarkers &amp; Prevention2003;12(9):866‐71. ">van den Brandt 1993</a> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 to 2.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 to 4.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 to 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>supplement use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0025" title="HansenRD , AlbieriV , TjonnelandA , OvervadK , AndersenKK , Raaschou‐NielsenO . Effects of smoking and antioxidant micronutrients on risk of colorectal cancer. Clinical Gastroenterology and Hepatology2013;11(4):406‐15.e3. [PUBMED: 23142208] TjonnelandA , OlsenA , BollK , StrippC , ChristensenJ , EngholmG , et al. Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population‐based prospective cohort study of 57,053 men and women in Denmark. Scandinavian Journal of Public Health2007;35(4):432‐41. [PUBMED: 17786808] ">Hansen 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 to 1.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0030" title="HughesDJ , FedirkoV , JenabM , SchomburgL , MeplanC , FreislingH , et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. International Journal of Cancer2015;136(5):1149‐61. [PUBMED: 25042282] ">Hughes 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 to 3.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 to 1.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Urological cancers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 to 0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dietary intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0005" title="BanimPJR , LubenR , McTaggartA , WelchA , WarehamN , KhawKT , et al. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut2013;62(10):1489‐96. BarrassB , RochesterM , LubenR , KhawKT , HartA . Dietary selenium and lower risk of developing renal cancer ‐ a prospective cohort study using food diaries in epic Norfolk. Journal of Urology2013;189(4):E248. ">Banim 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Urinary tract (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 to 1.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0029" title="HotalingJM , WrightJL , PocobelliG , BhattiP , PorterMP , WhiteE . Long‐term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. The Journal of Urology2011;185(4):1210‐5. ">Hotaling 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Respiratory tract</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cavum oris/pharynx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Zheng 1993) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign=""> <p><b>Skin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 to 3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0018" title="GarlandM , MorrisJS , StampferMJ , ColditzGA , SpateVL , BaskettCK , et al. Prospective study of toenail selenium levels and cancer among women. Journal of the National Cancer Institute1995;87(7):497‐505. HunterDJ , MorrisJS , StampferMJ , ColditzGA , SpeizerFE , WillettWC . A prospective study of selenium status and breast cancer risk. JAMA1990;264(9):1128‐31. ">Garland 1995</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 to 2.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Breslow 1995) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 to 1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0061" title="AsgariMM , MarutiSS , KushiLH , WhiteE . Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Archives of Dermatology2009;145(8):879‐82. PetersU , LittmanAJ , KristalAR , PattersonRE , PotterJD , WhiteE . Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control2008;19(1):75‐87. ">Peters 2008</a> (Asgari 2009) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any non‐melanoma cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0008" title="ClarkL , GrahamG , BrayJ . Nonmelanoma skin cancer and plasma selenium: a prospective cohort study. American Journal of Epidemiology1985;122(3):528. ">Clark 1985</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Basal cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0035" title="HakamaM , AaranRK , AlfthanG , AromaaA , HakulinenT , KnektP , et al. Linkage of serum sample bank and cancer registry in epidemiological studies. Progress in Clinical and Biological Research, v. 346. New York: Wiley‐Liss, 1990:169‐78. KnektP , AromaaA , AlfthanG , MaatelaJ , HakamaM , HakulinenT , et al. Re: Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(19):1408. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , HakamaM , et al. Serum selenium and subsequent risk of cancer among Finnish men and women. Journal of the National Cancer Institute1990;82(10):864‐8. KnektP , AromaaA , MaatelaJ , AlfthanG , AaranRK , TeppoL , et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. International Journal of Cancer1988;42(6):846‐50. KnektP , JarvinenR , SeppanenR , RissanenA , AromaaA , HeinonenOP , et al. Dietary antioxidants and the risk of lung cancer. American Journal of Epidemiology1991;134(5):471‐9. ">Knekt 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 to 4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Breslow 1995) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 to 1.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 to 1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Squamous cell carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 to 0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0010" title="CombsGFJr , ClarkLC , TurnbullBW , GrahamGF , SmithCL , SandersBJr , et al. Low plasma selenium (Se) predicts the 24 month incidence of squamous cell carcinoma of the skin in a cancer prevention trial. FASEB1993; Vol. 7, issue 3:A278. ">Combs 1993</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 to 1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0047" title="BatiehaAM , ArmenianHK , NorkusEP , MorrisJS , SpateVE , ComstockGW . Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1993;2(4):335‐9. BreslowRA , AlbergAJ , HelzlsouerKJ , BushTL , NorkusEP , MorrisJS , et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta‐carotene, lycopene, alpha‐tocopherol, and selenium. Cancer Epidemiology, Biomarkers &amp; Prevention1995;4(8):837‐42. BurneyPG , ComstockGW , MorrisJS . Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. American Journal of Clinical Nutrition1989;49(5):895‐900. HelzlsouerKJ , AlbergAJ , NorkusEP , MorrisJS , HoffmanSC , ComstockGW . Prospective study of serum micronutrients and ovarian cancer. Journal of the National Cancer Institute1996;88(1):32‐7. HelzlsouerKJ , ComstockGW , MorrisJS . Selenium, lycopene, alpha‐tocopherol, beta‐carotene, retinol, and subsequent bladder cancer. Cancer Research1989;49(21):6144‐8. KoW . The Associations of Serologic Precursors and the Anatomic‐Site Specific Incidence of Colon Cancer. Baltimore, MD: John Hopkins University, 1994. MenkesMJ . Vitamins A, E, selenium and risk of lung cancer. Dissertation Abstract International (Sci)1986a; Vol. 46, issue 11:3807. MenkesMS , ComstockGW , VuilleumierJP , HelsingKJ , RiderAA , BrookmeyerR . Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer. New England Journal of Medicine1986b;315(20):1250‐4. SchoberSE . Vitamin A, vitamin E, selenium, and colon cancer risk. Dissertation Abstract International (Sci)1986; Vol. 46, issue 11:3808. SchoberSE , ComstockGW , HelsingKJ , SalkeldRM , MorrisJS , RiderAA , BrookmeyerR . Serologic precursors of cancer. I. Prediagnostic serum nutrients and colon cancer risk. American Journal of Epidemiology1987;126(6):1033‐41. ZhengW , BlotWJ , DiamondEL , NorkusEP , SpateV , MorrisJS , et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Research1993;53(4):795‐8. ">Menkes 1986</a> (Breslow 1995) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47 to 1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0033" title="KaragasMR , GreenbergER , NierenbergD , StukelTA , MorrisJS , StevensMM , et al. Risk of squamous cell carcinoma of the skin in relation to plasma selenium, alpha‐tocopherol, beta‐carotene, and retinol: a nested case‐control study. Cancer Epidemiology, Biomarkers &amp; Prevention1997;6(1):25‐9. ">Karagas 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 to 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD005195-bbs2-0046" title="HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC , van derPolsJC . Intake of antioxidant nutrients and the risk of skin cancer. European Journal of Cancer2007;43(18):2707‐16. McNaughtonSA , MarksGC , GaffneyP , WilliamsG , GreenAC . Antioxidants and basal cell carcinoma of the skin: a nested case‐control study. Cancer Causes and Control2005;16(5):609‐18. van derPolsJC , HeinenMM , HughesMC , IbiebeleTI , MarksGC , GreenAC . Serum antioxidants and skin cancer risk: an 8‐year community‐based follow‐up study. Cancer Epidemiology, Biomarkers &amp; Prevention2009;18(4):1167‐73. ">McNaughton 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24 to 0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Other</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Haematological</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>serum/plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0009" title="CoatesRJ . Cancer risk in relation to serum levels of selenium, retinol, and copper. Dissertation Abstract International (Sci)1987; Vol. 47, issue 12:4836. CoatesRJ , WeissNS , DalingJR , MorrisJS , LabbeRF . Serum levels of selenium and retinol and the subsequent risk of cancer. American Journal of Epidemiology1988;128(3):515‐23. ">Coates 1988</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 to 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>suppl. intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005195-bbs2-0077" title="WalterRB , BraskyTM , MilanoF , WhiteE . Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(10):2298‐308. ">Walter 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Thyroid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 to 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>serum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0019" title="GlattreE , ThomassenY , ThoresenSO , HaldorsenT , Lund‐LarsenPG , TheodorsenL , et al. Prediagnostic serum selenium in a case‐control study of thyroid cancer. International Journal of Epidemiology1989;18(1):45‐9. ">Glattre 1989</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0 to 5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 to 1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 to 1.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD005195-bbs2-0054" title="O'GradyTJ , KitaharaCM , DiRienzoAG , GatesMA . The association between selenium and other micronutrients and thyroid cancer incidence in the NIH‐AARP Diet and Health Study. PloS One2014;9(10):e110886. [PUBMED: 25329812] ">O'Grady 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 to 2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 to 2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>women</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>n.r. = not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of observational studies not included in meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/full#CD005195-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005195-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Randomised controlled trials: highest versus lowest selenium exposure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Any cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cancer mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.49, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Head and neck cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.18, 5.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.52, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Oesophageal cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.06, 36.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.12, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Colorectal cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.41, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Liver cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.52 [0.37, 115.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.35, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Melanoma risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.41, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.63, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐melanoma skin cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.30, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.73, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Lung cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.89, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.78, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Breast cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.44, 9.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.96, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Bladder cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.76, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Prostate cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.75, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Leukaemia and lymphoma risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Studies with low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.52, 2.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Randomised controlled trials: highest versus lowest selenium exposure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005195-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Observational studies: highest versus lowest selenium exposure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total cancer incidence and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.55, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.59, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total cancer incidence and mortality (men) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.45, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total cancer incidence and mortality (women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.45, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total cancer incidence and mortality (ascending order of selenium levels) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.55, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total cancer incidence and mortality (ascending order of differences in selenium levels) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.55, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Stomach cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.43, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Stomach cancer risk (by sex) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.42, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 All (male + female)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.41, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.14, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.12, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Colorectal cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Colorectal cancer risk (by sex) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 All (male + female)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.68, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.61, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Colon cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Colon cancer risk (by sex) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 All (male + female)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.68, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Lung cancer incidence and mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Incidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.59, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.93, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Lung cancer risk (sex‐disaggregated data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.69, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 All (male + female)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.43, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.68, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.43, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Lung cancer risk (by exposure assessment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.95, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Serum or plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.11, 10.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Lung cancer risk (ascending order of selenium levels) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Lung cancer risk (ascending order of differences in selenium levels) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Breast cancer risk (women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.87, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Bladder cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.46, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 All (male + female)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.41, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.14, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Prostate cancer risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.75, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Prostate cancer risk (by exposure assessment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.75, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Intake and supplement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.85, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Serum or plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Toenail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.44, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Prostate cancer risk (ascending order of selenium levels) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Prostate cancer risk (ascending order of differences in selenium levels) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Observational studies: highest versus lowest selenium exposure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005195.pub4/references#CD005195-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005195.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005195-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005195-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005195-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD005195-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD005195-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD005195-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD005195-note-0016">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD005195-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005195-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005195\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005195\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005195\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005195\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005195\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005195.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005195.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005195.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005195.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005195.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715657972"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005195.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715657976"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005195.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8c6fb8fe9371',t:'MTc0MDcxNTY2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 